<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>289</serviceExecutionTime><Trial id="121485"><TitleDisplay>Safety and Immunogenicity of one or two Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine</TitleDisplay><TitleOfficial>A Phase IV, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01831050</Identifier><Identifier type="Organisational Study">IPV001ABMG</Identifier><Identifier type="Other">12-1460</Identifier><Identifier type="Other">IPV001BMG</Identifier><Identifier type="Trial Acronym">FIDEC</Identifier></Identifiers><Indications><Indication id="272">Poliovirus infection</Indication></Indications><BiomarkerNames><BiomarkerName id="2363" role="Therapeutic effect marker" type="Genomic;Proteomic">Immunoglobulin A</BiomarkerName><BiomarkerName id="3451" role="Therapeutic effect marker" type="Genomic;Proteomic">Immunoglobulin G</BiomarkerName><BiomarkerName id="44623" role="Therapeutic effect marker" type="Proteomic">Anti-poliovirus type 1 antibodies</BiomarkerName><BiomarkerName id="44624" role="Therapeutic effect marker" type="Proteomic">Anti-poliovirus type 2 antibodies</BiomarkerName><BiomarkerName id="44625" role="Therapeutic effect marker" type="Proteomic">Anti-poliovirus type 3 antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Bivalent oral polio vaccine (bOPV, Sanofi Pasteur)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Monovalent oral polio vaccine type 2 (mOPV2; Glaxo SmithKline)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Poliorix</Name><Drug id="87472">Poliorix</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Serum Institute of India IPV (SII IPV)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Trivalent oral polio vaccine (tOPV, Opvero, Sanofi Pasteur)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>polio vaccine, Sanofi Pasteur</Name><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1032580">Bill &amp; Melinda Gates Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1081936">Fighting Infectious Diseases in Emerging Countries (FIDEC)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26857">Centers for Disease Control and Prevention</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="87472">Poliorix</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1032580">Bill &amp; Melinda Gates Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1081936">Fighting Infectious Diseases in Emerging Countries (FIDEC)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26857">Centers for Disease Control and Prevention</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44408" type="Drug"><TargetEntity id="474138" type="siDrug">SP-059</TargetEntity></SourceEntity><SourceEntity id="1032580" type="Company"><TargetEntity id="4296505922" type="organizationId">Bill &amp; Melinda Gates Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="1081936" type="Company"><TargetEntity id="5031969487" type="organizationId">Fighting Infectious Diseases in Emerging Countries</TargetEntity></SourceEntity><SourceEntity id="26857" type="Company"><TargetEntity id="4296788697" type="organizationId">Centers For Disease Control And Prevention</TargetEntity></SourceEntity><SourceEntity id="272" type="ciIndication"><TargetEntity id="A80" type="ICD10"></TargetEntity><TargetEntity id="10036012" type="MEDDRA"></TargetEntity><TargetEntity id="D011051" type="MeSH"></TargetEntity><TargetEntity id="2912" type="ORPHANET"></TargetEntity><TargetEntity id="-250236249" type="omicsDisease"></TargetEntity><TargetEntity id="3005" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1081936">Fighting Infectious Diseases in Emerging Countries (FIDEC)</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1032580">Bill &amp; Melinda Gates Foundation</Company><Company id="26857">Centers for Disease Control and Prevention</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="12362">Whole organism vaccine</Class><Class id="12365">Inactivated vaccine</Class><Class id="12378">Prophylactic vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>1420</PatientCountEnrollment><PatientCountEvaluable>939</PatientCountEvaluable><DateStart>2013-05-31T00:00:00Z</DateStart><DateEnd type="actual">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-10-18T11:39:35Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Colorado, Denver</Affiliation><Name>Edwin J Asturias, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Fidec Corporation</Affiliation><Name>Ricardo Ruttimann, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age: 6 weeks (-7 to +14 days)&lt;/li&gt;&lt;li&gt;Healthy without obvious medical conditions that preclude the subject to be in the study as established by the medical history and physical examination&lt;/li&gt;&lt;li&gt;Written informed consent obtained from one or two parents or legal guardian as per country regulations&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous vaccination against poliovirus&lt;/li&gt;&lt;li&gt;Low birth weight (BW&amp;lt; 2,500 gm)&lt;/li&gt;&lt;li&gt;Multiple pregnancy (twins, triplets, etc)&lt;/li&gt;&lt;li&gt;Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus (HIV) infection&lt;/li&gt;&lt;li&gt;Family history of congenital or hereditary immunodeficiency&lt;/li&gt;&lt;li&gt;Major congenital defects or serious uncontrolled chronic illness (neurological, pulmonary, gastrointestinal, hepatic, renal, or endocrine)&lt;/li&gt;&lt;li&gt;Known allergy to any component of the study vaccines&lt;/li&gt;&lt;li&gt;Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections&lt;/li&gt;&lt;li&gt;Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period&lt;/li&gt;&lt;li&gt;Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination&lt;/li&gt;&lt;li&gt;Member of the subject's household (living in the same house or apartment unit) who has received OPV vaccine in the last 3 months&lt;/li&gt;&lt;li&gt;Subject who, in the opinion of the Investigator or sub-Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Superiority of bOPV-IPV schedules over bOPV alone: assessed by the primary endpoints of humoral immunity to all three serotypes and intestinal immunity to serotype 2</Description></Measure><Measure><Description>Change in the stool poliovirus excretion after mOPV2 challenge (shedding index): the basis for calculation of the quantitative shedding index endpoint is to measure the change of viral concentrations shed in stool post-mOPV2 challenge from the baseline timepoint at day 0 to 7, 14, 21 and 28 days as measured from time of mOPV challenge. Quantitative shedding index endpoint will be computed as an area under the viral shedding curve based on these 3 log10-transformed measurements</Description><Timeframe>Within 28 days of mOPV2 challenge</Timeframe></Measure><Measure><Description>Seroconversion and seroprotection to type 1, 2 and 3 poliovirus: the first serological response endpoint is neutralizing antibody titer defined as the estimated dilution at which 50% neutralizing activity is achieved. The second serological response endpoint is the binary seroconversion indicator. Seroconversion is considered to be achieved by the time of the subsequent time point if type-specific titers measured at that time are &gt;/= 1 : 8 and &gt; 4-fold over expected levels of maternally-derived antibody computed from the observed titer at baseline assuming an exponential decay with half life of 24 days. The third serological response endpoint of seroprotection is a binary outcome computed from a single antibody titer measurement with seroprotection being achieved if the measured titer is &gt; 1 : 8</Description><Timeframe>At 6 and 14 weeks, and then before and 1 week after mOPV2 challenge</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Intestinal immunity as judged by neutralization of virus and virus-specific IgA in stools</Description></Measure><Measure><Description>Comparability of seroconversion and seroprotection from different IPV vaccines: to determine whether IPVs from different manufacturers (Sanofi, GSK, SII) are comparable in their ability to induce/boost an antibody response to the three poliovirus serotypes in infants vaccinated with 1 or 2 IPV doses after receiving three doses of bOPV at 6, 10, and 14 weeks of age</Description><Timeframe>At 6 and 14 weeks, and then before and 1 week after mOPV2 challenge</Timeframe></Measure><Measure><Description>Safety of each vaccine (tOPV, bOPV, mOPV, Sanofi IPV, GSK IPV and SII IPV) and each vaccine schedule: Number of severe adverse events (SAE)throughout the study period; number of important medical events (IME) as protocol defined: up to 28 days post-vaccination; number of local and systemic solicited AEs: 3 days post-vaccination</Description><Timeframe>10 months for each subject</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In July 2016, results were published. Overall, 20 patients reported 21 serious adverse events, of which 2 were considered to be possibly related to the vaccines. Infections (86%) and infestations (80%) were the major serious adverse events reported. There were no deaths reported during the study [&lt;ulink linkType="Reference" linkID="1784728"&gt;1784728&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was a phase IV, open, randomized, multicenter, controlled vaccine trial conducted      in healthy Latin American infants, utilizing one or two supplemental doses of inactivated polio vaccine (IPV) in      children previously vaccinated with three doses of bivalent oral polio vaccines (bOPV).  This study would examine the impact of      supplemental IPV on stool shedding and humoral immunity, as well as intra-IPV manufacturer      comparability, and safety.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In July 2016, results were published. Type 1 and 3 seroconversion rates of at least 97.7% were elicited by three doses of bOPV or tOPV. Type 2 seroconversion rates were 9.6, 97.7, and 80.4% in groups 1/2, 3, and 4, respectively (p &amp;lt; 0.0001 for 3 versus 1/2 groups, and 4 verus 1/2 groups). In group 4, additionally 10% of children had seroconversion at 1 week after mOPV2 challenge, cumulating to 98% type 2 seroconversion rate. With bOPV plus two doses of IPV, all children had seroconverted to type 2 (100%; p &amp;lt; 0.001 versus 1/2 group). Following mOPV2 challenge, IPV had induced small, but significant decreases in a composite serotype 2 viral shedding index [&lt;ulink linkType="Reference" linkID="1784728"&gt;1784728&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, results were published. This analysis included infants (n = 210) from Guatemala and Dominican Republic. A total of 2 of 38 versus 59 of 85 and 53 of 87 infants in tOPV versus bOPV (p &amp;lt; 0.0001) and bOPV-IPV (p &amp;lt; 0.0001) groups, respectively, were shedding virus 1 week after challenge. Mucosal type 2 neutralization and type-specific IgA were seen primarily in response to tOPV. Virus shedding and both serum type 2 neutralization at challenge (p &amp;lt; 0.0001) and mucosal type 2 neutralization at challenge (p &amp;lt; 0.0001) were found to be inversely correlated [&lt;ulink linkType="Reference" linkID="1888687"&gt;1888687&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Impact of supplemental IPV's on      antibody formation in the blood, which was a marker of protection of the individual from      polio disease would be measured.  A secondary aim would be to compare the immunogenicity and safety of three      IPV's produced by different manufacturers.  The overall goal would be to inform policy makers      in polio eradication regarding the potential role that one or two doses of IPV might play in      the final steps toward polio eradication.&lt;/para&gt;&lt;para&gt;Children would  be randomized to one of the nine arms:&lt;br/&gt;Group 1:  children (n = 210)  would receive  bivalent oral polio vaccine (bOPV; &lt;ulink linkType="Company" linkID="1009547"&gt;Sanofi-Pasteur&lt;/ulink&gt;) at 6, 10 and 14 weeks with monovalent oral polio vaccine type 2 (mOPV2; &lt;ulink linkType="Company" linkID="28355"&gt;Glaxo SmithKline&lt;/ulink&gt;) challenge at 18 weeks.&lt;br/&gt;Group 2:  children (n = 210)  would receive  bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 40 weeks.&lt;br/&gt;Group 3: children (n = 100)  would receive trivalent oral polio vaccine (tOPV, Opvero) at 6, 10 and 14 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 18 weeks.&lt;br/&gt;Group 4: children (n = 210) would receive bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks and one dose of &lt;ulink linkType="Company" linkID="1009547"&gt;Sanofi-Pasteur&lt;/ulink&gt; IPV (&lt;ulink linkType="Drug" linkID="44408"&gt;Imovax&lt;/ulink&gt;) at 14 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 18 weeks.&lt;br/&gt;Group 5: children (n = 210) would receive bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks and two doses of &lt;ulink linkType="Company" linkID="1009547"&gt;Sanofi-Pasteur&lt;/ulink&gt; IPV (&lt;ulink linkType="Drug" linkID="44408"&gt;Imovax&lt;/ulink&gt;) at 14 and 36 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 40 weeks.&lt;br/&gt;Group 6: children (n = 50) would receive bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks and one dose of &lt;ulink linkType="Company" linkID="28355"&gt;Glaxo SmithKline&lt;/ulink&gt; IPV (GSK IPV, &lt;ulink linkType="Drug" linkID="87472"&gt;Poliorix&lt;/ulink&gt;) at 14 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 18 weeks.&lt;br/&gt;Group 7: children (n = 190) would receive bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks and two doses of &lt;ulink linkType="Company" linkID="28355"&gt;Glaxo SmithKline&lt;/ulink&gt; IPV (GSK IPV) at 14 and 36 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 40 weeks.&lt;br/&gt;Group 8: children (n = 50) would receive bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks and one dose of &lt;ulink linkType="Company" linkID="23305"&gt;Serum Institute of India&lt;/ulink&gt; IPV (SII IPV) at 14 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 18 weeks.&lt;br/&gt;Group 9: children (n = 190) would receive bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks and two doses of &lt;ulink linkType="Company" linkID="23305"&gt;Serum Institute of India&lt;/ulink&gt; IPV (SII IPV) at 14 and 36 weeks with monovalent oral polio vaccine type 2 (mOPV2) challenge at 40 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Children were randomized (1 : 1 : 1 : 1, permuted block method) to receive bOPV at 6, 10, and 14 weeks (groups 1 and 2; control groups), tOPV at 6, 10, and 14 weeks (group 3), bOPV plus one dose of IPV at 14 weeks (group 4), bOPV plus two doses of IPV at 14 and 36 weeks (group 5). At 18 weeks, children in groups 1, 3, and 4 were challenged with monovalent type 2 vaccine (mOPV2), while in groups 2 and 5, mOPV2 was challenged at 40 weeks [&lt;ulink linkType="Reference" linkID="1784728"&gt;1784728&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1888687"&gt;1888687&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Colombia"><Sites><Site><Name>Centro de Estudios en Infectologia Pediatrica - CEIP</Name><Address1>Cali</Address1><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Dominican Republic"><Sites><Site><Name>Hospital Maternidad Nuestra Señora de la Altagracia</Name><Address1>Santo Domingo</Address1><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Guatemala"><Sites><Site><Name>Clinica Niño Sano Hospital Roosevelt</Name><Address1>Guatemala</Address1><Address3>01011</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Panama"><Sites><Site><Name>Hospital del Niño de Panama</Name><Address1>Panama</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01831050</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Polio Vaccine" id="18508"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18510">Assessment of seropositivity/seroconversion rate</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Polio Vaccine" id="18508"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18510">Assessment of seropositivity/seroconversion rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Polio Vaccine" id="18513"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18514">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Polio Vaccine" id="34748"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="16830">Healthy infants</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Polio Vaccine" id="14311"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14313"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14314"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14315"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14316"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14317"><Criterion>Subjects with Autoimmune/Immunological Disorders</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14319"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="14322"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="14323">Subjects with prior history of/scheduled to receive immunoglobulins/blood products for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Polio Vaccine" id="14325"><Criterion>Subjects with Contraindications to Vaccine/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="Polio Vaccine" id="25975"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="14308">Subjects immunocompromized with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Polio Vaccine" id="26538"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="14320">Subjects with Prior Polio Vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.03 Months</EnrollmentPeriod><EnrollmentRate>118.04 Patients/Month</EnrollmentRate><DateFirstReceived>2013-04-10T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-05-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-12-15T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-08-03T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="202664"><TitleDisplay>Pediatric Aggression and Violence</TitleDisplay><TitleOfficial>Salivary Hormones and Pediatric Aggression and Violence: A Feasibility Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01253343</Identifier><Identifier type="Organisational Study">2010-0892</Identifier></Identifiers><Indications><Indication id="9">Aggression</Indication></Indications><BiomarkerNames><BiomarkerName id="1387" role="Disease marker" type="Biochemical">Testosterone</BiomarkerName><BiomarkerName id="2523" role="Disease marker" type="Biochemical">Dehydroepiandrosterone sulfate</BiomarkerName><BiomarkerName id="2534" role="Disease marker" type="Biochemical">Hydrocortisone</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="25631" type="Company"><TargetEntity id="5000071420" type="organizationId">Childrens Hospital Medical Center</TargetEntity></SourceEntity><SourceEntity id="9" type="ciIndication"><TargetEntity id="R45.5" type="ICD10"></TargetEntity><TargetEntity id="10001488" type="MEDDRA"></TargetEntity><TargetEntity id="D000374" type="MeSH"></TargetEntity><TargetEntity id="-569686292" type="omicsDisease"></TargetEntity><TargetEntity id="62" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25631">Cincinnati Children's Hospital Medical Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>African Ancestry</Term><Term>European Ancestry</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>24</PatientCountEnrollment><DateStart>2011-09-30T00:00:00Z</DateStart><DateEnd type="actual">2012-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-05-26T05:23:08Z</DateChangeLast><DateAdded>2014-07-24T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Prepubescent males (per parent report), African American or Caucasian, between 7 and 9 years old&lt;/li&gt;&lt;li&gt;Ability of the subject to provide assent&lt;/li&gt;&lt;li&gt;Ability of the guardian to give parental permission&lt;/li&gt;&lt;li&gt;Completion of the BRACHA questionnaire&lt;/li&gt;&lt;li&gt;Completion of the PAAS questionnaire&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Viral or bacterial infection or treatment with antibiotics within 2 weeks of screening&lt;/li&gt;&lt;li&gt;Recent surgery (within 8 weeks of screening)&lt;/li&gt;&lt;li&gt;Bleeding gums (within 8 weeks of screening)&lt;/li&gt;&lt;li&gt;Currently detained in a juvenile detention&lt;/li&gt;&lt;li&gt;Currently taking medications such as antipsychotic medications (besides aripiprazole), steroids and beta adrenergic agonists that affect hormones&lt;/li&gt;&lt;li&gt;If it is the investigator's clinical judgment that the subject should be excluded if it is in the subject's best interest or due to any other factor that may interfere with study results&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Salivary hormone correlation with brief rating of aggression by children and adolescent (BRACHA) score:  a total of three saliva samples from each subject was collected over a 24-h period on one of the initial three hospital days to determine the peripheral concentrations of cortisol, dehydroepiandrosterone (DHEA), and testosterone. These levels were compared with the participants BRACHA score. It was determined if hormone concentrations could improve the BRACHA's accuracy of predicting pediatric aggression during psychiatric hospitalization</Description><Timeframe>Collected on 1 or 2 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>BRACHA and the predatory affective aggression scales</Description><Timeframe>1 day</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is  to study salivary hormones  (cortisol,      testosterone, and dehydroepiandrosterone sulfate ([DHEAS]) in low      risk children and high risk children and to      improve the investigators current ability to predict the severity and type of pediatric      aggression and violence on the inpatient units by combining information from the Brief      Rating of Child and Adolescent Aggression (BRACHA), the predatory-affective aggression scale      (Vitiello et al, 1990), and salivary hormones.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 24 male subjects will be recruited to two groups from inpatient units at CCHMC:&lt;br/&gt;Inpatient high aggression group:  inpatient males (n = 12) (six African-American and six Caucasian) will be recruited based on completion of the BRACHA and the predatory-affective aggression scale.&lt;br/&gt;Inpatient low aggression group:  inpatient males (n = 12)  (six African-American and six Caucasian) will be recruited based on completion of the BRACHA and the predatory-affective aggression scales.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Cincinnati Childrens Hospital</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45229</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01253343</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Anticipated">2012-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>4.06 Months</EnrollmentPeriod><EnrollmentRate>5.91 Patients/Month</EnrollmentRate><DateFirstReceived>2010-11-01T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="216298"><TitleDisplay>Comparing the Efficacy of Tiotropium + Olodaterol (5/5 microg) Fixed-Dose Combination (FDC) Over Tiotropium 5 microg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease</TitleDisplay><TitleOfficial>A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Effect of 52 Weeks of Once-Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed-Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD (DYNAGITO)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02296138</Identifier><Identifier type="Secondary Organisational">2014-002275-28</Identifier><Identifier type="Organisational Study">1237.19</Identifier><Identifier type="Other">CTRI/2015/03/005597</Identifier><Identifier type="Other">NMRR-14-1457-23424</Identifier><Identifier type="Other">JapicCTI-152814</Identifier><Identifier type="Other">2015-CT0276</Identifier><Identifier type="Other">PHRR150622-001032</Identifier><Identifier type="Trial Acronym">DYNAGITO</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication></Indications><BiomarkerNames><BiomarkerName id="248" role="Therapeutic effect marker" type="Cellular">Eosinophils</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim</Name><Drug id="61047">olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>tiotropium bromide</Name><Drug id="8165">tiotropium bromide</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="61047">olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1122527">Boehringer Ingelheim Finland Ky</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="1122528">SCS Boehringer Ingelheim Comm.V</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22545">Boehringer Ingelheim AB</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22546">Boehringer Ingelheim GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22549">Boehringer Ingelheim Austria GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22553">Boehringer Ingelheim A/S</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22554">Boehringer Ingelheim BV</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22555">Boehringer Ingelheim Ellas AE</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22560">Boehringer Ingelheim Italia SpA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22563">Boehringer Ingelheim Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="22598">Unilfarma Lda</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="61047" type="Drug"><TargetEntity id="688557" type="siDrug">Olodaterol/tiotropium bromide</TargetEntity></SourceEntity><SourceEntity id="1122527" type="Company"><TargetEntity id="4298267375" type="organizationId">Boehringer Ingelheim Finland Ky</TargetEntity></SourceEntity><SourceEntity id="1122528" type="Company"><TargetEntity id="4298251659" type="organizationId">Boehringer Ingelheim SCS</TargetEntity></SourceEntity><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="22545" type="Company"><TargetEntity id="4298314115" type="organizationId">Boehringer Ingelheim AB</TargetEntity></SourceEntity><SourceEntity id="22546" type="Company"><TargetEntity id="4295869234" type="organizationId">Boehringer Ingelheim GmbH</TargetEntity></SourceEntity><SourceEntity id="22549" type="Company"><TargetEntity id="4296696385" type="organizationId">Boehringer Ingelheim Rcv GmbH &amp; Co Kg</TargetEntity></SourceEntity><SourceEntity id="22553" type="Company"><TargetEntity id="4298263080" type="organizationId">Boehringer Ingelheim Danmark A/S</TargetEntity></SourceEntity><SourceEntity id="22554" type="Company"><TargetEntity id="4298326415" type="organizationId">Boehringer Ingelheim BV</TargetEntity></SourceEntity><SourceEntity id="22555" type="Company"><TargetEntity id="4296121400" type="organizationId">Manufacture of Chemical and Pharmaceutical Products Societe Anonyme Boehringer Ingelheim Hellas SA</TargetEntity></SourceEntity><SourceEntity id="22560" type="Company"><TargetEntity id="4296121518" type="organizationId">Boehringer Ingelheim Italia SpA</TargetEntity></SourceEntity><SourceEntity id="22563" type="Company"><TargetEntity id="5000594307" type="organizationId">Boehringer Ingelheim Ltd</TargetEntity></SourceEntity><SourceEntity id="22598" type="Company"><TargetEntity id="5000664288" type="organizationId">Unilfarma Uniao Internacional de Laboratorios Farmaceuticos Lda</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="261" type="Action"><TargetEntity id="4" type="Mechanism">Muscarinic M1 Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="262" type="Action"><TargetEntity id="6" type="Mechanism">Muscarinic M3 Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="40" type="Action"><TargetEntity id="60" type="Mechanism">beta2-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>645</NumberOfSites><CompaniesSponsor><Company id="1122527">Boehringer Ingelheim Finland Ky</Company><Company id="1122528">SCS Boehringer Ingelheim Comm.V</Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><Company id="22545">Boehringer Ingelheim AB</Company><Company id="22546">Boehringer Ingelheim GmbH</Company><Company id="22549">Boehringer Ingelheim Austria GmbH</Company><Company id="22553">Boehringer Ingelheim A/S</Company><Company id="22554">Boehringer Ingelheim BV</Company><Company id="22555">Boehringer Ingelheim Ellas AE</Company><Company id="22560">Boehringer Ingelheim Italia SpA</Company><Company id="22563">Boehringer Ingelheim Ltd</Company><Company id="22598">Unilfarma Lda</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="261">Muscarinic M1 receptor antagonist</Action><Action id="262">Muscarinic M3 receptor antagonist</Action><Action id="40">Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1470">Respiratory system agent</Class><Class id="2953">Anti-inflammatory</Class><Class id="646">Bronchodilator</Class></Class><Technologies><Technology id="615">Aerosol formulation dermatological</Technology><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="586">Capsule formulation</Technology><Technology id="805">Daily dosing</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="898">Formulation powder</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>7903</PatientCountEnrollment><PatientCountEvaluable>7880</PatientCountEvaluable><DateStart>2015-01-13T00:00:00Z</DateStart><DateEnd type="actual">2017-03-29T00:00:00Z</DateEnd><DateChangeLast>2019-03-20T05:40:58Z</DateChangeLast><DateAdded>2014-11-24T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Liverpool, UK</Affiliation><Name>Peter M.A. Calverley</Name></Contact><Contact type="Scientific contact"><Affiliation>University of Texas Health Science Center</Affiliation><Name>Antonio Anzueto</Name></Contact><Contact type="Public contact"><Email>clintriage.rdg@boehringer-ingelheim.com</Email><Name>Boehringer Ingelheim Call Center</Name><Phone>1-800-243-0127</Phone></Contact><Contact type="Scientific contact"><Affiliation>Boehringer Ingelheim</Affiliation><Name>Boehringer Ingelheim</Name></Contact><Contact type="Scientific contact"><Affiliation>University of Liverpool</Affiliation><Name>Peter Calverley</Name></Contact><Contact type="Scientific contact"><Affiliation>Changi General Hospital</Affiliation><Name>Dr Augustine Tee Kim Huat</Name></Contact><Contact type="Scientific contact"><Affiliation>Boehringer-Ingelheim India Pvt Ltd</Affiliation><Email>mahesh.patil@boehringer-ingelheim.com</Email><Name>Mahesh Patil</Name></Contact><Contact type="Scientific contact"><Affiliation>Boehringer-Ingelheim India Pvt Ltd</Affiliation><Email>partha.gokhale@boehringer-ingelheim.com</Email><Name>Dr Pratha Gokhale</Name></Contact><Contact type="Scientific contact"><Name>Kalwinder Singh Khaira</Name></Contact><Contact type="Scientific contact"><Name>Ms Norzalwa binti Mohd Jali</Name></Contact><Contact type="Public contact"><Email>katia.giron@boehringer-ingelheim.com</Email><Name>Katia IF Idalia Girón Castillo</Name></Contact><Contact type="Public contact"><Affiliation>AMC Medical College &amp; seth L.G. general Hospital</Affiliation><Email>krutesh05@yahoo.co.in</Email><Name>Dr Sanjay Tripathi</Name><Phone>91-9825027487</Phone></Contact><Contact type="Public contact"><Affiliation>Andhra Hospitals</Affiliation><Email>drnathtrials@gmail.com</Email><Name>Dr Mangalagiri Ravindranath</Name><Phone>91-9502297778</Phone></Contact><Contact type="Public contact"><Affiliation>Apollo Gleneagles Hospitals</Affiliation><Email>subhasishghosh14@gmail.com</Email><Name>Dr Subhasish Ghosh</Name><Phone>91-9830084663</Phone></Contact><Contact type="Public contact"><Affiliation>Bala Medical Center and Hospitals</Affiliation><Email>shobana_apb@yahoo.co.in</Email><Name>Dr Srikanth Krishnamurthy</Name><Phone>91-9894257706</Phone></Contact><Contact type="Public contact"><Affiliation>Bangalore Medical College and Research Institute</Affiliation><Email>shashibushanbl@yahoo.com</Email><Name>Dr Shashibhushan Lakshmana Murthy</Name><Phone>91-9448239644</Phone></Contact><Contact type="Public contact"><Affiliation>BJ Medical College &amp; Civil Hospital</Affiliation><Email>drkartik@gmail.com</Email><Name>Dr Kartikeya Parmar</Name><Phone>91-9924643799</Phone></Contact><Contact type="Public contact"><Affiliation>Bowring and Lady Curzon Hospital</Affiliation><Email>drnagaraj.b@gmail.com</Email><Name>Dr Nagaraj Sharanappa</Name><Phone>91-9448094349</Phone></Contact><Contact type="Public contact"><Affiliation>Care Institute of Medical Sciences (CIMS) Hospital</Affiliation><Email>nitesh00@rediffmail.com</Email><Name>Dr Nitesh Shah</Name><Phone>91-9825027487</Phone></Contact><Contact type="Public contact"><Affiliation>Chest Research Foundation</Affiliation><Email>ssalvi@crfindia.com</Email><Name>Dr Sundeep Salvi</Name><Phone>91-9921211000</Phone></Contact><Contact type="Public contact"><Affiliation>Christian Medical College</Affiliation><Email>djchris@cmcvellore.ac.in</Email><Name>Dr Devasahayam Christopher</Name><Phone>91-416-2283373</Phone></Contact><Contact type="Public contact"><Affiliation>Dayanand Medical College &amp; Hospital</Affiliation><Email>anildoc11@gmail.com</Email><Name>Dr Anil Kumar Kashyap</Name><Phone>91-9815965112</Phone></Contact><Contact type="Public contact"><Affiliation>Eesha MultiSpeciality Hospital</Affiliation><Email>trirupsmo@gmail.com</Email><Name>Dr Pradyut Waghray</Name><Phone>91-8978680218</Phone></Contact><Contact type="Public contact"><Affiliation>Getwell Hospital &amp; Research Institute</Affiliation><Email>rakeshamte@yahoo.co.in</Email><Name>Dr Rajesh Swarnakar</Name><Phone>91-9822225130</Phone></Contact><Contact type="Public contact"><Affiliation>Global Hospitals</Affiliation><Email>drsamiuddin@hotmail.com</Email><Name>Dr Mohammed Samiuddin</Name><Phone>91-9848276079</Phone></Contact><Contact type="Public contact"><Affiliation>Government Medical college and New Civil Hospital</Affiliation><Email>mahendraz_patel@yahoo.com</Email><Name>Dr Mahendra Patel</Name><Phone>91-9427478093</Phone></Contact><Contact type="Public contact"><Affiliation>Grant Medical Foundation, Ruby Hall Clinic</Affiliation><Email>drm_modi@yahoo.co.in</Email><Name>Dr Mahavir Modi</Name><Phone>91-9822253596</Phone></Contact><Contact type="Public contact"><Affiliation>Institute of Respiratory Disease, S.M.S. Medical college &amp; hospital</Affiliation><Email>drnkhippal@rediffmail.com</Email><Name>Dr Narendra Khippal</Name><Phone>91-9829017619</Phone></Contact><Contact type="Public contact"><Affiliation>J S S Hospital</Affiliation><Email>mahesh1971in@yahoo.com</Email><Name>Dr Mahesh Padukudru Anand</Name><Phone>91-9448044003</Phone></Contact><Contact type="Public contact"><Affiliation>Kamineni Hospitals Private Limited</Affiliation><Email>rvndrreddy@yahoo.com</Email><Name>Dr Ravindra Reddy Etikala</Name><Phone>91-9394823703</Phone></Contact><Contact type="Public contact"><Affiliation>Karnataka Institute of Medical Sciences</Affiliation><Email>ramkaulgud@yahoo.com</Email><Name>Dr Ram Kaulgud</Name><Phone>91-9844426887</Phone></Contact><Contact type="Public contact"><Affiliation>KEM Hospital Research Centre</Affiliation><Email>drpgkhatavkar@gmail.com</Email><Name>Dr Parag Khatavkar</Name><Phone>91-9890141514</Phone></Contact><Contact type="Public contact"><Affiliation>Ketki Research Institute of Medical Sciences (KRIMS) Hospital</Affiliation><Email>priyankayadav.crc@gmail.com</Email><Name>Dr Ashok Arbat</Name><Phone>91-9822466640</Phone></Contact><Contact type="Public contact"><Affiliation>King George Hospital ,(Andhra Medical Collage)</Affiliation><Email>drnaveensnr@yahoo.com</Email><Name>Dr Narasinga Rao</Name><Phone>91-9848136704</Phone></Contact><Contact type="Public contact"><Affiliation>M.S. Ramaiah Medical College &amp; Hospita</Affiliation><Email>umamohan99@gmail.com</Email><Name>Dr Uma Maheshwari</Name><Phone>91-9483702412</Phone></Contact><Contact type="Public contact"><Affiliation>Marudhar Hospital</Affiliation><Email>inder072@gmail.com</Email><Name>Dr Inderjeet Godara</Name><Phone>91-9414525600</Phone></Contact><Contact type="Public contact"><Affiliation>Meenakshi Mission Hospital &amp; Research centre</Affiliation><Email>gvk.tbrd@gmail.com</Email><Name>Dr Gopal Velkumar</Name><Phone>91-9489105811</Phone></Contact><Contact type="Public contact"><Affiliation>Mysore Medical College and Research Institute</Affiliation><Email>drrangaswamy1@gmail.com</Email><Name>Dr Rangaswamy Kulle Gowda</Name><Phone>91-9448749643</Phone></Contact><Contact type="Public contact"><Affiliation>Nizams Institute of Medical Sciences</Affiliation><Email>dr.gkparam@gmail.com</Email><Name>Dr Gongati Kruparao Paramjyothi</Name><Phone>91-9849439706</Phone></Contact><Contact type="Public contact"><Affiliation>Paras Hospital</Affiliation><Email>neeraj.shubhra@gmail.com</Email><Name>Dr Neeraj Gupta</Name><Phone>91-9818244167</Phone></Contact><Contact type="Public contact"><Affiliation>S.P Medical College and A.G Hospitals</Affiliation><Email>manakgujrani@gmail.com</Email><Name>Dr Manak Gujarani</Name><Phone>91-9460128222</Phone></Contact><Contact type="Public contact"><Affiliation>S.R. Kalla Memorial Gastro and General Hosptial</Affiliation><Email>doctormanishjain2@gmail.com</Email><Name>Dr Manish Kumar Jain</Name><Phone>91-9414414834</Phone></Contact><Contact type="Public contact"><Affiliation>Sanjivani Superspeciality Hospital Pvt. Ltd</Affiliation><Email>parthivmehta@hotmail.com</Email><Name>Dr Parthiv Mehta</Name><Phone>91-9825031615</Phone></Contact><Contact type="Public contact"><Affiliation>Seth G S Medical College and King Edward Memorial Hospital</Affiliation><Email>arpazare@rediffmail.com</Email><Name>Dr Amar Pazare</Name><Phone>91-982057221</Phone></Contact><Contact type="Public contact"><Affiliation>Sheth Vadilal Sarabhai Genral Hospital, Smt N H L Municipal Medical College</Affiliation><Email>kham_jak@yahoo.co.in</Email><Name>DrJanak Khambholja</Name><Phone>91-9825447813</Phone></Contact><Contact type="Public contact"><Affiliation>Shree Krishna Hospital and Medical Research Centre</Affiliation><Email>rajivpp@charutarhealth.org</Email><Name>Dr Rajiv Paliwal</Name><Phone>91-9825056084</Phone></Contact><Contact type="Public contact"><Affiliation>Shreekrishna Hrudaya &amp; critical care Centre Ltd</Affiliation><Email>prafull.crc@gmail.com</Email><Name>Dr Vivek Gupta</Name><Phone>91-9373115548</Phone></Contact><Contact type="Public contact"><Affiliation>Sir Gangaram Hospital</Affiliation><Email>ujjwalparakh@yahoo.co.in</Email><Name>Dr Ujjawal Parakh</Name><Phone>91-9810672962</Phone></Contact><Contact type="Public contact"><Affiliation>SMS Medical College and Hospital</Affiliation><Email>dr.ajeetsingh@yahoo.com</Email><Name>Dr Ajeet Singh</Name><Phone>91-9829135692</Phone></Contact><Contact type="Public contact"><Affiliation>SRM Medical College Hospital and Research Centre</Affiliation><Email>srmclinicaltrials@gmail.com</Email><Name>Dr Nageswari Arcot</Name><Phone>91-9940044571</Phone></Contact><Contact type="Public contact"><Affiliation>St. Theresas General Hospital</Affiliation><Email>drnagaraj.b@gmail.com</Email><Name>Dr Nagraju Boyilla</Name><Phone>91-9848883444</Phone></Contact><Contact type="Public contact"><Affiliation>T.B and Chest Hospital</Affiliation><Email>drlalitafernandes@gmail.com</Email><Name>Dr Lalita Fernandes</Name><Phone>91-9822102177</Phone></Contact><Contact type="Public contact"><Affiliation>Topiwala National Medical College and B. Y. L. Nair Hospital</Affiliation><Email>drjoshijm@gmail.com</Email><Name>Dr Jyotsana Joshi</Name><Phone>91-9769384105</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female patients, &gt;/= 40 years of age&lt;/li&gt;&lt;li&gt;Diagnosis of COPD with a documented post-bronchodilator Forced expiratory volume in 1 s  FEV1&amp;lt; 60% of predicted normal and a post-bronchodilator FEV1/FVC &amp;lt; 70% at visit 1 &lt;/li&gt;&lt;li&gt;Documented history of at least one moderate to severe COPD exacerbation in the previous 12 months requiring treatment with systemic corticosteroids and/or antibiotics and/or related hospitalization&lt;/li&gt;&lt;li&gt;Symptomatically stable as defined by: no evidence of COPD exacerbation requiring use of either antibiotics and/or steroids 4 weeks prior to visit 1 and no evidence of change in their usual COPD medication 4 weeks prior to visit 1&lt;/li&gt;&lt;li&gt;Current or ex-smokers with a smoking history of &gt; 10 pack years&lt;/li&gt;&lt;li&gt;For patients participating in the spirometry sub-study, historical data will not be used for inclusion. These patients will perform a pre-dose pulmonary function test which will be followed by the administration of 400 microg salbutamol / albuterol followed by a post-dose pulmonary function test for qualification&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Significant disease other than COPD&lt;/li&gt;&lt;li&gt;Clinically relevant abnormal baseline hematology, blood chemistry, or creatinine&amp;gt; 2 x ULN will be excluded regardless of clinical condition (a repeat laboratory evaluation can be conducted if deemed necessary by the investigator)&lt;/li&gt;&lt;li&gt;Current documented diagnosis of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma&lt;/li&gt;&lt;li&gt;A diagnosis of thyrotoxicosis&lt;/li&gt;&lt;li&gt;A history of myocardial infarction in 6 months of screening visit&lt;/li&gt;&lt;li&gt;Life-threatening cardiac arrhythmia&lt;/li&gt;&lt;li&gt;Known active tuberculosis&lt;/li&gt;&lt;li&gt;Any malignancy unless free of disease for at least five years (patients with treated basal cell carcinoma or squamous cell skin cancers are allowed)&lt;/li&gt;&lt;li&gt;A history of cystic fibrosis&lt;/li&gt;&lt;li&gt;Clinically relevant bronchiectasis&lt;/li&gt;&lt;li&gt;Patients with severe emphysema requiring endobronchial interventions within 6 months prior to screening&lt;/li&gt;&lt;li&gt;A history of significant alcohol or drug abuse in the opinion of the investigator&lt;/li&gt;&lt;li&gt;Patients who have undergone thoracotomy with pulmonary resection&lt;/li&gt;&lt;li&gt;Patients being treated with oral or patch beta-adrenergics&lt;/li&gt;&lt;li&gt;Patients being treated with oral corticosteroid medication at unstable doses&lt;/li&gt;&lt;li&gt;Patients being treated with antibiotics for any reasons within 4 weeks of screening visit&lt;/li&gt;&lt;li&gt;Patients being treated with PDE4 inhibitors within 3 months of screening visit&lt;/li&gt;&lt;li&gt;Patients who have taken an investigational drug within 1 month or six half-lives&lt;/li&gt;&lt;li&gt;Pregnant or nursing women&lt;/li&gt;&lt;li&gt;Women of child-bearing potential not using a highly effective method of birth control&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period: Annualised rate of moderate to severe COPD exacerbations during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. Least Squares Means are actually exponentiated</Description><Timeframe>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse events, serious adverse events, adverse events leading to discontinuation and cardiovascular and respiratory events were evaluated: number of patients and exposure-adjusted rate of events</Description></Measure><Measure><Description>Number of Patients With at Least One Moderate to Severe COPD Exacerbation During the Actual Treatment Period: Key secondary endpoint: Number of patients with at least one moderate to severe COPD exacerbation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation is presented</Description><Timeframe>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</Timeframe></Measure><Measure><Description>Annualised Rate of Exacerbations Leading to Hospitalisation During the Actual Treatment Period: Annualised rate of exacerbations leading to hospitalisation during the actual treatment period was calculated per treatment per patient−year. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication</Description><Timeframe>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</Timeframe></Measure><Measure><Description>Number of Patients With at Least One COPD Exacerbation Leading to Hospitalisation During the Actual Treatment Period: Number of patients with at least one COPD exacerbation leading to hospitalisation during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with at least one moderate to severe COPD exacerbation leading to hospitalisation is presented</Description><Timeframe>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</Timeframe></Measure><Measure><Description>Number of Patients With All-cause Mortality Occurring During the Actual Treatment Period: Number of patients with all-cause mortality occurring during the actual treatment period per treatment. The actual treatment period was defined as the interval from first in-take of study medication until 1 day after last in-take of study medication. The median was not estimated due to less than 50% of patients having an event. Hence the number of patients with all-cause mortality is presented</Description><Timeframe>From first in-take of study medication until 1 day after last in-take of study medication, up to 361 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2018, final results were presented. No new side effects or safety concerns were reported in the study. Similar safety profile was reported between Spiolto Respimat and Spiriva Respimat [&lt;ulink linkType="Reference" linkID="2018273"&gt;2018273&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2018261"&gt;2018261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, results were presented. Patients in the tiotropium/olodaterol arm demonstrated higher likelihood of completing the trial when compared to those in the tiotropium arm (12.4 discontinued versus 16.5%, respectively) [&lt;ulink linkType="Reference" linkID="2035274"&gt;2035274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018,  pooled results of &lt;ulink linkType="Protocol" linkID="80828"&gt;TONADO 1&lt;/ulink&gt;,   &lt;ulink linkType="Protocol" linkID="80827"&gt;TONADO 2&lt;/ulink&gt;  and DYNAGITO study, to assess safety in patients (n = 9942) treated with tiotropium/olodaterol in comparison with tiotropium,  focusing on respiratory and cardiovascular events were published.  Fewer patients discontinued due to adverse events with tiotropium/olodaterol (5.9%) versus tiotropium (7.9%). No significant difference were observed in the incidence of adverse events, serious adverse events, cardiovascular adverse events or central nervous system vascular adverse events between treatments. Incidences of major adverse cardiovascular events  were 2.11 versus 2.22 per 100 patient-years and  incidences of fatal major adverse cardiovascular events (including death with undetermined cause) were 0.91 versus 1.00 per 100 patient-years with tiotropium/olodaterol versus tiotropium,  respectively. Respiratory adverse events were generally balanced among the treatment groups [&lt;ulink linkType="Reference" linkID="2089966"&gt;2089966&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The overall objective of the large, multinational, 52-week, double-blind, active-controlled, parallel-group study was to assess the effect of once-daily &lt;ulink linkType="Drug" linkID="61047"&gt;tiotropium + olodaterol&lt;/ulink&gt; (Stiolto Respimat) (5/5 microg) fixed-dose combination (FDC) compared to 5 microg &lt;ulink linkType="Drug" linkID="8165"&gt;tiotropium&lt;/ulink&gt; (Spiriva Respimat) (both delivered with the Respimat inhaler) on      moderate to severe chronic obstructive pulmonary disease (COPD) exacerbation in patients with severe to very severe COPD. The secondary objective of the trial was to compare the effect of tiotropium + olodaterol on hospitalization associated with exacerbations and survival [&lt;ulink linkType="Reference" linkID="2018273"&gt;2018273&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2018261"&gt;2018261&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2081598"&gt;2081598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The main objective of the trial was to compare the effect of tiotropium + olodaterol (2.5/2.5 microg) on COPD exacerbations. &lt;/para&gt;&lt;para&gt;Secondary objectives of the trial was to compare the effect of tiotropium + olodaterol on hospitalization associated with exacerbations and survival. &lt;/para&gt;&lt;para&gt;Spirometry substudy: an optional spirometry assessment substudy was conducted to allow better characterization of the air flow limitation. Additional lung function testing procedures would be added to the procedures of the main study for approximately 854 patients at selected sites. Pulmonary function testing would be performed at the screening visit (visit 1) to determine patient eligibility. At visits 2, 3, 4, 5 and 6 pulmonary function testing would be conducted prior to dosing and at selected time intervals up to 3 h post-dosing in the clinic. At visit 6a, additional pulmonaryfunction testing would be conducted up to 23 h 55 min post-dosing in clinic.&lt;/para&gt;&lt;para&gt;By January 2015, first patient was enrolled [&lt;ulink linkType="Reference" linkID="1629009"&gt;1629009&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2018, final results were presented. The study did not meet its primary endpoint. Patients who received Spiolto Respimat lowered the rate of moderate-to-severe exacerbations by 7% compared to Spiriva Respimat but the result was not significant (p = 0.0498) ie, the pre-specified significance level of p &amp;lt; 0.01 was not met. Spiolto Respimat treatment demonstrated fewer moderate-to-severe exacerbations that required a systemic corticosteroid, with or without antibiotics compared to  Spiriva Respimat: a 20% lower rate of moderate-to-severe exacerbations required treatment with a systemic corticosteroid (p = 0.0068); a 9% lower rate of exacerbations required the use of both a systemic corticosteroid and antibiotics (p = 0.0447) and no difference was observed in the rate of exacerbations that required antibiotics treatment only (p = 0.2062) [&lt;ulink linkType="Reference" linkID="2018273"&gt;2018273&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2018261"&gt;2018261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, further  results were presented. The study results also showed Stiolto Respimat significantly reduced COPD symptoms and improved health-related quality of life, as measured by the COPD Assessment Test (CAT), compared to Spiriva Respimat. This trial showed that Stiolto Respimat provides a clinically important benefit compared to Spiriva Respimat   [&lt;ulink linkType="Reference" linkID="2018261"&gt;2018261&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, results were presented. During the treatment period, a 7% reduction in the rate of moderate and severe exacerbations (primary endpoint) was observed with tiotropium/olodaterol when compared with tiotropium (rate ratio (RR) = 0.93; p = 0.0498), which did not meet the predefined two-sided type 1 error rate of 0.01. The effect appeared to be driven by severe exacerbations (RR = 0.89; p = 0.0903 for tiotropium/olodaterol versus tiotropium) and the decreased exacerbations observed with corticosteroids (with or without antibiotics) with tiotropium/olodaterol versus tiotropium [&lt;ulink linkType="Reference" linkID="2035274"&gt;2035274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, further results were presented. At all study visits, the COPD Assessment Test (CAT) score was lower with Stiolto Respimat versus Spiriva Respimat; the largest between-group difference was observed at week 13 (–0.7 units). Stiolto Respimat reduced the risk of CAT deterioration compared to Spiriva Respimat. The hazard ratio for time to first CAT deterioration with Stiolto Respimat versus Spiriva Respimat was 0.89 (p = 0.0002). Overall, a higher proportion of CAT responders were in the Stiolto Respimat arm (44.5%) than in the Spiriva Respimat arm (40.8%). At all time points (week-13, -26, -39 and -52), responder rates were higher with Stiolto Respimat versus Spiriva Respimat (odds ratio of 1.216, 1.200, 1.140 and 1.096, respectively). Responder rates were numerically higher for the medium (10 to 20), high (21 to 30) and very high (31 to 40) CAT score categories with Stiolto Respimat versus Spiriva Respimat (odds ratio of 1.214, 1.069 and 1.427, respectively) [&lt;ulink linkType="Reference" linkID="2035291"&gt;2035291&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, further results were presented. Treatment discontinuation rate was higher in Spiriva Respimat group (n = 650) than in Stiolto Respimat group (n = 488). A higher proportion of patients who discontinued treatment early compared with those who did not receive long-acting muscarinic antagonist/long-acting beta2-agonist/inhaled corticosteroid (ICS) at baseline (50.8 versus 37.9%); had a history of &gt;/= 2 moderate or &gt;/= 1 severe exacerbations (52.5 versus 42.9%); and had GOLD Stage 4 COPD (20.7 versus 11.2%). Stepwise regression analysis identified region (p &amp;lt; 0.0001), screening post-bronchodilator FEV1 % predicted (p &amp;lt; 0.0001), age (p &amp;lt; 0.0001), baseline COPD Assessment Test score (p &amp;lt; 0.0001), number of exacerbations leading to hospitalization in the year prior to randomization (p &amp;lt; 0.0003), sex (p &amp;lt; 0.0078), number of exacerbations treated with steroids and antibiotics in the year prior to randomization (p &amp;lt; 0.0148), and ICS use at baseline (p &amp;lt; 0.0339) as predictors for treatment discontinuation. In primary analysis, the rate ratio of moderate to severe exacerbations was 0.93 (p = 0.0498), which after adjusting for individual covariates such as number of exacerbations in the previous year, hospitalization exacerbation history, eosinophil count and ICS use at baseline was 0.91 (p = 0.0085), 0.94 (p = 0.0726), 0.93 (p = 0.0460) and 0.93 (p = 0.0602), respectively, indicating limited impact on the results. However, adjustment for multiple covariates increased the precision in identifying the effect of Stiolto Respimat, which led to an increased magnitude of effect and resulted in P values within the prespecified range of 0.01 [&lt;ulink linkType="Reference" linkID="2035209"&gt;2035209&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to receive ether tiotropium + olodaterol  high-dose   (5/5 microg) FDC or tiotropium (Spiriva Respimat) (5 microg),  solution for inhalation, qd,  two puffs  through Respimat inhaler, for 52 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  (n = 7880)  were randomized to receive Spiolto Respimat (tiotropium/olodaterol 5/5 microg; n = 3939) or Spiriva Respimat (n = 3941) [&lt;ulink linkType="Reference" linkID="2018273"&gt;2018273&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2035274"&gt;2035274&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2081598"&gt;2081598&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2035291"&gt;2035291&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2035209"&gt;2035209&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Argentina"><Sites><Site><Name>1237.19.54001 Boehringer Ingelheim Investigational Site</Name><Address1>Tucumán</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54002 Boehringer Ingelheim Investigational Site</Name><Address1>San Miguel de Tucuman</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54003 Boehringer Ingelheim Investigational Site</Name><Address1>Capital Federal</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54004 Boehringer Ingelheim Investigational Site</Name><Address1>Capital Federal</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54005 Boehringer Ingelheim Investigational Site</Name><Address1>Mendoza</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54006 Boehringer Ingelheim Investigational Site</Name><Address1>Quilmes</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54007 Boehringer Ingelheim Investigational Site</Name><Address1>Capital Federal</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54008 Boehringer Ingelheim Investigational Site</Name><Address1>Rosario</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54009 Boehringer Ingelheim Investigational Site</Name><Address1>Rosario</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54010 Boehringer Ingelheim Investigational Site</Name><Address1>La Plata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54011 Boehringer Ingelheim Investigational Site</Name><Address1>Ciudad de Buenos Aires</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54012 Boehringer Ingelheim Investigational Site</Name><Address1>Mar del Plata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54013 Boehringer Ingelheim Investigational Site</Name><Address1>Rosario</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54014 Boehringer Ingelheim Investigational Site</Name><Address1>Berazategui</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54015 Boehringer Ingelheim Investigational Site</Name><Address1>Bahía Blanca</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54016 Boehringer Ingelheim Investigational Site</Name><Address1>San Isidro</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54017 Boehringer Ingelheim Investigational Site</Name><Address1>Mar del Plata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54018 Boehringer Ingelheim Investigational Site</Name><Address1>Ciudad de Buenos Aires</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.54019 Boehringer Ingelheim Investigational Site</Name><Address1>Mar del Plata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Austria"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.43001 Boehringer Ingelheim Investigational Site</Name><Address1>Linz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.43002 Boehringer Ingelheim Investigational Site</Name><Address1>Wien</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.43003 Boehringer Ingelheim Investigational Site</Name><Address1>Leoben</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.43004 Boehringer Ingelheim Investigational Site</Name><Address1>Graz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.43005 Boehringer Ingelheim Investigational Site</Name><Address1>Salzburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.43006 Boehringer Ingelheim Investigational Site</Name><Address1>Feldbach</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70001 Boehringer Ingelheim Investigational Site</Name><Address1>Ryazan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Australia"><Sites><Site><Name>1237.19.61001 Boehringer Ingelheim Investigational Site</Name><Address1>Daw Park</Address1><Address2>South Australia</Address2><CountrySubDivision>South Australia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61002 Boehringer Ingelheim Investigational Site</Name><Address1>Glen Osmond</Address1><Address2>South Australia</Address2><CountrySubDivision>South Australia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61003 Boehringer Ingelheim Investigational Site</Name><Address1>Melbourne</Address1><Address2>Victoria</Address2><CountrySubDivision>Victoria</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61004 Boehringer Ingelheim Investigational Site</Name><Address1>Murdoch</Address1><Address2>Western Australia</Address2><CountrySubDivision>Western Australia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61006 Boehringer Ingelheim Investigational Site</Name><Address1>Chermside</Address1><Address2>Queensland</Address2><CountrySubDivision>Queensland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61007 Boehringer Ingelheim Investigational Site</Name><Address1>Woodville</Address1><Address2>South Australia</Address2><CountrySubDivision>South Australia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61008 Boehringer Ingelheim Investigational Site</Name><Address1>Randwick</Address1><Address2>New South Wales</Address2><CountrySubDivision>New South Wales</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61009 Boehringer Ingelheim Investigational Site</Name><Address1>Parkville</Address1><Address2>Victoria</Address2><CountrySubDivision>Victoria</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61010 Boehringer Ingelheim Investigational Site</Name><Address1>Cairns</Address1><Address2>Queensland</Address2><CountrySubDivision>Queensland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61011 Boehringer Ingelheim Investigational Site</Name><Address1>Kogarah</Address1><Address2>New South Wales</Address2><CountrySubDivision>New South Wales</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61012 Boehringer Ingelheim Investigational Site</Name><Address1>Campbelltown</Address1><Address2>New South Wales</Address2><CountrySubDivision>New South Wales</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.61013 Boehringer Ingelheim Investigational Site</Name><Address1>Box Hill</Address1><Address2>Victoria</Address2><CountrySubDivision>Victoria</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.32001 Boehringer Ingelheim Investigational Site</Name><Address1>Brussel</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.32002 Boehringer Ingelheim Investigational Site</Name><Address1>Turnhout</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.32003 Boehringer Ingelheim Investigational Site</Name><Address1>Lebbeke</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.32004 Boehringer Ingelheim Investigational Site</Name><Address1>Jambes</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.32005 Boehringer Ingelheim Investigational Site</Name><Address1>Zichem</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.32006 Boehringer Ingelheim Investigational Site</Name><Address1>Gilly</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.32007 Boehringer Ingelheim Investigational Site</Name><Address1>Brussels</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Bulgaria"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.35901 Boehringer Ingelheim Investigational Site</Name><Address1>Varna</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35902 Boehringer Ingelheim Investigational Site</Name><Address1>Ruse</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35903 Boehringer Ingelheim Investigational Site</Name><Address1>Sofia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35904 Boehringer Ingelheim Investigational Site</Name><Address1>Sofia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35905 Boehringer Ingelheim Investigational Site</Name><Address1>Plovdiv</Address1><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35906 Boehringer Ingelheim Investigational Site</Name><Address1>Sofia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35907 Boehringer Ingelheim Investigational Site</Name><Address1>Troyan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35908 Boehringer Ingelheim Investigational Site</Name><Address1>Vidin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Brazil"><Sites><Site><Name>1237.19.55001 Boehringer Ingelheim Investigational Site</Name><Address1>São Paulo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55002 Boehringer Ingelheim Investigational Site</Name><Address1>Porto Alegre</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55003 Boehringer Ingelheim Investigational Site</Name><Address1>Recife</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55005 Boehringer Ingelheim Investigational Site</Name><Address1>Sao Paulo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55006 Boehringer Ingelheim Investigational Site</Name><Address1>Porto Alegre</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55007 Boehringer Ingelheim Investigational Site</Name><Address1>Belo Horizonte</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55008 Boehringer Ingelheim Investigational Site</Name><Address1>Sao Paulo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55009 Boehringer Ingelheim Investigational Site</Name><Address1>Vitoria</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55010 Boehringer Ingelheim Investigational Site</Name><Address1>Porto Alegre</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55011 Boehringer Ingelheim Investigational Site</Name><Address1>Goiania</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55012 Boehringer Ingelheim Investigational Site</Name><Address1>Porto Alegre</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55013 Boehringer Ingelheim Investigational Site</Name><Address1>Botucatu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55014 Boehringer Ingelheim Investigational Site</Name><Address1>Santo Andre</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.55016 Boehringer Ingelheim Investigational Site</Name><Address1>Porto Alegre</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>1237.19.20002 Boehringer Ingelheim Investigational Site</Name><Address1>Saskatoon</Address1><Address2>Saskatchewan</Address2><CountrySubDivision>Saskatchewan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20003 Boehringer Ingelheim Investigational Site</Name><Address1>Victoriaville</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20004 Boehringer Ingelheim Investigational Site</Name><Address1>Longueuil</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20005 Boehringer Ingelheim Investigational Site</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20006 Boehringer Ingelheim Investigational Site</Name><Address1>Saint John</Address1><Address2>New Brunswick</Address2><CountrySubDivision>New Brunswick</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20007 Boehringer Ingelheim Investigational Site</Name><Address1>Windsor</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20008 Boehringer Ingelheim Investigational Site</Name><Address1>Point Claire</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20009 Boehringer Ingelheim Investigational Site</Name><Address1>Courtice</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20010 Boehringer Ingelheim Investigational Site</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20011 Boehringer Ingelheim Investigational Site</Name><Address1>Calgary</Address1><Address2>Alberta</Address2><CountrySubDivision>Alberta</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20012 Boehringer Ingelheim Investigational Site</Name><Address1>Waterloo</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20013 Boehringer Ingelheim Investigational Site</Name><Address1>St. John¿s</Address1><Address2>Newfoundland and Labrador</Address2><CountrySubDivision>Newfoundland and Labrador</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20014 Boehringer Ingelheim Investigational Site</Name><Address1>Quebec</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20015 Boehringer Ingelheim Investigational Site</Name><Address1>Winnipeg</Address1><Address2>Manitoba</Address2><CountrySubDivision>Manitoba</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20016 Boehringer Ingelheim Investigational Site</Name><Address1>Edmonton</Address1><Address2>Alberta</Address2><CountrySubDivision>Alberta</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20017 Boehringer Ingelheim Investigational Site</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20018 Boehringer Ingelheim Investigational Site</Name><Address1>Burlington</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20019 Boehringer Ingelheim Investigational Site</Name><Address1>Grimsby</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20020 Boehringer Ingelheim Investigational Site</Name><Address1>Calgary</Address1><Address2>Alberta</Address2><CountrySubDivision>Alberta</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20021 Boehringer Ingelheim Investigational Site</Name><Address1>Moncton</Address1><Address2>New Brunswick</Address2><CountrySubDivision>New Brunswick</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20022 Boehringer Ingelheim Investigational Site</Name><Address1>London</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20023 Boehringer Ingelheim Investigational Site</Name><Address1>Ste-Foy</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20025 Boehringer Ingelheim Investigational Site</Name><Address1>Edmonton</Address1><Address2>Alberta</Address2><CountrySubDivision>Alberta</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20026 Boehringer Ingelheim Investigational Site</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20027 Boehringer Ingelheim Investigational Site</Name><Address1>Saskatoon</Address1><Address2>Saskatchewan</Address2><CountrySubDivision>Saskatchewan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20029 Boehringer Ingelheim Investigational Site</Name><Address1>Corunna</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20030 Boehringer Ingelheim Investigational Site</Name><Address1>Sarnia</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20031 Boehringer Ingelheim Investigational Site</Name><Address1>St-Charles-Borromée</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20032 Boehringer Ingelheim Investigational Site</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20033 Boehringer Ingelheim Investigational Site</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20034 Boehringer Ingelheim Investigational Site</Name><Address1>Kelowna</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20035 Boehringer Ingelheim Investigational Site</Name><Address1>Coquitlam</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20036 Boehringer Ingelheim Investigational Site</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20037 Boehringer Ingelheim Investigational Site</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20038 Boehringer Ingelheim Investigational Site</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20039 Boehringer Ingelheim Investigational Site</Name><Address1>Trois-Rivieres</Address1><Address2>Quebec</Address2><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20040 Boehringer Ingelheim Investigational Site</Name><Address1>Ottawa</Address1><Address2>Ontario</Address2><CountrySubDivision>Ontario</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.20041 Boehringer Ingelheim Investigational Site</Name><Address1>Maple Ridge</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Switzerland"><Sites><Site><Name>1237.19.41001 Boehringer Ingelheim Investigational Site</Name><Address1>Liestal</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.41002 Boehringer Ingelheim Investigational Site</Name><Address1>Bern</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.41003 Boehringer Ingelheim Investigational Site</Name><Address1>Lugano</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.41004 Boehringer Ingelheim Investigational Site</Name><Address1>Ascona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Chile"><Sites><Site><Name>1237.19.53002 Boehringer Ingelheim Investigational Site</Name><Address1>Santiago de Chile</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.53003 Boehringer Ingelheim Investigational Site</Name><Address1>San Miguel</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.53004 Boehringer Ingelheim Investigational Site</Name><Address1>Quillota</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Colombia"><Sites><Site><Name>1237.19.57001 Boehringer Ingelheim Investigational Site</Name><Address1>Bogotá</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.57002 Boehringer Ingelheim Investigational Site</Name><Address1>Bogotá</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.57003 Boehringer Ingelheim Investigational Site</Name><Address1>Cali</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.57004 Boehringer Ingelheim Investigational Site</Name><Address1>Bogotá</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.57005 Boehringer Ingelheim Investigational Site</Name><Address1>Bogotá</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.57006 Boehringer Ingelheim Investigational Site</Name><Address1>Medellín</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.42001 Boehringer Ingelheim Investigational Site</Name><Address1>Beroun</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42002 Boehringer Ingelheim Investigational Site</Name><Address1>Jindrichuv Hradec</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42003 Boehringer Ingelheim Investigational Site</Name><Address1>Melnik</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42004 Boehringer Ingelheim Investigational Site</Name><Address1>Hradec Kralove</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42005 Boehringer Ingelheim Investigational Site</Name><Address1>Prague 8</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42006 Boehringer Ingelheim Investigational Site</Name><Address1>Krnov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42007 Boehringer Ingelheim Investigational Site</Name><Address1>Liberec</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42008 Boehringer Ingelheim Investigational Site</Name><Address1>Praha</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42009 Boehringer Ingelheim Investigational Site</Name><Address1>Varnsdorf</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42010 Boehringer Ingelheim Investigational Site</Name><Address1>Cesky Krumlov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.49001 Boehringer Ingelheim Investigational Site</Name><Address1>Großhansdorf</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49002 Boehringer Ingelheim Investigational Site</Name><Address1>Düren</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49003 Boehringer Ingelheim Investigational Site</Name><Address1>Leipzig</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49004 Boehringer Ingelheim Investigational Site</Name><Address1>Aschaffenburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49005 Boehringer Ingelheim Investigational Site</Name><Address1>Koblenz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49006 Boehringer Ingelheim Investigational Site</Name><Address1>München</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49007 Boehringer Ingelheim Investigational Site</Name><Address1>Leipzig</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49008 Boehringer Ingelheim Investigational Site</Name><Address1>Gütersloh</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49009 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49010 Boehringer Ingelheim Investigational Site</Name><Address1>Leverkusen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49011 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49012 Boehringer Ingelheim Investigational Site</Name><Address1>Essen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49013 Boehringer Ingelheim Investigational Site</Name><Address1>München</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49014 Boehringer Ingelheim Investigational Site</Name><Address1>Peine</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49016 Boehringer Ingelheim Investigational Site</Name><Address1>Mannheim</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49017 Boehringer Ingelheim Investigational Site</Name><Address1>Frankfurt</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49018 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49019 Boehringer Ingelheim Investigational Site</Name><Address1>Frankfurt</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49022 Boehringer Ingelheim Investigational Site</Name><Address1>Heidelberg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49023 Boehringer Ingelheim Investigational Site</Name><Address1>Witten</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49024 Boehringer Ingelheim Investigational Site</Name><Address1>Bergisch Gladbach</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49025 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49026 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49028 Boehringer Ingelheim Investigational Site</Name><Address1>Halle/Saale</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49029 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49030 Boehringer Ingelheim Investigational Site</Name><Address1>Leipzig</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49032 Boehringer Ingelheim Investigational Site</Name><Address1>Teuchern</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49034 Boehringer Ingelheim Investigational Site</Name><Address1>Köln</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49035 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49036 Boehringer Ingelheim Investigational Site</Name><Address1>Marburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49037 Boehringer Ingelheim Investigational Site</Name><Address1>Lübeck</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49038 Boehringer Ingelheim Investigational Site</Name><Address1>Hamburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49040 Boehringer Ingelheim Investigational Site</Name><Address1>Wiesloch</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49041 Boehringer Ingelheim Investigational Site</Name><Address1>Ahlen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49042 Boehringer Ingelheim Investigational Site</Name><Address1>Bad Wörishofen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49043 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49044 Boehringer Ingelheim Investigational Site</Name><Address1>Fulda</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49045 Boehringer Ingelheim Investigational Site</Name><Address1>Radebeul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49046 Boehringer Ingelheim Investigational Site</Name><Address1>Mannheim</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49047 Boehringer Ingelheim Investigational Site</Name><Address1>Paderborn</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49048 Boehringer Ingelheim Investigational Site</Name><Address1>Bonn</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49049 Boehringer Ingelheim Investigational Site</Name><Address1>Kiel</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49050 Boehringer Ingelheim Investigational Site</Name><Address1>Solingen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49051 Boehringer Ingelheim Investigational Site</Name><Address1>Wardenburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49052 Boehringer Ingelheim Investigational Site</Name><Address1>Frankfurt</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49053 Boehringer Ingelheim Investigational Site</Name><Address1>Rheine</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49054 Boehringer Ingelheim Investigational Site</Name><Address1>Minden</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49055 Boehringer Ingelheim Investigational Site</Name><Address1>Hannover</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49056 Boehringer Ingelheim Investigational Site</Name><Address1>Höchstädt</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49057 Boehringer Ingelheim Investigational Site</Name><Address1>Fürstenwalde</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49058 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49059 Boehringer Ingelheim Investigational Site</Name><Address1>Augsburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49060 Boehringer Ingelheim Investigational Site</Name><Address1>Rüdersdorf</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49061 Boehringer Ingelheim Investigational Site</Name><Address1>Leipzig</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49062 Boehringer Ingelheim Investigational Site</Name><Address1>Frankfurt</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49063 Boehringer Ingelheim Investigational Site</Name><Address1>Leipzig</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49064 Boehringer Ingelheim Investigational Site</Name><Address1>Bochum</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49065 Boehringer Ingelheim Investigational Site</Name><Address1>Berlin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49067 Boehringer Ingelheim Investigational Site</Name><Address1>Roth</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49070 Boehringer Ingelheim Investigational Site</Name><Address1>Leipzig</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49072 Boehringer Ingelheim Investigational Site</Name><Address1>Bamberg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49073 Boehringer Ingelheim Investigational Site</Name><Address1>Landsberg am Lech</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49074 Boehringer Ingelheim Investigational Site</Name><Address1>Potsdam</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49076 Boehringer Ingelheim Investigational Site</Name><Address1>Bielefeld</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.49077 Boehringer Ingelheim Investigational Site</Name><Address1>Hannover</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Denmark"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.45001 Boehringer Ingelheim Investigational Site</Name><Address1>Odense</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45002 Boehringer Ingelheim Investigational Site</Name><Address1>Hvidovre</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45003 Boehringer Ingelheim Investigational Site</Name><Address1>Vaerløse</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45004 Boehringer Ingelheim Investigational Site</Name><Address1>Ålborg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45005 Boehringer Ingelheim Investigational Site</Name><Address1>Kolding</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45006 Boehringer Ingelheim Investigational Site</Name><Address1>Holstebro</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45007 Boehringer Ingelheim Investigational Site</Name><Address1>Aarhus</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.45008 Boehringer Ingelheim Investigational Site</Name><Address1>Roskilde</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Ecuador"><Sites><Site><Name>1237.19.56001 Boehringer Ingelheim Investigational Site</Name><Address1>Guayas, Guayaquil</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.56002 Boehringer Ingelheim Investigational Site</Name><Address1>Guayaquil</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.56003 Boehringer Ingelheim Investigational Site</Name><Address1>Quito</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.56004 Boehringer Ingelheim Investigational Site</Name><Address1>Quito</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.34001 Boehringer Ingelheim Investigational Site</Name><Address1>Liencres (Pielagos)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34002 Boehringer Ingelheim Investigational Site</Name><Address1>Zaragoza</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34003 Boehringer Ingelheim Investigational Site</Name><Address1>L'Hospitalet Llobregat (BCN)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34004 Boehringer Ingelheim Investigational Site</Name><Address1>Pamplona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34005 Boehringer Ingelheim Investigational Site</Name><Address1>Madrid</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34006 Boehringer Ingelheim Investigational Site</Name><Address1>Valencia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34007 Boehringer Ingelheim Investigational Site</Name><Address1>Cáceres</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34009 Boehringer Ingelheim Investigational Site</Name><Address1>Malaga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34011 Boehringer Ingelheim Investigational Site</Name><Address1>Barakaldo (Bilbao)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34012 Boehringer Ingelheim Investigational Site</Name><Address1>Barcelona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34013 Boehringer Ingelheim Investigational Site</Name><Address1>Palma de Mallorca</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34014 Boehringer Ingelheim Investigational Site</Name><Address1>Sevilla</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34015 Boehringer Ingelheim Investigational Site</Name><Address1>Girona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34017 Boehringer Ingelheim Investigational Site</Name><Address1>Alicante</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34018 Boehringer Ingelheim Investigational Site</Name><Address1>Pozuelo de Alarcón</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34019 Boehringer Ingelheim Investigational Site</Name><Address1>Mérida</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34020 Boehringer Ingelheim Investigational Site</Name><Address1>Madrid</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34021 Boehringer Ingelheim Investigational Site</Name><Address1>Barcelona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34022 Boehringer Ingelheim Investigational Site</Name><Address1>Vilanova i la Geltrú</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34023 Boehringer Ingelheim Investigational Site</Name><Address1>Sabadell</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34024 Boehringer Ingelheim Investigational Site</Name><Address1>Badalona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34025 Boehringer Ingelheim Investigational Site</Name><Address1>Aranjuez</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34026 Boehringer Ingelheim Investigational Site</Name><Address1>Vic</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34027 Boehringer Ingelheim Investigational Site</Name><Address1>Granollers (Barcelona)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34028 Boehringer Ingelheim Investigational Site</Name><Address1>Centelles</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.34029 Boehringer Ingelheim Investigational Site</Name><Address1>Valladolid</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Finland"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.35801 Boehringer Ingelheim Investigational Site</Name><Address1>Turku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35803 Boehringer Ingelheim Investigational Site</Name><Address1>Turku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35804 Boehringer Ingelheim Investigational Site</Name><Address1>Helsinki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35805 Boehringer Ingelheim Investigational Site</Name><Address1>Oulu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>1237.19.33001 Boehringer Ingelheim Investigational Site</Name><Address1>Paris</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33002 Boehringer Ingelheim Investigational Site</Name><Address1>Pessac</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33003 Boehringer Ingelheim Investigational Site</Name><Address1>Montpellier cedex 5</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33005 Boehringer Ingelheim Investigational Site</Name><Address1>Saint Laurent du Var</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33006 Boehringer Ingelheim Investigational Site</Name><Address1>Reims</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33007 Boehringer Ingelheim Investigational Site</Name><Address1>Toulouse cedex 9</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33010 Boehringer Ingelheim Investigational Site</Name><Address1>Vieux Condé</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33012 Boehringer Ingelheim Investigational Site</Name><Address1>Saint-Pierre Cedex - La Réunion</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33013 Boehringer Ingelheim Investigational Site</Name><Address1>Marseille</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33014 Boehringer Ingelheim Investigational Site</Name><Address1>La Tronche</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33016 Boehringer Ingelheim Investigational Site</Name><Address1>Cannes</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33017 Boehringer Ingelheim Investigational Site</Name><Address1>Nice</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33018 Boehringer Ingelheim Investigational Site</Name><Address1>Nîmes cedex 9</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33019 Boehringer Ingelheim Investigational Site</Name><Address1>Nîmes</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33020 Boehringer Ingelheim Investigational Site</Name><Address1>MARSEILLE Cedex 08</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33021 Boehringer Ingelheim Investigational Site</Name><Address1>Rennes Cedex 9</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33022 Boehringer Ingelheim Investigational Site</Name><Address1>Strasbourg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33023 Boehringer Ingelheim Investigational Site</Name><Address1>TOURS Cedex 9</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.33024 Boehringer Ingelheim Investigational Site</Name><Address1>Nantes Cedex 01</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.44001 Boehringer Ingelheim Investigational Site</Name><Address1>Bradford</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.44002 Boehringer Ingelheim Investigational Site</Name><Address1>Chertsey</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.44003 Boehringer Ingelheim Investigational Site</Name><Address1>South Shields</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.44004 Boehringer Ingelheim Investigational Site</Name><Address1>Coventry</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.44006 Boehringer Ingelheim Investigational Site</Name><Address1>Birmingham</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.44007 Boehringer Ingelheim Investigational Site</Name><Address1>Doncaster</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.44008 Boehringer Ingelheim Investigational Site</Name><Address1>Bedford</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Greece"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.30001 Boehringer Ingelheim Investigational Site</Name><Address1>Thessaloniki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30002 Boehringer Ingelheim Investigational Site</Name><Address1>Nafplio</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30003 Boehringer Ingelheim Investigational Site</Name><Address1>Athens</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30004 Boehringer Ingelheim Investigational Site</Name><Address1>Heraklion</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30005 Boehringer Ingelheim Investigational Site</Name><Address1>Serres</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30006 Boehringer Ingelheim Investigational Site</Name><Address1>Thessaloniki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30007 Boehringer Ingelheim Investigational Site</Name><Address1>Athens</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.30008 Boehringer Ingelheim Investigational Site</Name><Address1>Athens</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Guatemala"><Sites><Site><Name>1237.19.50201 Boehringer Ingelheim Investigational Site</Name><Address1>Guatemala</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.50202 Boehringer Ingelheim Investigational Site</Name><Address1>Guatemala</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.50203 Boehringer Ingelheim Investigational Site</Name><Address1>Guatemala</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.50204 Boehringer Ingelheim Investigational Site</Name><Address1>Guatemala</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.50205 Boehringer Ingelheim Investigational Site</Name><Address1>Guatemala</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Hong Kong"><Sites><Site><Name>1237.19.85201 Boehringer Ingelheim Investigational Site</Name><Address1>Hong Kong</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.85202 Boehringer Ingelheim Investigational Site</Name><Address1>Hong Kong</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.85203 Boehringer Ingelheim Investigational Site</Name><Address1>Hong Kong</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Croatia"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.38501 Boehringer Ingelheim Investigational Site</Name><Address1>Rijeka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38502 Boehringer Ingelheim Investigational Site</Name><Address1>Zagreb</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38503 Boehringer Ingelheim Investigational Site</Name><Address1>Zagreb</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>clintriage.rdg@boehringer-ingelheim.com</Email><Name>QRPE PSC CT Information Disclosure</Name><Phone>+18002430127</Phone></Contact></Contacts></Site><Site><Name>1237.19.36001 Boehringer Ingelheim Investigational Site</Name><Address1>Szeged</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36002 Boehringer Ingelheim Investigational Site</Name><Address1>Godollo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36003 Boehringer Ingelheim Investigational Site</Name><Address1>Pecs</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36004 Boehringer Ingelheim Investigational Site</Name><Address1>Pecs</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36005 Boehringer Ingelheim Investigational Site</Name><Address1>Debrecen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36006 Boehringer Ingelheim Investigational Site</Name><Address1>Budapest</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36007 Boehringer Ingelheim Investigational Site</Name><Address1>Nyiregyhaza</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36008 Boehringer Ingelheim Investigational Site</Name><Address1>Edeleny</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36009 Boehringer Ingelheim Investigational Site</Name><Address1>Komarom</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36010 Boehringer Ingelheim Investigational Site</Name><Address1>Szazhalombatta</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36011 Boehringer Ingelheim Investigational Site</Name><Address1>Farkasgyepu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36012 Boehringer Ingelheim Investigational Site</Name><Address1>Budapest</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36013 Boehringer Ingelheim Investigational Site</Name><Address1>Kapuvar</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36014 Boehringer Ingelheim Investigational Site</Name><Address1>Hajdunanas</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.36015 Boehringer Ingelheim Investigational Site</Name><Address1>Debrecen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Ireland"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.35301 Boehringer Ingelheim Investigational Site</Name><Address1>Dublin 24</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35302 Boehringer Ingelheim Investigational Site</Name><Address1>Wilton</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="India"><Sites><Site><Name>Topiwala National Medical College and B. Y. L. Nair Hospital</Name><Address1>Mumbai</Address1><Address2>MAHARASHTRA</Address2><Address3>400008</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>T.B and Chest Hospital</Name><Address1>North Goa</Address1><Address2>GOA</Address2><Address3>403002</Address3><CountrySubDivision>GOA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>1237.19.91001 Boehringer Ingelheim Investigational Site</Name><Address1>Nagpur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91002 Boehringer Ingelheim Investigational Site</Name><Address1>Nagpur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91003 Boehringer Ingelheim Investigational Site</Name><Address1>Nagpur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91004 Boehringer Ingelheim Investigational Site</Name><Address1>Coimbatore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91005 Boehringer Ingelheim Investigational Site</Name><Address1>Hyderabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91006 Boehringer Ingelheim Investigational Site</Name><Address1>Jaipur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91007 Boehringer Ingelheim Investigational Site</Name><Address1>Madurai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91008 Boehringer Ingelheim Investigational Site</Name><Address1>Vellore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91010 Boehringer Ingelheim Investigational Site</Name><Address1>Ludhiana</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91013 Boehringer Ingelheim Investigational Site</Name><Address1>Ahmedabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91014 Boehringer Ingelheim Investigational Site</Name><Address1>Mysore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91016 Boehringer Ingelheim Investigational Site</Name><Address1>Ahmadabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91019 Boehringer Ingelheim Investigational Site</Name><Address1>Hyderabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91020 Boehringer Ingelheim Investigational Site</Name><Address1>Hyderabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91021 Boehringer Ingelheim Investigational Site</Name><Address1>Mysore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91022 Boehringer Ingelheim Investigational Site</Name><Address1>Vijayawada</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91023 Boehringer Ingelheim Investigational Site</Name><Address1>Pune</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91024 Boehringer Ingelheim Investigational Site</Name><Address1>Panjim</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91025 Boehringer Ingelheim Investigational Site</Name><Address1>Hyderabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91026 Boehringer Ingelheim Investigational Site</Name><Address1>Karamsad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91027 Boehringer Ingelheim Investigational Site</Name><Address1>New Delhi</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91028 Boehringer Ingelheim Investigational Site</Name><Address1>Vishakhapatnam</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91032 Boehringer Ingelheim Investigational Site</Name><Address1>Bangalore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91033 Boehringer Ingelheim Investigational Site</Name><Address1>Gurgaon</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91034 Boehringer Ingelheim Investigational Site</Name><Address1>Kolkata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91035 Boehringer Ingelheim Investigational Site</Name><Address1>Pune</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91040 Boehringer Ingelheim Investigational Site</Name><Address1>Ahmedabad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91042 Boehringer Ingelheim Investigational Site</Name><Address1>Jaipur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.91044 Boehringer Ingelheim Investigational Site</Name><Address1>Jaipur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>AMC Medical College &amp; seth L.G. general Hospital</Name><Address1>Ahmadabad</Address1><Address2>GUJARAT</Address2><Address3>380008</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Andhra Hospitals</Name><Address1>Hyderabad</Address1><Address2>ANDHRA PRADESH</Address2><Address3>520002</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Apollo Gleneagles Hospitals</Name><Address1>Kolkata</Address1><Address2>WEST BENGAL</Address2><Address3>700054</Address3><CountrySubDivision>WEST BENGAL</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bala Medical Center and Hospitals</Name><Address1>Coimbatore</Address1><Address2>TAMIL NADU</Address2><Address3>641045</Address3><CountrySubDivision>TAMIL NADU</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bangalore Medical College and Research Institute</Name><Address1>Bangalore</Address1><Address2>KARNATAKA</Address2><Address3>560002</Address3><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>BJ Medical College &amp; Civil Hospital</Name><Address1>Ahmadabad</Address1><Address2>GUJARAT</Address2><Address3>380016</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bowring and Lady Curzon Hospital</Name><Address1>Bangalore</Address1><Address2>KARNATAKA</Address2><Address3>560001</Address3><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Care Institute of Medical Sciences (CIMS) Hospital</Name><Address1>Ahmadabad</Address1><Address2>GUJARAT</Address2><Address3>380060</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Chest Research Foundation</Name><Address1>Pune</Address1><Address2>MAHARASHTRA</Address2><Address3>411014</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Christian Medical College</Name><Address1>Vellore</Address1><Address2>TAMIL NADU</Address2><Address3>632004</Address3><CountrySubDivision>TAMIL NADU</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Dayanand Medical College &amp; Hospital</Name><Address1>Ludhiana</Address1><Address2>PUNJAB</Address2><Address3>141001</Address3><CountrySubDivision>PUNJAB</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Eesha MultiSpeciality Hospital</Name><Address1>Hyderabad</Address1><Address2>ANDHRA PRADESH</Address2><Address3>500082</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Getwell Hospital &amp; Research Institute</Name><Address1>Nagpur</Address1><Address2>MAHARASHTRA</Address2><Address3>440012</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Global Hospitals</Name><Address1>Hyderabad</Address1><Address2>ANDHRA PRADESH</Address2><Address3>500004</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Government Medical college and New Civil Hospital</Name><Address1>Surat</Address1><Address2>GUJARAT</Address2><Address3>395001</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Grant Medical Foundation, Ruby Hall Clinic</Name><Address1>Pune</Address1><Address2>MAHARASHTRA</Address2><Address3>411001</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Institute of Respiratory Disease, S.M.S. Medical college &amp; hospital</Name><Address1>Jaipur</Address1><Address2>RAJASTHAN</Address2><Address3>302016</Address3><CountrySubDivision>RAJASTHAN</CountrySubDivision><Contacts></Contacts></Site><Site><Name>J S S Hospital</Name><Address1>Mysore</Address1><Address2>KARNATAKA</Address2><Address3>570004</Address3><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Kamineni Hospitals Private Limited</Name><Address1>Hyderabad</Address1><Address2>ANDHRA PRADESH</Address2><Address3>500068</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Karnataka Institute of Medical Sciences</Name><Address1>Dharwad</Address1><Address2>KARNATAKA</Address2><Address3>580022</Address3><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>KEM Hospital Research Centre</Name><Address1>Pune</Address1><Address2>MAHARASHTRA</Address2><Address3>411011</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Ketki Research Institute of Medical Sciences (KRIMS) Hospital</Name><Address1>Nagpur</Address1><Address2>MAHARASHTRA</Address2><Address3>440010</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>King George Hospital ,(Andhra Medical Collage)</Name><Address1>Visakhapatnam</Address1><Address2>ANDHRA PRADESH</Address2><Address3>530002</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>M.S. Ramaiah Medical College &amp; Hospita</Name><Address1>Bangalore</Address1><Address2>KARNATAKA</Address2><Address3>560054</Address3><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Marudhar Hospital</Name><Address1>Jaipur</Address1><Address2>RAJASTHAN</Address2><Address3>302012</Address3><CountrySubDivision>RAJASTHAN</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Meenakshi Mission Hospital &amp; Research centre</Name><Address1>Madurai</Address1><Address2>TAMIL NADU</Address2><Address3>625107</Address3><CountrySubDivision>TAMIL NADU</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mysore Medical College and Research Institute</Name><Address1>Mysore</Address1><Address2>KARNATAKA</Address2><Address3>570001</Address3><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Nizams Institute of Medical Sciences</Name><Address1>Hyderabad</Address1><Address2>ANDHRA PRADESH</Address2><Address3>500082</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Paras Hospital</Name><Address1>Gurgaon</Address1><Address2>HARYANA</Address2><Address3>122002</Address3><CountrySubDivision>HARYANA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>S.P Medical College and A.G Hospitals</Name><Address1>Bikaner</Address1><Address2>RAJASTHAN</Address2><Address3>334001</Address3><CountrySubDivision>RAJASTHAN</CountrySubDivision><Contacts></Contacts></Site><Site><Name>S.R. Kalla Memorial Gastro and General Hosptial</Name><Address1>Jaipur</Address1><Address2>RAJASTHAN</Address2><Address3>302001</Address3><CountrySubDivision>RAJASTHAN</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sanjivani Superspeciality Hospital Pvt. Ltd</Name><Address1>Ahmadabad</Address1><Address2>GUJARAT</Address2><Address3>380015</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Seth G S Medical College and King Edward Memorial Hospital</Name><Address1>Mumbai</Address1><Address2>MAHARASHTRA</Address2><Address3>400012</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sheth Vadilal Sarabhai Genral Hospital, Smt N H L Municipal Medical College</Name><Address1>Ahmadabad</Address1><Address2>GUJARAT</Address2><Address3>380006</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Shree Krishna Hospital and Medical Research Centre</Name><Address1>Karamsad</Address1><Address2>GUJARAT</Address2><Address3>388325</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Shreekrishna Hrudaya &amp; critical care Centre Ltd</Name><Address1>Nagpur</Address1><Address2>MAHARASHTRA</Address2><Address3>440012</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sir Gangaram Hospital</Name><Address1>New Delhi</Address1><Address2>DELHI</Address2><Address3>110060</Address3><CountrySubDivision>DELHI</CountrySubDivision><Contacts></Contacts></Site><Site><Name>SMS Medical College and Hospital</Name><Address1>Jaipur</Address1><Address2>RAJASTHAN</Address2><Address3>302004</Address3><CountrySubDivision>RAJASTHAN</CountrySubDivision><Contacts></Contacts></Site><Site><Name>SRM Medical College Hospital and Research Centre</Name><Address1>Kancheepuram</Address1><Address2>TAMIL NADU</Address2><Address3>603203</Address3><CountrySubDivision>TAMIL NADU</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Theresas General Hospital</Name><Address1>Hyderabad</Address1><Address2>ANDHRA PRADESH</Address2><Address3>500018</Address3><CountrySubDivision>ANDHRA PRADESH</CountrySubDivision><Contacts></Contacts></Site><Site><Name>T.B and Chest Hospital</Name><Address1>Panjim</Address1><Address2>GOA</Address2><Address3>403002</Address3><CountrySubDivision>GOA</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Topiwala National Medical College and B. Y. L. Nair Hospital</Name><Address1>Mumbai</Address1><Address2>MAHARASHTRA</Address2><Address3>400008</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.39001 Boehringer Ingelheim Investigational Site</Name><Address1>Pisa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39002 Boehringer Ingelheim Investigational Site</Name><Address1>Milano</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39003 Boehringer Ingelheim Investigational Site</Name><Address1>Roma</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39004 Boehringer Ingelheim Investigational Site</Name><Address1>Roma</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39005 Boehringer Ingelheim Investigational Site</Name><Address1>Pavia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39006 Boehringer Ingelheim Investigational Site</Name><Address1>Parma</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39007 Boehringer Ingelheim Investigational Site</Name><Address1>Perugia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39008 Boehringer Ingelheim Investigational Site</Name><Address1>Piacenza</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39010 Boehringer Ingelheim Investigational Site</Name><Address1>Messina</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39011 Boehringer Ingelheim Investigational Site</Name><Address1>Cittadella (PD)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39012 Boehringer Ingelheim Investigational Site</Name><Address1>Roma</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39013 Boehringer Ingelheim Investigational Site</Name><Address1>Pordenone</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39014 Boehringer Ingelheim Investigational Site</Name><Address1>Ferrara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39015 Boehringer Ingelheim Investigational Site</Name><Address1>Monza</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39016 Boehringer Ingelheim Investigational Site</Name><Address1>Milano</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39017 Boehringer Ingelheim Investigational Site</Name><Address1>Sassari</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39018 Boehringer Ingelheim Investigational Site</Name><Address1>Isernia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39019 Boehringer Ingelheim Investigational Site</Name><Address1>Scafati (SA)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39020 Boehringer Ingelheim Investigational Site</Name><Address1>Pisa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39021 Boehringer Ingelheim Investigational Site</Name><Address1>San Pietro Vernotico (BR)</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39022 Boehringer Ingelheim Investigational Site</Name><Address1>Treviso</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39023 Boehringer Ingelheim Investigational Site</Name><Address1>Milano</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39024 Boehringer Ingelheim Investigational Site</Name><Address1>Palermo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.39025 Boehringer Ingelheim Investigational Site</Name><Address1>Padova</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Japan"><Sites><Site><Name>1237.19.81001 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81002 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81003 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Tomakomai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81004 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81005 Boehringer Ingelheim Investigational Site</Name><Address1>Miyagi, Sendai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81006 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81007 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Chitose</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81008 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81009 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Obihiro</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81010 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Asahikawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81011 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81012 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Hakodate</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81013 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Hakodate</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81014 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81015 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Obihiro</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81016 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Otaru</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81017 Boehringer Ingelheim Investigational Site</Name><Address1>Hokkaido, Sapporo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81018 Boehringer Ingelheim Investigational Site</Name><Address1>Iwate, Morioka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81019 Boehringer Ingelheim Investigational Site</Name><Address1>Miyagi, Sendai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81020 Boehringer Ingelheim Investigational Site</Name><Address1>Miyagi, Sendai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81021 Boehringer Ingelheim Investigational Site</Name><Address1>Yamagata, Yonezawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81022 Boehringer Ingelheim Investigational Site</Name><Address1>Fukushima, Fukushima</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81023 Boehringer Ingelheim Investigational Site</Name><Address1>Ibaraki, Naka-gun</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81024 Boehringer Ingelheim Investigational Site</Name><Address1>Ibaraki, Hitachinaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81025 Boehringer Ingelheim Investigational Site</Name><Address1>Gunma, Fujioka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81026 Boehringer Ingelheim Investigational Site</Name><Address1>Gunma, Takasaki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81027 Boehringer Ingelheim Investigational Site</Name><Address1>Gunma, Maebashi</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81028 Boehringer Ingelheim Investigational Site</Name><Address1>Saitama, Koshigaya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81029 Boehringer Ingelheim Investigational Site</Name><Address1>Saitama, Saitama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81030 Boehringer Ingelheim Investigational Site</Name><Address1>Chiba, Chiba</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81031 Boehringer Ingelheim Investigational Site</Name><Address1>Chiba, Kamogawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81032 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Minato-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81033 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Shinjuku-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81034 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Meguro-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81035 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Itabashi-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81036 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Chuo-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81037 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Bunkyo-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81038 Boehringer Ingelheim Investigational Site</Name><Address1>Miyagi, Sendai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81039 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Hachioji</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81040 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Chuo-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81041 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Shinjuku-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81042 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Shinjuku-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81043 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Itabashi-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81044 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Tachikawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81045 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Sumida-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81046 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Koto-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81047 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Shinagawa-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81048 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Toshima-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81049 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Yokohama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81050 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Isehara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81051 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Yokohama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81052 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Kawasaki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81053 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Kawasaki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81054 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Sagamihara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81055 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Kawasaki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81056 Boehringer Ingelheim Investigational Site</Name><Address1>Kanagawa, Sagamihara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81057 Boehringer Ingelheim Investigational Site</Name><Address1>Niigata, Niigata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81058 Boehringer Ingelheim Investigational Site</Name><Address1>Niigata, Niigata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81059 Boehringer Ingelheim Investigational Site</Name><Address1>Niigata, Niigata</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81060 Boehringer Ingelheim Investigational Site</Name><Address1>Ishikawa, Kanazawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81061 Boehringer Ingelheim Investigational Site</Name><Address1>Fukui, Fukui</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81062 Boehringer Ingelheim Investigational Site</Name><Address1>Yamanashi, Kofu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81063 Boehringer Ingelheim Investigational Site</Name><Address1>Nagano, Matumoto</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81064 Boehringer Ingelheim Investigational Site</Name><Address1>Nagano, Matsumoto</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81065 Boehringer Ingelheim Investigational Site</Name><Address1>Gifu, Ogaki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81066 Boehringer Ingelheim Investigational Site</Name><Address1>Gifu, Mizunami</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81067 Boehringer Ingelheim Investigational Site</Name><Address1>Shizuoka, Hamamatsu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81068 Boehringer Ingelheim Investigational Site</Name><Address1>Shizuoka, Shizuoka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81069 Boehringer Ingelheim Investigational Site</Name><Address1>Aichi, Seto</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81070 Boehringer Ingelheim Investigational Site</Name><Address1>Aichi, Nagoya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81071 Boehringer Ingelheim Investigational Site</Name><Address1>Aichi, Obu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81072 Boehringer Ingelheim Investigational Site</Name><Address1>Aichi, Komaki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81073 Boehringer Ingelheim Investigational Site</Name><Address1>Aichi, Nagoya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81074 Boehringer Ingelheim Investigational Site</Name><Address1>Aichi, Nagoya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81075 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo, Chiyoda-ku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81076 Boehringer Ingelheim Investigational Site</Name><Address1>Mie, Matsusaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81077 Boehringer Ingelheim Investigational Site</Name><Address1>Kyoto, Kyoto</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81078 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Osakasayama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81079 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Osaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81080 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Osaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81081 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Takatsuki</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81082 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Kishiwada</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81083 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Sakai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81084 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Osakasayama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81085 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Toyonaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81086 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Osaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81087 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Yao</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81088 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Osaka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81089 Boehringer Ingelheim Investigational Site</Name><Address1>Osaka, Ikeda</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81090 Boehringer Ingelheim Investigational Site</Name><Address1>Hyogo, Himeji</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81091 Boehringer Ingelheim Investigational Site</Name><Address1>Hyogo, Kobe</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81092 Boehringer Ingelheim Investigational Site</Name><Address1>Hyogo, Nishinomiya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81093 Boehringer Ingelheim Investigational Site</Name><Address1>Hyogo, Himeji</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81094 Boehringer Ingelheim Investigational Site</Name><Address1>Hyogo, Kobe-city</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81095 Boehringer Ingelheim Investigational Site</Name><Address1>Nara, Ikoma</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81096 Boehringer Ingelheim Investigational Site</Name><Address1>Wakayama, Wakayama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81097 Boehringer Ingelheim Investigational Site</Name><Address1>Wakayama, Hidaka-gun</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81098 Boehringer Ingelheim Investigational Site</Name><Address1>Shimane, Izumo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81099 Boehringer Ingelheim Investigational Site</Name><Address1>Shimane, Izumo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81100 Boehringer Ingelheim Investigational Site</Name><Address1>Okayama, Okayama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81101 Boehringer Ingelheim Investigational Site</Name><Address1>Hiroshima, Fukuyama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81102 Boehringer Ingelheim Investigational Site</Name><Address1>Hiroshima, Kure</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81103 Boehringer Ingelheim Investigational Site</Name><Address1>Hiroshima, Kure</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81104 Boehringer Ingelheim Investigational Site</Name><Address1>Hiroshima, Hiroshima</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81105 Boehringer Ingelheim Investigational Site</Name><Address1>Yamaguchi, Ube</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81106 Boehringer Ingelheim Investigational Site</Name><Address1>Yamaguchi, Iwakuni</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81107 Boehringer Ingelheim Investigational Site</Name><Address1>Kagawa, Takamatsu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81108 Boehringer Ingelheim Investigational Site</Name><Address1>Kagawa, Sakaide</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81109 Boehringer Ingelheim Investigational Site</Name><Address1>Kagawa, Takamatsu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81110 Boehringer Ingelheim Investigational Site</Name><Address1>Kochi, Kochi</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81111 Boehringer Ingelheim Investigational Site</Name><Address1>Fukuoka, Kurume</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81112 Boehringer Ingelheim Investigational Site</Name><Address1>Fukuoka, Kitakyushu-city</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81113 Boehringer Ingelheim Investigational Site</Name><Address1>Fukuoka, Koga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81114 Boehringer Ingelheim Investigational Site</Name><Address1>Fukuoka, Yanagawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81115 Boehringer Ingelheim Investigational Site</Name><Address1>Fukuoka, Yukuhashi</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81116 Boehringer Ingelheim Investigational Site</Name><Address1>Fukuoka, Fukuoka</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81117 Boehringer Ingelheim Investigational Site</Name><Address1>Nagasaki, Isahaya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81118 Boehringer Ingelheim Investigational Site</Name><Address1>Kagoshima, Kagoshima</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81119 Boehringer Ingelheim Investigational Site</Name><Address1>Okinawa, Urasoe</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81120 Boehringer Ingelheim Investigational Site</Name><Address1>Okinawa, Uruma</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81121 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81122 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo,</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81123 Boehringer Ingelheim Investigational Site</Name><Address1>Tochigi</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81124 Boehringer Ingelheim Investigational Site</Name><Address1>Yamagata,</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81125 Boehringer Ingelheim Investigational Site</Name><Address1>Okayama</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81126 Boehringer Ingelheim Investigational Site</Name><Address1>Tokyo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81127 Boehringer Ingelheim Investigational Site</Name><Address1>Mie</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81128 Boehringer Ingelheim Investigational Site</Name><Address1>Shiga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81129 Boehringer Ingelheim Investigational Site</Name><Address1>Ibaraki, Inashiki-gun</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.81130 Boehringer Ingelheim Investigational Site</Name><Address1>Kochi, Nankoku</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="South Korea"><Sites><Site><Name>1237.19.82001 Boehringer Ingelheim Investigational Site</Name><Address1>Seoul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82002 Boehringer Ingelheim Investigational Site</Name><Address1>Seoul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82003 Boehringer Ingelheim Investigational Site</Name><Address1>Wonju</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82004 Boehringer Ingelheim Investigational Site</Name><Address1>Bucheon</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82005 Boehringer Ingelheim Investigational Site</Name><Address1>Seoul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82006 Boehringer Ingelheim Investigational Site</Name><Address1>Gwangju</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82007 Boehringer Ingelheim Investigational Site</Name><Address1>Seoul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82008 Boehringer Ingelheim Investigational Site</Name><Address1>Seoul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82009 Boehringer Ingelheim Investigational Site</Name><Address1>Goyang</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.82010 Boehringer Ingelheim Investigational Site</Name><Address1>Seoul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Lithuania"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.37001 Boehringer Ingelheim Investigational Site</Name><Address1>Vilnius</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37002 Boehringer Ingelheim Investigational Site</Name><Address1>Kaunas</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37003 Boehringer Ingelheim Investigational Site</Name><Address1>Klaipeda</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37004 Boehringer Ingelheim Investigational Site</Name><Address1>Klaipeda</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Latvia"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.37101 Boehringer Ingelheim Investigational Site</Name><Address1>Riga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37102 Boehringer Ingelheim Investigational Site</Name><Address1>Valmiera</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37103 Boehringer Ingelheim Investigational Site</Name><Address1>Daugavpils</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37104 Boehringer Ingelheim Investigational Site</Name><Address1>Tukums</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37105 Boehringer Ingelheim Investigational Site</Name><Address1>Riga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.37106 Boehringer Ingelheim Investigational Site</Name><Address1>Riga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Mexico"><Sites><Site><Name>Center for Prevention and Rehabilitation of Chronic Lung Diseases (CEPREP)</Name><Address1>Monterrey</Address1><Address2>Nuevo Leon</Address2><CountrySubDivision>Nuevo Leon</CountrySubDivision><Contacts></Contacts></Site><Site><Name>1237.19.52001 Boehringer Ingelheim Investigational Site</Name><Address1>Monterrey</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.52002 Boehringer Ingelheim Investigational Site</Name><Address1>Zapopan</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.52003 Boehringer Ingelheim Investigational Site</Name><Address1>México</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.52004 Boehringer Ingelheim Investigational Site</Name><Address1>Tijuana</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.52005 Boehringer Ingelheim Investigational Site</Name><Address1>León</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.52006 Boehringer Ingelheim Investigational Site</Name><Address1>Aguascalientes</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.52007 Boehringer Ingelheim Investigational Site</Name><Address1>Guadalajara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Malaysia"><Sites><Site><Contacts></Contacts></Site><Site><Name>1237.19.60001 Boehringer Ingelheim Investigational Site</Name><Address1>Kuching</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.60002 Boehringer Ingelheim Investigational Site</Name><Address1>Kuala Lumpur</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.60004 Boehringer Ingelheim Investigational Site</Name><Address1>Kuala Terengganu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.60006 Boehringer Ingelheim Investigational Site</Name><Address1>Kota Bahru</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.31001 Boehringer Ingelheim Investigational Site</Name><Address1>Breda</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31002 Boehringer Ingelheim Investigational Site</Name><Address1>Eindhoven</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31003 Boehringer Ingelheim Investigational Site</Name><Address1>EDE</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31004 Boehringer Ingelheim Investigational Site</Name><Address1>Zutphen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31005 Boehringer Ingelheim Investigational Site</Name><Address1>Groningen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31006 Boehringer Ingelheim Investigational Site</Name><Address1>Veldhoven</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31007 Boehringer Ingelheim Investigational Site</Name><Address1>Sittard - Geleen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31008 Boehringer Ingelheim Investigational Site</Name><Address1>Rotterdam</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31010 Boehringer Ingelheim Investigational Site</Name><Address1>Harderwijk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31011 Boehringer Ingelheim Investigational Site</Name><Address1>Amsterdam</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31012 Boehringer Ingelheim Investigational Site</Name><Address1>Hoofddorp</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31013 Boehringer Ingelheim Investigational Site</Name><Address1>Hoorn</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31014 Boehringer Ingelheim Investigational Site</Name><Address1>Assen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31015 Boehringer Ingelheim Investigational Site</Name><Address1>Almelo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31016 Boehringer Ingelheim Investigational Site</Name><Address1>Leiden</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31017 Boehringer Ingelheim Investigational Site</Name><Address1>Alkmaar</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.31018 Boehringer Ingelheim Investigational Site</Name><Address1>Leeuwarden</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Norway"><Sites><Site><Name>1237.19.47001 Boehringer Ingelheim Investigational Site</Name><Address1>Hønefoss</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47002 Boehringer Ingelheim Investigational Site</Name><Address1>Arendal</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47003 Boehringer Ingelheim Investigational Site</Name><Address1>Tananger</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47004 Boehringer Ingelheim Investigational Site</Name><Address1>Oslo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47005 Boehringer Ingelheim Investigational Site</Name><Address1>Skedsmokorset</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47006 Boehringer Ingelheim Investigational Site</Name><Address1>Kløfta</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47007 Boehringer Ingelheim Investigational Site</Name><Address1>Lierskogen</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.47008 Boehringer Ingelheim Investigational Site</Name><Address1>Hamar</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="New Zealand"><Sites><Site><Name>1237.19.64001 Boehringer Ingelheim Investigational Site</Name><Address1>Greenlane East Auckland NZ</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64002 Boehringer Ingelheim Investigational Site</Name><Address1>Christchurch</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64003 Boehringer Ingelheim Investigational Site</Name><Address1>Auckland, New Zealand</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64004 Boehringer Ingelheim Investigational Site</Name><Address1>Christchurch Central</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64005 Boehringer Ingelheim Investigational Site</Name><Address1>Hamilton</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64007 Boehringer Ingelheim Investigational Site</Name><Address1>Dunedin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64008 Boehringer Ingelheim Investigational Site</Name><Address1>Dunedin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.64009 Boehringer Ingelheim Investigational Site</Name><Address1>Tauranga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Philippines"><Sites><Site><Name>1237.19.63001 Boehringer Ingelheim Investigational Site</Name><Address1>Cebu City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.63002 Boehringer Ingelheim Investigational Site</Name><Address1>Quezon City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.63003 Boehringer Ingelheim Investigational Site</Name><Address1>Dasmarinas</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.63005 Boehringer Ingelheim Investigational Site</Name><Address1>Manila</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.63006 Boehringer Ingelheim Investigational Site</Name><Address1>Iloilo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.63007 Boehringer Ingelheim Investigational Site</Name><Address1>Angeles City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.63008 Boehringer Ingelheim Investigational Site</Name><Address1>Davao City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.48001 Boehringer Ingelheim Investigational Site</Name><Address1>Katowice</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48002 Boehringer Ingelheim Investigational Site</Name><Address1>Poznan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48003 Boehringer Ingelheim Investigational Site</Name><Address1>Wolomin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48004 Boehringer Ingelheim Investigational Site</Name><Address1>Poznan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48005 Boehringer Ingelheim Investigational Site</Name><Address1>Krakow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48006 Boehringer Ingelheim Investigational Site</Name><Address1>Lodz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48007 Boehringer Ingelheim Investigational Site</Name><Address1>Krakow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48008 Boehringer Ingelheim Investigational Site</Name><Address1>Lodz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48009 Boehringer Ingelheim Investigational Site</Name><Address1>Bialystok</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48010 Boehringer Ingelheim Investigational Site</Name><Address1>Bydgoszcz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48011 Boehringer Ingelheim Investigational Site</Name><Address1>Olsztyn</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48012 Boehringer Ingelheim Investigational Site</Name><Address1>Zgierz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48013 Boehringer Ingelheim Investigational Site</Name><Address1>Ostow Wielkopolski</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48014 Boehringer Ingelheim Investigational Site</Name><Address1>Poznan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48015 Boehringer Ingelheim Investigational Site</Name><Address1>Libiaz</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48016 Boehringer Ingelheim Investigational Site</Name><Address1>Skierniewice</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48017 Boehringer Ingelheim Investigational Site</Name><Address1>Szczecin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48018 Boehringer Ingelheim Investigational Site</Name><Address1>Zawadzkie</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48019 Boehringer Ingelheim Investigational Site</Name><Address1>Ostroda</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48020 Boehringer Ingelheim Investigational Site</Name><Address1>Piaseczno</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48021 Boehringer Ingelheim Investigational Site</Name><Address1>Swidnik</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48022 Boehringer Ingelheim Investigational Site</Name><Address1>Warszawa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48023 Boehringer Ingelheim Investigational Site</Name><Address1>Wroclaw</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48024 Boehringer Ingelheim Investigational Site</Name><Address1>Kielce</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48025 Boehringer Ingelheim Investigational Site</Name><Address1>Lublin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48026 Boehringer Ingelheim Investigational Site</Name><Address1>Bialystok</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48029 Boehringer Ingelheim Investigational Site</Name><Address1>Chojnice</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48030 Boehringer Ingelheim Investigational Site</Name><Address1>Tarnobrzeg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.48031 Boehringer Ingelheim Investigational Site</Name><Address1>Bialystok</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Portugal"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE pSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.35001 Boehringer Ingelheim Investigational Site</Name><Address1>Coimbra</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35002 Boehringer Ingelheim Investigational Site</Name><Address1>Lisboa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35003 Boehringer Ingelheim Investigational Site</Name><Address1>Porto</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35004 Boehringer Ingelheim Investigational Site</Name><Address1>Lisboa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35005 Boehringer Ingelheim Investigational Site</Name><Address1>Amadora</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35006 Boehringer Ingelheim Investigational Site</Name><Address1>Vila Nova de Gaia</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35008 Boehringer Ingelheim Investigational Site</Name><Address1>Aveiro</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35009 Boehringer Ingelheim Investigational Site</Name><Address1>Braga</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35010 Boehringer Ingelheim Investigational Site</Name><Address1>Almada</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.35012 Boehringer Ingelheim Investigational Site</Name><Address1>Guimarães</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Romania"><Sites><Site><Name>1237.19.40002 Boehringer Ingelheim Investigational Site</Name><Address1>Constanta</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.40003 Boehringer Ingelheim Investigational Site</Name><Address1>Bucharest</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.40004 Boehringer Ingelheim Investigational Site</Name><Address1>Bucharest</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.40005 Boehringer Ingelheim Investigational Site</Name><Address1>Bucharest</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.40006 Boehringer Ingelheim Investigational Site</Name><Address1>Timisoara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.40007 Boehringer Ingelheim Investigational Site</Name><Address1>Bragadiru</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.40008 Boehringer Ingelheim Investigational Site</Name><Address1>Bucharest</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Serbia"><Sites><Site><Name>1237.19.38101 Boehringer Ingelheim Investigational Site</Name><Address1>Belgrade</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38102 Boehringer Ingelheim Investigational Site</Name><Address1>Belgrade</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38103 Boehringer Ingelheim Investigational Site</Name><Address1>Sremska Kamenica</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38104 Boehringer Ingelheim Investigational Site</Name><Address1>Kragujevac</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38105 Boehringer Ingelheim Investigational Site</Name><Address1>Belgrade</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38106 Boehringer Ingelheim Investigational Site</Name><Address1>Sombor</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38107 Boehringer Ingelheim Investigational Site</Name><Address1>Belgrade</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38108 Boehringer Ingelheim Investigational Site</Name><Address1>Nis</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Name>Federal State Institution "Polyclinic № 5" Administration of the President of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Federal State Institution "Polyclinic № 3" Office of the President of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Limited Liability Company "Alliance-Russian Biomedical Group"</Name><Contacts></Contacts></Site><Site><Name>St. Petersburg State Institution of Health «City Consultative and Diagnostic Centre №1</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Additional Professional Education "Russian Medical Academy of Postgraduate Education" of the Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Health Care Institution "Regional Hospital"</Name><Contacts></Contacts></Site><Site><Name>Affordable Health Care Institution of Omsk region "City Clinical Hospital № 1 named Kabanov AN"</Name><Contacts></Contacts></Site><Site><Name>Public health agency Ulyanovsk Regional Hospital</Name><Contacts></Contacts></Site><Site><Name>Public health agency "Pskov regional hospital"</Name><Contacts></Contacts></Site><Site><Name>Public health agency of the Yaroslavl Region Hospital ambulance behalf NV Solovyov</Name><Contacts></Contacts></Site><Site><Name>State Institution of Health in Moscow City Clinical Hospital №11 Moscow Health Department</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Saratov State Medical University named after VI Razumovsky "of the Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Saratov State Medical University named after VI Razumovsky "of the Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Federal State Institution "Scientific Research Institute of Pulmonology" Federal Medical-Biological Agency</Name><Contacts></Contacts></Site><Site><Name>St. Petersburg State Institution of Health City hospital № 26</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Novosibirsk State Medical University" Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Siberian State Medical University" Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Kazan State Medical University" Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Regional state budgetary institution Health "City Hospital № 5, Barnaul"</Name><Contacts></Contacts></Site><Site><Name>St. Petersburg State Health Care Institution "City Hospital № 2"</Name><Contacts></Contacts></Site><Site><Name>Limited Liability Company "Medical Association" New Hospital "</Name><Contacts></Contacts></Site><Site><Name>Autonomous regional state health care institution "Tomsk Regional Clinical Hospital"</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Kemerovo State Medical Academy" of the Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "The first St. Petersburg State Medical University named after Academician IP Pavlova "of the Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Municipal Health City Clinical Hospital № 4</Name><Contacts></Contacts></Site><Site><Name>State Institution of Health of the Novosibirsk region "Novosibirsk State Regional Hospital"</Name><Contacts></Contacts></Site><Site><Name>Federal State Institution "Research Institute of complex problems of cardiovascular disease", Siberian Branch of the Russian Academy of Medical Sciences</Name><Contacts></Contacts></Site><Site><Name>State Institution of Rostov region "Rostov Regional Hospital"</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Kirov State Medical Academy" of the Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Ryazan State Medical University named after Academician Pavlov," the Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Federal State Educational Institution of Higher Professional Education "Penza State University"</Name><Contacts></Contacts></Site><Site><Name>St. Petersburg State Institution of Health «City clinic number 25 Nevsky district"</Name><Contacts></Contacts></Site><Site><Name>Federal State Institution "North Medical Clinical Center. NASemashko Federal Medical-Biological Agency"</Name><Contacts></Contacts></Site><Site><Name>Municipal budgetary institutions of public health "Gatchinskaya Central Regional Hospital"</Name><Contacts></Contacts></Site><Site><Name>State Institution of Health of the Leningrad Region "Lomonosov Interdistrict Hospital. IN Yudchenko "</Name><Contacts></Contacts></Site><Site><Name>St. Petersburg public health agency "Polyclinic number 94 Nevsky district"</Name><Contacts></Contacts></Site><Site><Name>Limited Liability Company "REAVITA"</Name><Contacts></Contacts></Site><Site><Name>Regional state budgetary institution Health "Regional Clinical Hospital"</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education First Moscow State Medical University named after IM Sechenov Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Limited Liability Company "Institute for Medical Research"</Name><Contacts></Contacts></Site><Site><Name>Limited Liability Company "Institute for Medical Research"</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "The first St. Petersburg State Medical University named after Academician IP Pavlova "of the Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>St. Petersburg State Health Care Institution "consultative and diagnostic center number 85"</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Volgograd State Medical University" Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education First Moscow State Medical University named after IM Sechenov Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Novosibirsk State Medical University" Ministry of Health and Social Development of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>State Educational Institution of Higher Professional Education "Ural State Medical University" Ministry of Health of the Russian Federation</Name><Contacts></Contacts></Site><Site><Name>Autonomous Nonprofit Organization "Polyclinic Petersburg metro"</Name><Contacts></Contacts></Site><Site><Name>Regional Budget Institution of Health «Ivanovo Hospital name Kuvaeva"</Name><Contacts></Contacts></Site><Site><Name>1237.19.70002 Boehringer Ingelheim Investigational Site</Name><Address1>Moscow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70003 Boehringer Ingelheim Investigational Site</Name><Address1>Moscow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70004 Boehringer Ingelheim Investigational Site</Name><Address1>Arkhangelsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70005 Boehringer Ingelheim Investigational Site</Name><Address1>Saratov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70006 Boehringer Ingelheim Investigational Site</Name><Address1>Kemerovo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70007 Boehringer Ingelheim Investigational Site</Name><Address1>Lomonosov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70008 Boehringer Ingelheim Investigational Site</Name><Address1>Tomsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70009 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70010 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70011 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70012 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70014 Boehringer Ingelheim Investigational Site</Name><Address1>Gatchina</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70015 Boehringer Ingelheim Investigational Site</Name><Address1>Rostov-na-Donu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70017 Boehringer Ingelheim Investigational Site</Name><Address1>Chelyabinsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70018 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70019 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70020 Boehringer Ingelheim Investigational Site</Name><Address1>Ekaterinburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70021 Boehringer Ingelheim Investigational Site</Name><Address1>Pskov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70022 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70023 Boehringer Ingelheim Investigational Site</Name><Address1>Kemerovo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70024 Boehringer Ingelheim Investigational Site</Name><Address1>Novosibirsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70025 Boehringer Ingelheim Investigational Site</Name><Address1>Novosibirsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70026 Boehringer Ingelheim Investigational Site</Name><Address1>Tomsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70028 Boehringer Ingelheim Investigational Site</Name><Address1>Barnaul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70030 Boehringer Ingelheim Investigational Site</Name><Address1>Volgograd</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70031 Boehringer Ingelheim Investigational Site</Name><Address1>Kirov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70032 Boehringer Ingelheim Investigational Site</Name><Address1>Moscow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70033 Boehringer Ingelheim Investigational Site</Name><Address1>Penza</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70034 Boehringer Ingelheim Investigational Site</Name><Address1>Novosibirsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70035 Boehringer Ingelheim Investigational Site</Name><Address1>Omsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70036 Boehringer Ingelheim Investigational Site</Name><Address1>Yaroslavl</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70037 Boehringer Ingelheim Investigational Site</Name><Address1>Ulyanovsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70038 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70040 Boehringer Ingelheim Investigational Site</Name><Address1>Saratov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70041 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70042 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70044 Boehringer Ingelheim Investigational Site</Name><Address1>Saratov</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70046 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70047 Boehringer Ingelheim Investigational Site</Name><Address1>Moscow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70048 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70049 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70050 Boehringer Ingelheim Investigational Site</Name><Address1>Kazan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70051 Boehringer Ingelheim Investigational Site</Name><Address1>Ivanovo</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.70052 Boehringer Ingelheim Investigational Site</Name><Address1>Rosto-on-Don</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.46001 Boehringer Ingelheim Investigational Site</Name><Address1>Lund</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.46002 Boehringer Ingelheim Investigational Site</Name><Address1>Göteborg</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.46004 Boehringer Ingelheim Investigational Site</Name><Address1>Höllviken</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.46005 Boehringer Ingelheim Investigational Site</Name><Address1>Rättvik</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.46007 Boehringer Ingelheim Investigational Site</Name><Address1>Stockholm</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.46008 Boehringer Ingelheim Investigational Site</Name><Address1>Härnösand</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Singapore"><Sites><Site><Name>Changi General Hospital</Name><Contacts></Contacts></Site><Site><Name>1237.19.65001 Boehringer Ingelheim Investigational Site</Name><Address1>Singapore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.65002 Boehringer Ingelheim Investigational Site</Name><Address1>Singapore</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Slovenia"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.38601 Boehringer Ingelheim Investigational Site</Name><Address1>Golnik</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38602 Boehringer Ingelheim Investigational Site</Name><Address1>Topolsica</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38603 Boehringer Ingelheim Investigational Site</Name><Address1>Pohorje</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Slovakia"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>QRPE PSC CT Information Disclosure</Name></Contact></Contacts></Site><Site><Name>1237.19.42101 Boehringer Ingelheim Investigational Site</Name><Address1>Bratislava</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42102 Boehringer Ingelheim Investigational Site</Name><Address1>Kosice</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42103 Boehringer Ingelheim Investigational Site</Name><Address1>Spisska Nova Ves</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42104 Boehringer Ingelheim Investigational Site</Name><Address1>Humenne</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42105 Boehringer Ingelheim Investigational Site</Name><Address1>Vrable</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42106 Boehringer Ingelheim Investigational Site</Name><Address1>Martin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.42107 Boehringer Ingelheim Investigational Site</Name><Address1>Poprad</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Thailand"><Sites><Site><Name>1237.19.66001 Boehringer Ingelheim Investigational Site</Name><Address1>Muang</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.66002 Boehringer Ingelheim Investigational Site</Name><Address1>Muang</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.66003 Boehringer Ingelheim Investigational Site</Name><Address1>Maerim</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.66004 Boehringer Ingelheim Investigational Site</Name><Address1>Rajathevee</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.66005 Boehringer Ingelheim Investigational Site</Name><Address1>Hat Yai</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.66007 Boehringer Ingelheim Investigational Site</Name><Address1>Patumwan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.66008 Boehringer Ingelheim Investigational Site</Name><Address1>Dusit</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Turkey"><Sites><Site><Name>1237.19.90000 Boehringer Ingelheim Investigational Site</Name><Address1>Mersin</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90001 Boehringer Ingelheim Investigational Site</Name><Address1>Kocaeli</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90002 Boehringer Ingelheim Investigational Site</Name><Address1>Denizli</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90003 Boehringer Ingelheim Investigational Site</Name><Address1>Izmir</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90004 Boehringer Ingelheim Investigational Site</Name><Address1>Izmir</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90005 Boehringer Ingelheim Investigational Site</Name><Address1>Izmir</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90006 Boehringer Ingelheim Investigational Site</Name><Address1>Ankara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90007 Boehringer Ingelheim Investigational Site</Name><Address1>Ankara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90008 Boehringer Ingelheim Investigational Site</Name><Address1>Antalya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90009 Boehringer Ingelheim Investigational Site</Name><Address1>Konya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90010 Boehringer Ingelheim Investigational Site</Name><Address1>Bursa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90011 Boehringer Ingelheim Investigational Site</Name><Address1>Izmir</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90012 Boehringer Ingelheim Investigational Site</Name><Address1>Istanbul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90013 Boehringer Ingelheim Investigational Site</Name><Address1>Istanbul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90014 Boehringer Ingelheim Investigational Site</Name><Address1>Istanbul</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90015 Boehringer Ingelheim Investigational Site</Name><Address1>Ankara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.90016 Boehringer Ingelheim Investigational Site</Name><Address1>Ankara</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Taiwan"><Sites><Site><Name>1237.19.88001 Boehringer Ingelheim Investigational Site</Name><Address1>Taipei</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88003 Boehringer Ingelheim Investigational Site</Name><Address1>Tao-Yuan</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88004 Boehringer Ingelheim Investigational Site</Name><Address1>New Taipei</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88005 Boehringer Ingelheim Investigational Site</Name><Address1>Taipei</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88006 Boehringer Ingelheim Investigational Site</Name><Address1>Taichung</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88007 Boehringer Ingelheim Investigational Site</Name><Address1>Taipei City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88008 Boehringer Ingelheim Investigational Site</Name><Address1>Taipei</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88009 Boehringer Ingelheim Investigational Site</Name><Address1>New Taipei City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88010 Boehringer Ingelheim Investigational Site</Name><Address1>Kaohsiung</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88011 Boehringer Ingelheim Investigational Site</Name><Address1>Kaohsiung</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88012 Boehringer Ingelheim Investigational Site</Name><Address1>Kaohsiung City</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.88013 Boehringer Ingelheim Investigational Site</Name><Address1>Taipei</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Ukraine"><Sites><Site><Name>1237.19.38001 Boehringer Ingelheim Investigational Site</Name><Address1>Kharkiv</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38002 Boehringer Ingelheim Investigational Site</Name><Address1>Kyiv</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38003 Boehringer Ingelheim Investigational Site</Name><Address1>Kyiv</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38004 Boehringer Ingelheim Investigational Site</Name><Address1>Kyiv</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38005 Boehringer Ingelheim Investigational Site</Name><Address1>Kiev</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38006 Boehringer Ingelheim Investigational Site</Name><Address1>Kyiv</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38007 Boehringer Ingelheim Investigational Site</Name><Address1>Kiev</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38008 Boehringer Ingelheim Investigational Site</Name><Address1>Vinnytsya</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38009 Boehringer Ingelheim Investigational Site</Name><Address1>Ivano-Frankivsk</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.38010 Boehringer Ingelheim Investigational Site</Name><Address1>Odesa</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>1237.19.10000 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10001 Boehringer Ingelheim Investigational Site</Name><Address1>Morgantown</Address1><Address2>West Virginia</Address2><CountrySubDivision code="WV">West Virginia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10003 Boehringer Ingelheim Investigational Site</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10005 Boehringer Ingelheim Investigational Site</Name><Address1>Delaware</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10006 Boehringer Ingelheim Investigational Site</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10007 Boehringer Ingelheim Investigational Site</Name><Address1>Rapid City</Address1><Address2>South Dakota</Address2><CountrySubDivision code="SD">South Dakota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10008 Boehringer Ingelheim Investigational Site</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10009 Boehringer Ingelheim Investigational Site</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10010 Boehringer Ingelheim Investigational Site</Name><Address1>Union</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10011 Boehringer Ingelheim Investigational Site</Name><Address1>Gainesville</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10012 Boehringer Ingelheim Investigational Site</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10014 Boehringer Ingelheim Investigational Site</Name><Address1>Calabash</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10016 Boehringer Ingelheim Investigational Site</Name><Address1>West Allis</Address1><Address2>Wisconsin</Address2><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10019 Boehringer Ingelheim Investigational Site</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10020 Boehringer Ingelheim Investigational Site</Name><Address1>Orlando</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10021 Boehringer Ingelheim Investigational Site</Name><Address1>Medford</Address1><Address2>Oregon</Address2><CountrySubDivision code="OR">Oregon</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10023 Boehringer Ingelheim Investigational Site</Name><Address1>Gaffney</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10024 Boehringer Ingelheim Investigational Site</Name><Address1>Greenville</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10025 Boehringer Ingelheim Investigational Site</Name><Address1>Rock Hill</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10027 Boehringer Ingelheim Investigational Site</Name><Address1>Fall River</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10029 Boehringer Ingelheim Investigational Site</Name><Address1>Clearwater</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10030 Boehringer Ingelheim Investigational Site</Name><Address1>Gaffney</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10031 Boehringer Ingelheim Investigational Site</Name><Address1>Chesterfield</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10032 Boehringer Ingelheim Investigational Site</Name><Address1>Winter Park</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10033 Boehringer Ingelheim Investigational Site</Name><Address1>Spartanburg</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10034 Boehringer Ingelheim Investigational Site</Name><Address1>Livonia</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10035 Boehringer Ingelheim Investigational Site</Name><Address1>Burlington</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10036 Boehringer Ingelheim Investigational Site</Name><Address1>Spartanburg</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10037 Boehringer Ingelheim Investigational Site</Name><Address1>Eagle</Address1><Address2>Idaho</Address2><CountrySubDivision code="ID">Idaho</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10039 Boehringer Ingelheim Investigational Site</Name><Address1>Andalusia</Address1><Address2>Alabama</Address2><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10040 Boehringer Ingelheim Investigational Site</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10041 Boehringer Ingelheim Investigational Site</Name><Address1>East Providence</Address1><Address2>Rhode Island</Address2><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10042 Boehringer Ingelheim Investigational Site</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10043 Boehringer Ingelheim Investigational Site</Name><Address1>Fridley</Address1><Address2>Minnesota</Address2><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10047 Boehringer Ingelheim Investigational Site</Name><Address1>Houston</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10048 Boehringer Ingelheim Investigational Site</Name><Address1>Bowling Green</Address1><Address2>Kentucky</Address2><CountrySubDivision code="KY">Kentucky</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10049 Boehringer Ingelheim Investigational Site</Name><Address1>Elizabeth City</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10050 Boehringer Ingelheim Investigational Site</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10051 Boehringer Ingelheim Investigational Site</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10053 Boehringer Ingelheim Investigational Site</Name><Address1>Shelby</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10054 Boehringer Ingelheim Investigational Site</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10055 Boehringer Ingelheim Investigational Site</Name><Address1>Toledo</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10058 Boehringer Ingelheim Investigational Site</Name><Address1>Easley</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10059 Boehringer Ingelheim Investigational Site</Name><Address1>Kingwood</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10060 Boehringer Ingelheim Investigational Site</Name><Address1>Reno</Address1><Address2>Nevada</Address2><CountrySubDivision code="NV">Nevada</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10061 Boehringer Ingelheim Investigational Site</Name><Address1>McKinney</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10062 Boehringer Ingelheim Investigational Site</Name><Address1>Wilmington</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10063 Boehringer Ingelheim Investigational Site</Name><Address1>Topeka</Address1><Address2>Kansas</Address2><CountrySubDivision code="KS">Kansas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10065 Boehringer Ingelheim Investigational Site</Name><Address1>River Forest</Address1><Address2>Illinois</Address2><CountrySubDivision code="IL">Illinois</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10066 Boehringer Ingelheim Investigational Site</Name><Address1>Tampa</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10069 Boehringer Ingelheim Investigational Site</Name><Address1>Flagstaff</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10070 Boehringer Ingelheim Investigational Site</Name><Address1>Boerne</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10071 Boehringer Ingelheim Investigational Site</Name><Address1>Myrtle Beach</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10072 Boehringer Ingelheim Investigational Site</Name><Address1>Hollywood</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10074 Boehringer Ingelheim Investigational Site</Name><Address1>Poway</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10075 Boehringer Ingelheim Investigational Site</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10076 Boehringer Ingelheim Investigational Site</Name><Address1>Lynchburg</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10077 Boehringer Ingelheim Investigational Site</Name><Address1>Florence</Address1><Address2>Alabama</Address2><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10078 Boehringer Ingelheim Investigational Site</Name><Address1>San Jose</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10080 Boehringer Ingelheim Investigational Site</Name><Address1>Duluth</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10081 Boehringer Ingelheim Investigational Site</Name><Address1>Marlton</Address1><Address2>New Jersey</Address2><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10082 Boehringer Ingelheim Investigational Site</Name><Address1>Traverse City</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10083 Boehringer Ingelheim Investigational Site</Name><Address1>Columbia</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10084 Boehringer Ingelheim Investigational Site</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10085 Boehringer Ingelheim Investigational Site</Name><Address1>Peoria</Address1><Address2>Arizona</Address2><CountrySubDivision code="AZ">Arizona</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10086 Boehringer Ingelheim Investigational Site</Name><Address1>Columbia</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10087 Boehringer Ingelheim Investigational Site</Name><Address1>Huntersville</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10089 Boehringer Ingelheim Investigational Site</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10091 Boehringer Ingelheim Investigational Site</Name><Address1>Abingdon</Address1><Address2>Virginia</Address2><CountrySubDivision code="VA">Virginia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10092 Boehringer Ingelheim Investigational Site</Name><Address1>Tacoma</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10093 Boehringer Ingelheim Investigational Site</Name><Address1>Stamford</Address1><Address2>Connecticut</Address2><CountrySubDivision code="CT">Connecticut</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10094 Boehringer Ingelheim Investigational Site</Name><Address1>Brooklyn</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10095 Boehringer Ingelheim Investigational Site</Name><Address1>Opelousas</Address1><Address2>Louisiana</Address2><CountrySubDivision code="LA">Louisiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10096 Boehringer Ingelheim Investigational Site</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10097 Boehringer Ingelheim Investigational Site</Name><Address1>Missoula</Address1><Address2>Montana</Address2><CountrySubDivision code="MT">Montana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10098 Boehringer Ingelheim Investigational Site</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10099 Boehringer Ingelheim Investigational Site</Name><Address1>Indian Land</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10101 Boehringer Ingelheim Investigational Site</Name><Address1>St. Charles</Address1><Address2>Missouri</Address2><CountrySubDivision code="MO">Missouri</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10103 Boehringer Ingelheim Investigational Site</Name><Address1>Worcester</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10104 Boehringer Ingelheim Investigational Site</Name><Address1>Hickory</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10106 Boehringer Ingelheim Investigational Site</Name><Address1>Clearwater</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10107 Boehringer Ingelheim Investigational Site</Name><Address1>Corsicana</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10108 Boehringer Ingelheim Investigational Site</Name><Address1>Fort Mitchell</Address1><Address2>Kentucky</Address2><CountrySubDivision code="KY">Kentucky</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10109 Boehringer Ingelheim Investigational Site</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><CountrySubDivision code="LA">Louisiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10110 Boehringer Ingelheim Investigational Site</Name><Address1>Lincoln</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10111 Boehringer Ingelheim Investigational Site</Name><Address1>Killeen</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10112 Boehringer Ingelheim Investigational Site</Name><Address1>Lawrenceville</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10113 Boehringer Ingelheim Investigational Site</Name><Address1>Shreveport</Address1><Address2>Louisiana</Address2><CountrySubDivision code="LA">Louisiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10115 Boehringer Ingelheim Investigational Site</Name><Address1>Jasper</Address1><Address2>Alabama</Address2><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10117 Boehringer Ingelheim Investigational Site</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10118 Boehringer Ingelheim Investigational Site</Name><Address1>Los Angeles</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10120 Boehringer Ingelheim Investigational Site</Name><Address1>Spokane</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10121 Boehringer Ingelheim Investigational Site</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10122 Boehringer Ingelheim Investigational Site</Name><Address1>Muncie</Address1><Address2>Indiana</Address2><CountrySubDivision code="IN">Indiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10123 Boehringer Ingelheim Investigational Site</Name><Address1>Everett</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10126 Boehringer Ingelheim Investigational Site</Name><Address1>Johnston</Address1><Address2>Rhode Island</Address2><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10127 Boehringer Ingelheim Investigational Site</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10128 Boehringer Ingelheim Investigational Site</Name><Address1>Greenville</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10129 Boehringer Ingelheim Investigational Site</Name><Address1>Erie</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10130 Boehringer Ingelheim Investigational Site</Name><Address1>O'Fallon</Address1><Address2>Illinois</Address2><CountrySubDivision code="IL">Illinois</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10131 Boehringer Ingelheim Investigational Site</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10133 Boehringer Ingelheim Investigational Site</Name><Address1>Norwalk</Address1><Address2>Connecticut</Address2><CountrySubDivision code="CT">Connecticut</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10135 Boehringer Ingelheim Investigational Site</Name><Address1>St. Petersburg</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10136 Boehringer Ingelheim Investigational Site</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10137 Boehringer Ingelheim Investigational Site</Name><Address1>Larchmont</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10138 Boehringer Ingelheim Investigational Site</Name><Address1>North Dartmounth</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10139 Boehringer Ingelheim Investigational Site</Name><Address1>Shreveport</Address1><Address2>Louisiana</Address2><CountrySubDivision code="LA">Louisiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10140 Boehringer Ingelheim Investigational Site</Name><Address1>Oaks</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10142 Boehringer Ingelheim Investigational Site</Name><Address1>Wheat Ridge</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10143 Boehringer Ingelheim Investigational Site</Name><Address1>Syracuse</Address1><Address2>New York</Address2><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10144 Boehringer Ingelheim Investigational Site</Name><Address1>Mt. Pleasant</Address1><Address2>South Carolina</Address2><CountrySubDivision code="SC">South Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10145 Boehringer Ingelheim Investigational Site</Name><Address1>Tamarac</Address1><Address2>Florida</Address2><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10146 Boehringer Ingelheim Investigational Site</Name><Address1>Tulsa</Address1><Address2>Oklahoma</Address2><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10147 Boehringer Ingelheim Investigational Site</Name><Address1>Kettering</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10148 Boehringer Ingelheim Investigational Site</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10149 Boehringer Ingelheim Investigational Site</Name><Address1>Austell</Address1><Address2>Georgia</Address2><CountrySubDivision code="GA">Georgia</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10151 Boehringer Ingelheim Investigational Site</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10153 Boehringer Ingelheim Investigational Site</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10154 Boehringer Ingelheim Investigational Site</Name><Address1>Gastonia</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.10157 Boehringer Ingelheim Investigational Site</Name><Address1>Lafayette</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Vietnam"><Sites><Site><Name>1237.19.84001 Boehringer Ingelheim Investigational Site</Name><Address1>Ho Chi Minh</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.84002 Boehringer Ingelheim Investigational Site</Name><Address1>Ho Chi Minh</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.84003 Boehringer Ingelheim Investigational Site</Name><Address1>Ha Noi</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="South Africa"><Sites><Site><Name>1237.19.27001 Boehringer Ingelheim Investigational Site</Name><Address1>Cape Town</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27002 Boehringer Ingelheim Investigational Site</Name><Address1>Cape Town</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27003 Boehringer Ingelheim Investigational Site</Name><Address1>Cape Town</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27004 Boehringer Ingelheim Investigational Site</Name><Address1>Pretoria</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27006 Boehringer Ingelheim Investigational Site</Name><Address1>Amanzimtoti</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27007 Boehringer Ingelheim Investigational Site</Name><Address1>Cape Town</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27008 Boehringer Ingelheim Investigational Site</Name><Address1>Pretoria</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27009 Boehringer Ingelheim Investigational Site</Name><Address1>Cape Town</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27010 Boehringer Ingelheim Investigational Site</Name><Address1>Parow</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>1237.19.27011 Boehringer Ingelheim Investigational Site</Name><Address1>Morningside, Sandton</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="556">Subjects with Stable COPD</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="559">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="3736">Smokers</SubSegment><SubSegment id="3738">Ex-smokers</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="562">Subjects with GOLD Stage 3/Severe COPD</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="563">Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02296138</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2014-002275-28</Identifier></Identifiers></Registry><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier>JapicCTI-152814</Identifier></Identifiers></Registry><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2015/03/005597</Identifier></Identifiers></Registry><Registry><Name id="1021">National Medical Research Register Malaysia (NMRR)</Name><Identifiers><Identifier>NMRR-14-1457-23424</Identifier></Identifiers></Registry><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier></Identifier></Identifiers></Registry><Registry><Name id="1033">Federal Commission for Protection against Health Risks (COFEPRIS) Clinical Trials Registry
</Name><Identifiers><Identifier></Identifier></Identifiers></Registry><Registry><Name id="1035">Singapore Health Services Authority Clinical Trials Registry
</Name><Identifiers><Identifier></Identifier></Identifiers></Registry><Registry><Name id="1038">Philippine Health Research Registry (PHRR)</Name><Identifiers><Identifier>PHRR150622-001032</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4473"><Endpoint>Assessment of Exacerbations</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4474">Assessment of exacerbation rate/frequency/number</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4479">Assessment of exacerbation severity - moderate</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4480">Assessment of exacerbation severity - severe</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="43848"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4566">Assessment of all cause mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4473"><Endpoint>Assessment of Exacerbations</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4474">Assessment of exacerbation rate/frequency/number</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4476">Assessment of exacerbation requiring hospitalization</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4479">Assessment of exacerbation severity - moderate</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4480">Assessment of exacerbation severity - severe</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4481">Assessment of time to first exacerbation</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4483"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2064">Subjects with stable COPD</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2069"><Criterion>Subjects Included Based on Response to Bronchodilator Reversibility</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2099"><Criterion>Subjects with Exacerbations</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2101">Subjects with 1 exacerbation within the past 1 year</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2151"><Criterion>Subjects with Abnormal Pulmonary Function Parameters</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="22348">Subjects with abnormal/required FEV1 levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2171"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="33821"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="4301">Current smokers</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="4302">Non smokers/exsmokers</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="4304">Subjects with smoking history of &gt;= 10 pack years</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="34771"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2067">Subjects with GOLD Stage 3/Severe COPD</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="2068">Subjects with GOLD Stage 4/Very Severe COPD</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3044"><Criterion>Subjects with Specific Stage/Type of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="3285">Subjects with homogeneous emphysema</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3058"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3076"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3095"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3111"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3151"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="20269">Subjects with history of/scheduled for COPD drug therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3194"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="6974"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20271"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20272"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20273"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20274"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2016-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>14.61 Months</EnrollmentPeriod><EnrollmentRate>540.93 Patients/Month</EnrollmentRate><DateFirstReceived>2014-11-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-11-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-04-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-02-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-02-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-05-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-04-02T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2019-03-20T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="221456"><TitleDisplay>X-NOAC Study</TitleDisplay><TitleOfficial>Effects of Rivaroxaban on Renal Function in Non-valvular Atrial Fibrillation Patients With Chronic Kidney Diseases</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000016296</Identifier><Identifier type="Trial Acronym">X-NOAC</Identifier></Identifiers><Indications><Indication id="3251">End stage renal disease</Indication></Indications><BiomarkerNames><BiomarkerName id="118" role="Therapeutic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="743" role="Therapeutic effect marker" type="Genomic;Proteomic">Osteocalcin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rivaroxaban</Name><Drug id="32677">rivaroxaban</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>warfarin</Name><Drug id="44375">warfarin</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="32677">rivaroxaban</Drug><IndicationsPioneer><Indication id="3251">End stage renal disease</Indication></IndicationsPioneer><Companies><Company><Company id="1007081">Saga University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1066644">Kameda Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1079096">Dokkyo Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1081076">Tokyo Metropolitan Hiroo Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1111658">Yokohama Minami Kyosai Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159751">Imari Arita Kyoritsu Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="14557">Bayer Yakuhin Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="32677" type="Drug"><TargetEntity id="307796" type="siDrug">Rivaroxaban</TargetEntity></SourceEntity><SourceEntity id="1007081" type="Company"><TargetEntity id="4298189804" type="organizationId">SAGA University</TargetEntity></SourceEntity><SourceEntity id="1066644" type="Company"><TargetEntity id="5034749414" type="organizationId">Medical Corporation Tesshokai</TargetEntity></SourceEntity><SourceEntity id="1079096" type="Company"><TargetEntity id="5038068148" type="organizationId">Dokkyo Medical University</TargetEntity></SourceEntity><SourceEntity id="1081076" type="Company"><TargetEntity id="5038914172" type="organizationId">Tokyo Metropolitan Hiroo Hospital</TargetEntity></SourceEntity><SourceEntity id="1111658" type="Company"><TargetEntity id="5046434771" type="organizationId">Yokohama Minami Kyousai Hospital</TargetEntity></SourceEntity><SourceEntity id="1159751" type="Company"><TargetEntity id="5060606704" type="organizationId">Imari Arita Kyoritsu Hospital</TargetEntity></SourceEntity><SourceEntity id="14557" type="Company"><TargetEntity id="4296353174" type="organizationId">Bayer Yakuhin Ltd</TargetEntity></SourceEntity><SourceEntity id="3251" type="ciIndication"><TargetEntity id="N18.6" type="ICD10"></TargetEntity><TargetEntity id="D007676" type="MeSH"></TargetEntity><TargetEntity id="1890" type="siCondition"></TargetEntity><TargetEntity id="1604" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="120" type="Action"><TargetEntity id="679" type="Mechanism">Coagulation Factor Xa Inhibitors</TargetEntity><TargetEntity id="6421" type="Mechanism">Anti-Factor Xa</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1007081">Saga University</Company><Company id="1066644">Kameda Medical Center</Company><Company id="1079096">Dokkyo Medical University</Company><Company id="1081076">Tokyo Metropolitan Hiroo Hospital</Company><Company id="1111658">Yokohama Minami Kyosai Hospital</Company><Company id="1159751">Imari Arita Kyoritsu Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="14557">Bayer Yakuhin Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="120">Factor Xa antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="449">Antiarrhythmic agent</Class><Class id="659">Coagulation inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="743">Granule</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>160</PatientCountEnrollment><DateStart>2015-03-01T00:00:00Z</DateStart><DateChangeLast>2018-07-25T04:41:04Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Saga University Faculty of Medicine, Department of Cardiovascular Medicine</Affiliation><Email>node@cc.saga-u.ac.jp</Email><Name>Koichi Node</Name><Phone>0952-34-2364</Phone></Contact><Contact type="Public contact"><Affiliation>Saga University Faculty of Medicine, Department of Cardiovascular Medicine</Affiliation><Email>node@cc.saga-u.ac.jp</Email><Name>Koichi Node</Name><Phone>0952-34-2364</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt;/= 30 years old&lt;/li&gt;&lt;li&gt;Patients who had initiated anticoagulation therapy or patients who had already received&lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; therapy&lt;/li&gt;&lt;li&gt;Estimated glomerular filtration rate&amp;gt; 30 and &amp;lt; 60 ml/min/1.73 m2: CKD grade G2 to G3b&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with onset of acute coronary syndrome or stroke within 6 months&lt;/li&gt;&lt;li&gt;Patients scheduled to undergo percutaneous coronary intervention (PCI) or catheter ablation&lt;/li&gt;&lt;li&gt;Patients receiving dual antiplatelet therapy (DAPT)&lt;/li&gt;&lt;li&gt;Patients with a history of hypersensitivity to the components of&lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Patients with active bleeding (non-major clinically relevant bleeding events, such as intracranial hemorrhage, gastrointestinal hemorrhage)&lt;/li&gt;&lt;li&gt;Patients with hepatic disorders associated with coagulation abnormalities&lt;/li&gt;&lt;li&gt;Patients with moderate or severe hepatic disorder (equivalent to Child-Pugh classification B or C)&lt;/li&gt;&lt;li&gt;Patients with renal failure (creatinine clearance&amp;lt; 30 ml/min)&lt;/li&gt;&lt;li&gt;Pregnant women or women with pregnancy potential&lt;/li&gt;&lt;li&gt;Patients receiving HIV protease inhibitors (ritonavir, atazanavir, indinavir, etc,)&lt;/li&gt;&lt;li&gt;Patients receiving oral or intravenous administration of azole antifungal drugs (itraconazole, voriconazole, or ketoconazole)&lt;/li&gt;&lt;li&gt;Patients receiving vitamin K agents for osteoporosis&lt;/li&gt;&lt;li&gt;Patients receiving iguratimod&lt;/li&gt;&lt;li&gt;Patients with acute bacterial endocarditis&lt;/li&gt;&lt;li&gt;Patients who did not give informed consent&lt;/li&gt;&lt;li&gt;Other patients considered by the investigator to be unsuitable for participation in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The primary endpoint was the change amount in urinary albumin</Description><Timeframe>3 months after registration</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The secondary endpoints were changes amount in endothelial functions, inflammatory markers, renal function markers, osteocalcin markers</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to determine whether &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; will have an impact on the renal function in patients with non-valvular atrial fibrillation compared to &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive either &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Kameda general hospital</Name><Address1>Chiba</Address1><Contacts></Contacts></Site><Site><Name>Metropolitan Hiroo Hospital</Name><Address1>Tokyo</Address1><Contacts></Contacts></Site><Site><Name>Yokohama Minami Mutual Hospital</Name><Address1>Kanagawa</Address1><Contacts></Contacts></Site><Site><Name>Saigama Medical Center</Name><Address1>Saitama</Address1><Contacts></Contacts></Site><Site><Name>Imari Arita Kyoritsu Hospital</Name><Address1>Saga</Address1><Contacts></Contacts></Site><Site><Name>Saga University Medical School Hospital</Name><Address1>Saga Prefecture</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7703">Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</PatientSegment><SubSegments><SubSegment id="7699">Subjects with stage 2 chronic kidney disease</SubSegment><SubSegment id="7700">Subjects with stage 3 chronic kidney disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000016296</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22509"><Endpoint>Assessment of Urinary Protein Excretion/Proteinuria</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22521"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22532">Assessment of other inflammatory/oxidative stress markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22565"><Endpoint>Assessment of Bone</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17629"><Criterion>Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17638">Subjects with stage 2 chronic kidney disease</SubCriterion><SubCriterion disease="End stage renal disease" id="17642">Subjects with stage 3 chronic kidney disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17690"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17698">Subjects on anticoagulants</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17700"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17515"><Criterion>Subjects with Renal Function Outside of Protocol Specified Limits</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17521"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17522"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17528"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17541"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17548">Subjects with history of/scheduled for nutritional supplements/dietary therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17555"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2018-07-24T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>40.77 Months</EnrollmentPeriod><EnrollmentRate>3.92 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Company</Type><Type>Government</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-07-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="297198"><TitleDisplay>The effect of fresh frozen plasma on rotational thromboelastometry (Rotem) parameters and received blood products in children under cardiac surgery</TitleDisplay><TitleOfficial>Effect of fresh frozen plasma for priming cardiopulmonary bypass machine on rotational thromboelastometry (Rotem) parameters and received blood products in children undergoing cardiac surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2016101313785N3</Identifier><Identifier type="Secondary Organisational">IR.IUMS.REC 1394.9211584202</Identifier></Identifiers><Indications><Indication id="3045">Cardiac surgical procedure</Indication></Indications><BiomarkerNames><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Open heart surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>packed cell</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>fresh frozen plasma</Name></Intervention><Intervention type="InterventionPrimary"><Name>heparin</Name></Intervention><Intervention type="InterventionPrimary"><Name>protamin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>heparin</Name></Intervention><Intervention type="InterventionControl"><Name>hydroxyethyl starch</Name></Intervention><Intervention type="InterventionControl"><Name>protamin</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1035896" type="Company"><TargetEntity id="5035541621" type="organizationId">Iran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="3045" type="ciIndication"><TargetEntity id="D006348" type="MeSH"></TargetEntity><TargetEntity id="-1544243259" type="omicsDisease"></TargetEntity><TargetEntity id="1044" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1035896">Iran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>84</PatientCountEnrollment><DateStart>2016-04-03T00:00:00Z</DateStart><DateChangeLast>2017-05-12T10:54:01Z</DateChangeLast><DateAdded>2017-05-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>hamidpeyravi@yahoo.com</Email><Name>Dr. Hamid Peyrovi</Name><Phone>00982143651705 00989125160897</Phone></Contact><Contact type="Scientific contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>hamidpeyravi@yahoo.com</Email><Name>Dr. Hamid Peyrovi</Name><Phone>00982143651705 00989125160897</Phone></Contact><Contact type="Public contact"><Affiliation>School of Nursing and Midwifery, Iran University of Medical Sciences</Affiliation><Email>hamidpeyravi@yahoo.com</Email><Name>Dr. Hamid Peyrovi</Name><Phone>00982143651705 00989125160897</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;No history of sternotomy&lt;/li&gt;&lt;li&gt;No coagulopathy&lt;/li&gt;&lt;li&gt;No hepatic diasese&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Dying patient&lt;/li&gt;&lt;li&gt;Giving up participation in the study&lt;/li&gt;&lt;li&gt;Blood or blood products transfusion within the last 24 h&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Rotem parameters: rotem measurement system</Description><Timeframe>Before anesthesia induction and after weaning from cardiopulmonary bypass machine</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Received blood products: ml</Description><Timeframe>During operation and 24 h after surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to examine the effect of fresh frozen plasma (FFP) for priming cardiopulmonary bypass machine on rotational thromboelastometry (Rotem) parameters and received blood products in children undergoing cardiac surgery.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Rotem parameters and the volume of received blood products will be compared between the groups using statistical tests.&lt;br/&gt;The study will consist of two groups:&lt;br/&gt;Intervention group: ّpatients will receive or every kg of body weight, 10 to 20 ml fresh frozen plasma (FFP) and 100 to 200 ml crystalloid solution (Ringer dolurion) will be used as priming solution. To maintain hematocrit at 20 percent, all patients will receive packed cell. After surgery, to alleviate the effect of heparin, 1 mg protamin/ kg body weight will be injected and then the patient will be weaned from bypass machine.&lt;br/&gt;Control group: patients will receive for every kg of body weight, 10 to 20 ml hydroxyethyl starch with proportion of 130 to 0.4 and 100 to 200 ml crystalloid solution (Ringer dolurion) will be used as priming solution. To maintain hematocrit at 20 percent, all patients will receive packed cell. After surgery, to alleviate the effect of heparin, 1 mg protamin/ kg body weight will be injected and then the patient will be weaned from bypass machine.&lt;br/&gt;Remaining of the cardiovascular bypass process will be the same for both groups. Rotem parameters will be measured two times, before anesthesia induction and 10 min after protamine injection. Rotem parameters and the volume of received blood products will be compared between the groups using statistical tests.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Rajaei Cardiovascular, Medical and Research Center</Name><Address1>Tehran</Address1><Address2>Tehran</Address2><CountrySubDivision>Tehran</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr. Hamid Peyrovi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2016101313785N3</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><ExclusionCriteria><Exclusion disease="Other cardiovascular disease" id="23962"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24585"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="25605"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2017-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.94 Months</EnrollmentPeriod><EnrollmentRate>8.45 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="301414"><TitleDisplay>The Impact of Nigella Sativa on After Pain</TitleDisplay><TitleOfficial>Comparison Between Nigella Sativa Capsule and Mefenamic Acid Capsule on After Pain in Multipaorus Women</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2017041033356N1</Identifier><Identifier type="Secondary Organisational">IR.SBMU.PHNM.1395.458</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>Nigella sativa capsule</Name></Intervention><Intervention type="InterventionPrimary"><Name>mefenamic acid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>mefenamic acid</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1061107" type="Company"><TargetEntity id="5035552918" type="organizationId">Shahid Beheshti University</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1061107">Shahid Beheshti University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2017-05-05T00:00:00Z</DateStart><DateChangeLast>2018-01-31T22:06:41Z</DateChangeLast><DateAdded>2017-06-16T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>nursing and midwifery faculty of shahid beheshti medical science university</Affiliation><Email>padidehjanati@yahoo.com</Email><Name>padideh janati ataii</Name><Phone>00982188655366 00989123248042</Phone></Contact><Contact type="Scientific contact"><Affiliation>nursing and midwifery faculty of shahid beheshti medical science university</Affiliation><Email>padidehjanati@yahoo.com</Email><Name>padideh janati ataii</Name><Phone>00982188655366 00989123248042</Phone></Contact><Contact type="Public contact"><Affiliation>nursing and midwifery faculty of shahid beheshti medical science university</Affiliation><Email>padidehjanati@yahoo.com</Email><Name>padideh janati ataii</Name><Phone>00982188655366 00989123248042</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Being Iranian&lt;/li&gt;&lt;li&gt;Can read and write&lt;/li&gt;&lt;li&gt;Vaginal delivery&lt;/li&gt;&lt;li&gt;Spontaneous exit of plasenta and membranes&lt;/li&gt;&lt;li&gt;Multiparous&lt;/li&gt;&lt;li&gt;Gestational age between 37 to 42 weeks&lt;/li&gt;&lt;li&gt;Be complained of moderate or severe pain after delivery&lt;/li&gt;&lt;li&gt;No instrumental delivery or pressure on uterus&lt;/li&gt;&lt;li&gt;No 3 or 4 degree lacerration&lt;/li&gt;&lt;li&gt;No History of cesarian section or pelvic operation&lt;/li&gt;&lt;li&gt;Not used any narcotic drug during labor and delivery or used atleast 4 h ago&lt;/li&gt;&lt;li&gt;Not used epidural or spinal anesthesia during labor and delivery&lt;/li&gt;&lt;li&gt;Mother dosent have any drug addiction&lt;/li&gt;&lt;li&gt;Maternal history of herbal drugs allergy&lt;/li&gt;&lt;li&gt;Feeding is started ansd will be continued&lt;/li&gt;&lt;li&gt;Mother age between 15 to 44 years&lt;/li&gt;&lt;li&gt;Deliver a singleton and healthy baby&lt;/li&gt;&lt;li&gt;No maternal history of chronic disease&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Herbal drug sensitivity happen in mother during study&lt;/li&gt;&lt;li&gt;Mother uses other methods or drugs to relive pain during study&lt;/li&gt;&lt;li&gt;Mother is suffering serious complications after delivery (such as high blood pressure, severe bleeding after childbirth, fever, etc.)&lt;/li&gt;&lt;li&gt;Breastfeeding because of mother or baby causes, is disconnected&lt;/li&gt;&lt;li&gt;Mothers doesn't tend to have continued cooperation with the researcher&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>After pain: Mc gill pain ruler</Description><Timeframe>Before intervention and 1 h after it</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Drug side effects: side effect questionnaire</Description><Timeframe>After intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this randomized, double-blind control trial with placebo is to determine the effect of the capsule Nigella sativa and mefenamic acid on the after pain in multiparous women referring to Persian Gulf Shohada Hospital of Bushehr on 1396.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be divided into two groups:&lt;br/&gt;Group 1: patients (n = 50)  will receive 500 mg Nigella sativa capsule every 6 h till 24 h with a mefenamic aqcid capsule that is routine treatment. Nigella Sativa capsules will be made in Shahid Beheshti pharmacy laboratory.&lt;br/&gt;Group 2: patients will receive placebo capsules that will be similar to Nigella sativa capsules every 6 h with mefenamic acid that will be routine treatment. Placebo capsules will be made in Shahid Beheshti Pharmacy laboratory.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>persian golf shohada teaching hospital</Name><Address1>bushehr</Address1><Address2>bushehr</Address2><CountrySubDivision>bushehr</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>maryam chananeh</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8389">Subjects with Moderate to Severe Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2017041033356N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25876">Based on McGill Pain Questionnaire</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22091"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Pain" id="22093">Subjects with moderate pain</SubCriterion><SubCriterion disease="Pain" id="22094">Subjects with severe pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22264">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2017-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.87 Months</EnrollmentPeriod><EnrollmentRate>34.84 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-10-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="305078"><TitleDisplay>A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain</TitleDisplay><TitleOfficial>A Phase III Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03213457</Identifier><Identifier type="Organisational Study">M14-702</Identifier></Identifiers><Indications><Indication id="113">Endometriosis</Indication><Indication id="20">Pain</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>elagolix</Name><Drug id="48547">elagolix</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>elagolix</Name><Drug id="48547">elagolix</Drug></Intervention><Intervention type="InterventionPrimary"><Name>estradiol + norethindrone acetate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="48547">elagolix</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1072507">AbbVie Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="48547">elagolix</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1072507">AbbVie Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="48547" type="Drug"><TargetEntity id="395035" type="siDrug">Elagolix sodium</TargetEntity><TargetEntity id="395035" type="siDrug">Elagolix sodium</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="113" type="ciIndication"><TargetEntity id="N80" type="ICD10"></TargetEntity><TargetEntity id="617.0" type="ICD9"></TargetEntity><TargetEntity id="10014778" type="MEDDRA"></TargetEntity><TargetEntity id="D004715" type="MeSH"></TargetEntity><TargetEntity id="-1297427982" type="omicsDisease"></TargetEntity><TargetEntity id="546" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="455" type="Action"><TargetEntity id="589" type="Mechanism">GnRH (LHRH) Antagonists</TargetEntity><TargetEntity id="2681" type="Mechanism">Anti-LHRH</TargetEntity><TargetEntity id="4654" type="Mechanism">Anti-Gonadotropin Releasing Hormone (GnRH)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>186</NumberOfSites><CompaniesSponsor><Company id="1072507">AbbVie Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="455">GNRH receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="5564">Estrogen synthesis inhibitor</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>680</PatientCountEnrollment><DateStart>2017-07-07T00:00:00Z</DateStart><DateEnd type="estimated">2021-03-30T00:00:00Z</DateEnd><DateChangeLast>2019-05-06T06:30:56Z</DateChangeLast><DateAdded>2017-07-17T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>AbbVie</Affiliation><Name>AbbVie Inc.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participant is a premenopausal female 18 to 49 years of age (inclusive) at the time of Screening&lt;/li&gt;&lt;li&gt;Participant has a documented surgical diagnosis (e.g., laparoscopy or laparotomy) of endometriosis established by visualization within 10 years prior to entry into Washout or Screening&lt;/li&gt;&lt;li&gt;Participant must agree to use only protocol specified rescue analgesics during the Screening and Treatment Periods for endometriosis-associated pain&lt;/li&gt;&lt;li&gt;Participant must have the following documented in the e-Diary during the last 35 days prior to study day 1:&lt;ul&gt;&lt;li&gt;At least 2 days of 'moderate' or 'severe' dysmenorrhea (DYS) and either&lt;/li&gt;&lt;li&gt;At least 2 days of 'moderate' or 'severe' non-menstrual pelvic pain (NMPP) and an average NMPP score of at least 1.0, or&lt;/li&gt;&lt;li&gt;At least 4 days of 'moderate' or 'severe' NMPP and an average NMPP score of at least 0.5&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participant has chronic pelvic pain that is not caused by endometriosis, that requires chronic analgesic therapy, which would interfere with the assessment of endometriosis-related pain&lt;/li&gt;&lt;li&gt;Participant is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled or intranasal corticosteroids are allowed&lt;/li&gt;&lt;li&gt;Participant has a history of any major depression or post-traumatic stress disorder (PTSD) within 2 years of the screening visit or other major psychiatric disorder at any time&lt;/li&gt;&lt;li&gt;Participant has a history of suicide attempts or answered 'yes' to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the last one year at Screening or prior to randomization on Day 1&lt;/li&gt;&lt;li&gt;Participant has any history of osteoporosis or other metabolic bone disease or any condition that would interfere with obtaining adequate Dual Energy X-Ray Absorptiometry (DXA) measurements&lt;/li&gt;&lt;li&gt;Screening DXA results of the lumbar spine (L1-L4), femoral neck or total hip Bone Mineral Density (BMD) corresponding to less than 2.0 or more standard deviations below normal&lt;/li&gt;&lt;li&gt;Participant has either:&lt;ul&gt;&lt;li&gt;A newly diagnosed, clinically significant medical condition that requires therapeutic intervention (eg, new onset hypertension), that has not been stabilized 30 days prior to randomization on Day 1 or&lt;/li&gt;&lt;li&gt;A clinically significant medical condition that is anticipated to require intervention during the course of study participation (eg, anticipated major elective surgery) or&lt;/li&gt;&lt;li&gt;An unstable medical condition that makes the subject an unsuitable candidate for the study in the opinion of the Investigator, (including, but not limited to, uncontrolled diabetes mellitus, uncontrolled hypertension, epilepsy requiring anti-epileptic medication, unstable angina, confirmed inflammatory bowel disease, hyperprolactinemia, clinically significant infection or injury)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Participant has any conditions contraindicated with use of E2/NETA&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportion of responders based on dysmenorrhea (DYS): it is measured by the Endometriosis Daily Pain Impact scale in the e-Diary</Description><Timeframe>At month 6</Timeframe></Measure><Measure><Description>Proportion of responders based on non-menstrual pelvic pain (NMPP) : it is measured by the Endometriosis Daily Pain Impact scale in the e-Diary</Description><Timeframe>At month 6</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change from baseline in dysmenorrhea (DYS): it is measured by the Endometriosis Daily Pain Impact scale in the eDiary</Description><Timeframe>From month 0 (baseline) at month 3, 6 and 12</Timeframe></Measure><Measure><Description>Change from baseline in non-menstrual pelvic pain (NMPP): it is measured by the Endometriosis Daily Pain Impact scale in the eDiary</Description><Timeframe>From month 0 (baseline) at month 3, 6 and 12</Timeframe></Measure><Measure><Description>Change from baseline in Numeric Rating Scale (NRS): this is assessed using overall endometriosis associated pain questionnaire, 11-point Numeric Rating Scale (NRS)</Description><Timeframe>From month 0 (baseline) at month 3, 6 and 12</Timeframe></Measure><Measure><Description>Change from baseline in dyspareunia: this will be assessed using e-diary</Description><Timeframe>From month 0 (baseline) at month 3, 6 and 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study is to evaluate safety and efficacy of &lt;ulink linkType="Drug" linkID="48547"&gt;elagolix&lt;/ulink&gt; (ABT-620) in the management      of moderate to severe endometriosis-associated pain in adult premenopausal female subjectsincluding the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study will consist of three arms:&lt;br/&gt;Arm 1 : subjects will receive twice-daily and estradiol/norethindrone acetate (E2/NETA) administered once-daily.&lt;br/&gt;Arm 2 : subjects will receive elagolix tablet twice-daily.&lt;br/&gt;Arm 3 : subjects will receive a matching placebo for elagolix tablet and E2/NETA capsules.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Medicor Research Inc. /ID# 151453</Name><Address1>Sudbury</Address1><Address2>Ontario</Address2><Address3>P3A 1W8</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mount Sinai Hosp.-Toronto /ID# 148972</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5G 1X5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Strand Clinic /ID# 152582</Name><Address1>St. John's</Address1><Address2>Newfoundland and Labrador</Address2><Address3>A1A 4Y3</Address3><CountrySubDivision>Newfoundland and Labrador</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Ottawa Hospital /ID# 148927</Name><Address1>Ottawa</Address1><Address2>Ontario</Address2><Address3>K1H 8L6</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Victory Reproductive Care /ID# 149016</Name><Address1>Windsor</Address1><Address2>Ontario</Address2><Address3>N8W 5R7</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Puerto Rico"><Sites><Site><Name>Clinical Research Puerto Rico /ID# 149018</Name><Address1>San Juan</Address1><Address3>0090</Address3><Contacts></Contacts></Site><Site><Name>Puerto Rico Medical Research /ID# 152040</Name><Address1>Ponce</Address1><Address3>00717</Address3><Contacts></Contacts></Site><Site><Name>Rodriguez-Ginorio, San Juan /ID# 145545</Name><Address1>San Juan</Address1><Address3>00917</Address3><Contacts></Contacts></Site><Site><Name>School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 145546</Name><Address1>San Juan</Address1><Address3>00935</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>AA (Austin Area) ObGyn PLLC /ID# 205696</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78758-5653</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Accent Clinical Trials /ID# 147109</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89106-4017</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Access Clinical Trials, Inc. /ID# 145224</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Advanced Clinical Research /ID# 147086</Name><Address1>Meridian</Address1><Address2>Idaho</Address2><Address3>83642</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Advanced Women's Health Institution /ID# 145396</Name><Address1>Greenwood Village</Address1><Address2>Colorado</Address2><Address3>80111</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Advances in Health, Inc. /ID# 145425</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Affinity Clinical Research /ID# 151469</Name><Address1>Oak Brook</Address1><Address2>Illinois</Address2><Address3>60523</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Agile Clinical Research Trials /ID# 145494</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30328</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Alabama Clinical Therapeutics, LLC /ID# 145503</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35235-3430</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Alabama Clinical Therapeutics, LLC /ID# 151468</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35235-3430</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Albuquerque Clinical Trials, Inc /ID# 154747</Name><Address1>Albuquerque</Address1><Address2>New Mexico</Address2><Address3>87102</Address3><CountrySubDivision code="NM">New Mexico</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Alliance Research Centers /ID# 151240</Name><Address1>Laguna Hills</Address1><Address2>California</Address2><Address3>92653-3621</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Alliance Womens Health /ID# 148770</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23226-1930</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Alta California Medical Group /ID# 155706</Name><Address1>Simi Valley</Address1><Address2>California</Address2><Address3>93065</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>American Health Network of Ind /ID# 167996</Name><Address1>Avon</Address1><Address2>Indiana</Address2><Address3>46123-7960</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Apogee Women's Health Inc. /ID# 145149</Name><Address1>College Park</Address1><Address2>Georgia</Address2><Address3>30349</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Arizona Research Assoc /ID# 161703</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85712</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Asr, Llc /Id# 161680</Name><Address1>Nampa</Address1><Address2>Idaho</Address2><Address3>83687</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Atlanta Gynecology Research Institute /ID# 149322</Name><Address1>Suwanee</Address1><Address2>Georgia</Address2><Address3>30024-7159</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Atlanta Women's Research Inst /ID# 145543</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30342</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Aventiv Research, Inc. /ID# 162896</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43213</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Axcess Medical Center /ID# 148169</Name><Address1>Loxahatchee Groves</Address1><Address2>Florida</Address2><Address3>33470</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Baltimore Suburban Health /ID# 147164</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21208</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Baylor Scott &amp; White /ID# 170430</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><Address3>76104-4110</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bluegrass Clinical Research /ID# 151209</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40291</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bosque Women's Care /ID# 147084</Name><Address1>Albuquerque</Address1><Address2>New Mexico</Address2><Address3>87109</Address3><CountrySubDivision code="NM">New Mexico</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Brown Clinic, PLLP /ID# 154372</Name><Address1>Watertown</Address1><Address2>South Dakota</Address2><Address3>57201</Address3><CountrySubDivision code="SD">South Dakota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Brown, Pearson, Guepet Gynecology /ID# 148750</Name><Address1>Fairhope</Address1><Address2>Alabama</Address2><Address3>36532</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CTI Clinical Research Center /ID# 145428</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45212</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>California Medical Research As /ID# 154746</Name><Address1>Northridge</Address1><Address2>California</Address2><Address3>91324</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Center for Assisted Reprod. /ID# 154748</Name><Address1>Bedford</Address1><Address2>Texas</Address2><Address3>76022</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Center for Women's Research, Inc /ID# 145486</Name><Address1>Palos Heights</Address1><Address2>Illinois</Address2><Address3>60463-1440</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Center of Reproductive Medicin /ID# 145467</Name><Address1>Webster</Address1><Address2>Texas</Address2><Address3>77598</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Centex Studies, Inc /ID# 148776</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77058-2705</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Central Research Associates /ID# 163087</Name><Address1>Birmingham</Address1><Address2>Alabama</Address2><Address3>35205</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Chattanooga Medical Research /ID# 145184</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3>37404</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>ClinSite, LLC /ID# 145314</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><Address3>48105</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Inquest Center Ltd /ID# 147107</Name><Address1>Beavercreek</Address1><Address2>Ohio</Address2><Address3>45431-2573</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Physiology Associates /ID# 145237</Name><Address1>Fort Myers</Address1><Address2>Florida</Address2><Address3>33912</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Research Adv, Inc. /ID# 149257</Name><Address1>Puyallup</Address1><Address2>Washington</Address2><Address3>98372</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Research Partners, LL /ID# 145392</Name><Address1>North Chesterfield</Address1><Address2>Virginia</Address2><Address3>23235-4722</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Research Partners, LL /ID# 145416</Name><Address1>North Chesterfield</Address1><Address2>Virginia</Address2><Address3>23235-4722</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Research Prime /ID# 161724</Name><Address1>Idaho Falls</Address1><Address2>Idaho</Address2><Address3>83404</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Trials Management,LLC /ID# 145220</Name><Address1>Covington</Address1><Address2>Louisiana</Address2><Address3>70433</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Trials Management,LLC /ID# 145520</Name><Address1>Covington</Address1><Address2>Louisiana</Address2><Address3>70433</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Trials Virginia, Inc. /ID# 145430</Name><Address1>Richmond</Address1><Address2>Virginia</Address2><Address3>23225</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Trials of Texas,Inc. /ID# 147100</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78229</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Columbia Univ Medical Center /ID# 145334</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10032-3725</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Columbus Regional Research Ins /ID# 159752</Name><Address1>Columbus</Address1><Address2>Georgia</Address2><Address3>31904</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Comprehensive Clinical Trials /ID# 145148</Name><Address1>West Palm Beach</Address1><Address2>Florida</Address2><Address3>33409</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Comprehensive Women's Care /ID# 145492</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43214</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Continental Clinical Solutions /ID# 152041</Name><Address1>Towson</Address1><Address2>Maryland</Address2><Address3>21204</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Core Healthcare Group /ID# 149321</Name><Address1>Cerritos</Address1><Address2>California</Address2><Address3>90703</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Corner Canyon Obstetrics and G /ID# 145519</Name><Address1>Draper</Address1><Address2>Utah</Address2><Address3>84020</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cwrwc /Id# 145356</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27713</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cypress Medical Research Ctr /ID# 147159</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67226</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>DJL Clinical Research, PLLC /ID# 154679</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3>28210-8508</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Discovery Clinical Trials-San Antonio /ID# 145363</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78258</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Downtown Womens Health Care /ID# 147955</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3>80209</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Drexel Univ College of Med /ID# 149789</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19129</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Eastern Carolina Women's Centr /ID# 145386</Name><Address1>New Bern</Address1><Address2>North Carolina</Address2><Address3>28562</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Eastern Maine Medical Center /ID# 161681</Name><Address1>Bangor</Address1><Address2>Maine</Address2><Address3>04401</Address3><CountrySubDivision code="ME">Maine</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Eclipse Clinical Research /ID# 155600</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85745</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>FMC Science /ID# 150981</Name><Address1>Lampasas</Address1><Address2>Texas</Address2><Address3>76550</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Frontier Clinical Research /ID# 162091</Name><Address1>Smithfield</Address1><Address2>Pennsylvania</Address2><Address3>15478</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Futura Research, Inc. /ID# 145406</Name><Address1>Norwalk</Address1><Address2>California</Address2><Address3>90650</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Gadolin Research, LLC /ID# 201383</Name><Address1>Beaumont</Address1><Address2>Texas</Address2><Address3>77702-1100</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Genesis Clinical Research /ID# 148573</Name><Address1>Fall River</Address1><Address2>Massachusetts</Address2><Address3>02723</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Genoma Research Group, Inc /ID# 152558</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33165</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Glendale Adventist Medical Ctr /ID# 160530</Name><Address1>Glendale</Address1><Address2>California</Address2><Address3>91206</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Great Lakes Research Group,Inc /ID# 145308</Name><Address1>Bay City</Address1><Address2>Michigan</Address2><Address3>48706</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Gulf Coast Research Group /ID# 162895</Name><Address1>Brandon</Address1><Address2>Florida</Address2><Address3>33510</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>HRC Fertility /ID# 154143</Name><Address1>Encino</Address1><Address2>California</Address2><Address3>91436</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hamburg Regional Gynecology Gr /ID# 161705</Name><Address1>Orchard Park</Address1><Address2>New York</Address2><Address3>14127</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Health Research of Hampton Roads, Inc. (HRHR) /ID# 156477</Name><Address1>Newport News</Address1><Address2>Virginia</Address2><Address3>23606</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Healthcare Partners Med Group /ID# 152045</Name><Address1>Redondo Beach</Address1><Address2>California</Address2><Address3>90277-3416</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Helix Biomedics, LLC /ID# 147108</Name><Address1>Boynton Beach</Address1><Address2>Florida</Address2><Address3>33436-6634</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Holston Medical Group /ID# 145449</Name><Address1>Bristol</Address1><Address2>Tennessee</Address2><Address3>37620-7346</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hope Clin Research /ID# 150282</Name><Address1>Kissimmee</Address1><Address2>Florida</Address2><Address3>34741</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Horizon Research Group /ID# 148171</Name><Address1>Eunice</Address1><Address2>Louisiana</Address2><Address3>70535</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Houston Ctr for Clin Research /ID# 148799</Name><Address1>Sugar Land</Address1><Address2>Texas</Address2><Address3>77479</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Houston Methodist Hospital /ID# 170586</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Huntington Medical Foundation /ID# 154750</Name><Address1>Pasadena</Address1><Address2>California</Address2><Address3>91105</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>James A. Simon, MD, PC /ID# 145480</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20036</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>James T. Martin, Jr., MD., Obs /ID# 148755</Name><Address1>North Charleston</Address1><Address2>South Carolina</Address2><Address3>29406</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Jersey Shore University Medical Center /ID# 148756</Name><Address1>Neptune</Address1><Address2>New Jersey</Address2><Address3>07753-4859</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>KO Clinical Research, LLC /ID# 145410</Name><Address1>Fort Lauderdale</Address1><Address2>Florida</Address2><Address3>33316</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Long Beach Clinical Trial Serv /ID# 152428</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3>90806</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Lotus Gynecology /ID# 148479</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78703-1448</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>MD Strategies Research Centers /ID# 152429</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92119</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mabey, Las Vegas, NV /ID# 145361</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89128</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Madigan Army Medical Center /ID# 145186</Name><Address1>Tacoma</Address1><Address2>Washington</Address2><Address3>98431</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Magnolia Ob/Gyn Research Cente /ID# 145336</Name><Address1>Myrtle Beach</Address1><Address2>South Carolina</Address2><Address3>29572</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Main Line Fertility Center /ID# 150099</Name><Address1>Bryn Mawr</Address1><Address2>Pennsylvania</Address2><Address3>19010</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Manhattan Medical Research /ID# 145175</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016-6023</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Meridian Clinical Research, LLC /ID# 148176</Name><Address1>Savannah</Address1><Address2>Georgia</Address2><Address3>31406-2675</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Meridien Research /ID# 145345</Name><Address1>Kenneth City</Address1><Address2>Florida</Address2><Address3>33709-3113</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mesa Obstetricians and Gynecol /ID# 147320</Name><Address1>Mesa</Address1><Address2>Arizona</Address2><Address3>85209</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Mobile, Ob-Gyn, P.C. /ID# 145364</Name><Address1>Mobile</Address1><Address2>Alabama</Address2><Address3>36608</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Neccr /Id# 145329</Name><Address1>Fall River</Address1><Address2>Massachusetts</Address2><Address3>02720-2972</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Next Innovative Clinical Research /ID# 203863</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77004-6031</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>North Spokane Women's Health /ID# 145382</Name><Address1>Spokane</Address1><Address2>Washington</Address2><Address3>99207</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Northern California Research /ID# 159753</Name><Address1>Carmichael</Address1><Address2>California</Address2><Address3>95831</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>OB.GYN Associates of WNY /ID# 161665</Name><Address1>West Seneca</Address1><Address2>New York</Address2><Address3>14224</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>OB/GYN Associates of Erie /ID# 157935</Name><Address1>Erie</Address1><Address2>Pennsylvania</Address2><Address3>16507-1423</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Ocean Blue Med Research Ctr /ID# 145514</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33166</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Ochsner Baptist OB/GYN Clinic /ID# 147144</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70115</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Office of Edmond E. Pack, MD /ID# 148747</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89113</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Olympian Clinical Research /ID# 148167</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33614</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Olympic Clinical Trials /ID# 202325</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90036-4667</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Omega Research Consultants, LLC /ID# 145167</Name><Address1>DeBary</Address1><Address2>Florida</Address2><Address3>32713-2260</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Omni Fertility and Laser Insti /ID# 145532</Name><Address1>Shreveport</Address1><Address2>Louisiana</Address2><Address3>71118</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Oncova Clinical Research, Inc. /ID# 148175</Name><Address1>Saint Cloud</Address1><Address2>Florida</Address2><Address3>34769</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Oregon Health and Science University /ID# 155705</Name><Address1>Portland</Address1><Address2>Oregon</Address2><Address3>97239-3098</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts></Contacts></Site><Site><Name>PMG Research of Charlotte /ID# 145432</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3>28209</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>PMG Research of Wilmington /ID# 152555</Name><Address1>Wilmington</Address1><Address2>North Carolina</Address2><Address3>28401-6638</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>PRN Professional Research Network of Kansas, LLC /ID# 151463</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67205</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Palmetto Clinical Research /ID# 150992</Name><Address1>Summerville</Address1><Address2>South Carolina</Address2><Address3>29485-7539</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Palmetto Professional Research /ID# 153838</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33186-1309</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Paramount Research Solutions /ID# 145226</Name><Address1>Alpharetta</Address1><Address2>Georgia</Address2><Address3>30005</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Paramount Research Solutions /ID# 149320</Name><Address1>Alpharetta</Address1><Address2>Georgia</Address2><Address3>30005</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Penn State University and Milton S. Hershey Medical Center /ID# 145231</Name><Address1>Hershey</Address1><Address2>Pennsylvania</Address2><Address3>17033</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Physician Care Clin. Res., LLC /ID# 145511</Name><Address1>Sarasota</Address1><Address2>Florida</Address2><Address3>34239</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pinewest Ob-Gyn, Inc. /ID# 151743</Name><Address1>High Point</Address1><Address2>North Carolina</Address2><Address3>27262</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Praetorian Pharmaceutical Res /ID# 145405</Name><Address1>Marrero</Address1><Address2>Louisiana</Address2><Address3>70072</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Precision Research Institute - Houston /ID# 154370</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77036</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Precision Research Institute - San Diego /ID# 152557</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92114-3643</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Precision Research Org, LLC /ID# 145337</Name><Address1>Miami Lakes</Address1><Address2>Florida</Address2><Address3>33016-1501</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Prism Research /ID# 159751</Name><Address1>Saint Paul</Address1><Address2>Minnesota</Address2><Address3>55114</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Red Rocks OB/GYN /ID# 145325</Name><Address1>Lakewood</Address1><Address2>Colorado</Address2><Address3>80228-1810</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Memphis Associates, LLC /ID# 150100</Name><Address1>Memphis</Address1><Address2>Tennessee</Address2><Address3>38119-3895</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Revere Health /ID# 145540</Name><Address1>American Fork</Address1><Address2>Utah</Address2><Address3>84003</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Rutgers Robert Wood Johnson /ID# 152858</Name><Address1>New Brunswick</Address1><Address2>New Jersey</Address2><Address3>08901</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>SUNY Downstate Medical Center /ID# 148749</Name><Address1>Brooklyn</Address1><Address2>New York</Address2><Address3>11203</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Saginaw Valley Med Res Group /ID# 145527</Name><Address1>Saginaw</Address1><Address2>Michigan</Address2><Address3>48604</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Salom Tangir, LLC /ID# 148739</Name><Address1>Miramar</Address1><Address2>Florida</Address2><Address3>33027</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Scott Research Inc. /ID# 161704</Name><Address1>Laurelton</Address1><Address2>New York</Address2><Address3>11413</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Seattle Women's Health, Research, Gynecology /ID# 145341</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98105</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Signature Gyn Services /ID# 145534</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><Address3>76104</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sirius Clinical Research, LLC /ID# 154749</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78759</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Solutions Through Adv Rch /ID# 148768</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32256</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sonora Clinical Research /ID# 145541</Name><Address1>Meridian</Address1><Address2>Idaho</Address2><Address3>83646-1144</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Southampton Women's Health /ID# 151691</Name><Address1>Franklin</Address1><Address2>Virginia</Address2><Address3>23851</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>St. Joseph's Regional Medical /ID# 157759</Name><Address1>Totowa</Address1><Address2>New Jersey</Address2><Address3>07512</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Stedman Clinical Trials /ID# 152554</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33613</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Suncoast Clinical Research /ID# 145484</Name><Address1>New Port Richey</Address1><Address2>Florida</Address2><Address3>34652</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Tanner Clinic /ID# 148786</Name><Address1>Layton</Address1><Address2>Utah</Address2><Address3>84041</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Texas Health Presbyterian Hosp /ID# 150098</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75231</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Adv Gynecologic Surg Ins /ID# 151459</Name><Address1>Park Ridge</Address1><Address2>Illinois</Address2><Address3>60068</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Christ Hospital /ID# 149244</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45219</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Iowa Clinic /ID# 145409</Name><Address1>West Des Moines</Address1><Address2>Iowa</Address2><Address3>50266</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Jackson Clinic, PA /ID# 145303</Name><Address1>Jackson</Address1><Address2>Tennessee</Address2><Address3>38305</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Ohio State University /ID# 145444</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210-1257</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Woman's Hospital of Texas /ID# 145316</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77054</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Women's Health Group - Thornton /ID# 203707</Name><Address1>Thornton</Address1><Address2>Colorado</Address2><Address3>80229-4385</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Tidewater Clinical Research /ID# 145397</Name><Address1>Virginia Beach</Address1><Address2>Virginia</Address2><Address3>23456</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Treasure Coast Research /ID# 148174</Name><Address1>Stuart</Address1><Address2>Florida</Address2><Address3>34996</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Trinity Health Center Town /ID# 147102</Name><Address1>Minot</Address1><Address2>North Dakota</Address2><Address3>58701</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>UT Southwestern Medical Center /ID# 145201</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75390-7208</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Unified Women's Clinical Resea /ID# 145353</Name><Address1>Raleigh</Address1><Address2>North Carolina</Address2><Address3>27607</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Unified Women's Clinical Research-Greensboro /ID# 155543</Name><Address1>Greensboro</Address1><Address2>North Carolina</Address2><Address3>27408</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Unity Health- Searcy Medical Center /ID# 203674</Name><Address1>Searcy</Address1><Address2>Arkansas</Address2><Address3>72143-4802</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Univ Hosp Cleveland /ID# 148741</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44106</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Univ Maryland School Medicine /ID# 151739</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21201</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University Medical Group /ID# 148777</Name><Address1>Greenville</Address1><Address2>South Carolina</Address2><Address3>29605</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Cincinnati /ID# 145496</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45267-0585</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Louisville /ID# 154751</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40202</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Pennsylvania /ID# 145470</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104-5502</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of South Alabama /ID# 148774</Name><Address1>Mobile</Address1><Address2>Alabama</Address2><Address3>36604-3302</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of South Florida /ID# 145424</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Toledo /ID# 145403</Name><Address1>Toledo</Address1><Address2>Ohio</Address2><Address3>43614</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Victorium Clinical Research /ID# 151745</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78230</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Virginia Mason Medical Center /ID# 145387</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98101</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Virtus Research Consultant,LLC /ID# 147101</Name><Address1>Wellington</Address1><Address2>Florida</Address2><Address3>33414</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Vista Clinical Research /ID# 148767</Name><Address1>Columbia</Address1><Address2>South Carolina</Address2><Address3>29201</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Vista Health Research, LLC /ID# 151455</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33176</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>WR-ClinSearch /ID# 145205</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3>37421-1605</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Wayne State University Physician Group - Southfield /ID# 145431</Name><Address1>Southfield</Address1><Address2>Michigan</Address2><Address3>48034</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Willowbend Health and Wellness /ID# 145245</Name><Address1>Frisco</Address1><Address2>Texas</Address2><Address3>75035</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Women Under Study, LLC /ID# 151216</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70125-1923</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Women's Health Advantage /ID# 145495</Name><Address1>Fort Wayne</Address1><Address2>Indiana</Address2><Address3>46825</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Women's Health Alliance of Mobile /ID# 150083</Name><Address1>Mobile</Address1><Address2>Alabama</Address2><Address3>36604-1410</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Women's Health Clinic /ID# 155707</Name><Address1>Shreveport</Address1><Address2>Louisiana</Address2><Address3>71118-3133</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Women's Health Practice, LLC /ID# 145517</Name><Address1>Champaign</Address1><Address2>Illinois</Address2><Address3>61820</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Womens &amp; Family Care, LLC dba /ID# 145211</Name><Address1>Shawnee Mission</Address1><Address2>Kansas</Address2><Address3>66218</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Womens Clinic of Lincoln, P.C. /ID# 145366</Name><Address1>Lincoln</Address1><Address2>Nebraska</Address2><Address3>68510</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Womens Healthcare Assoc, DBA /ID# 148744</Name><Address1>Idaho Falls</Address1><Address2>Idaho</Address2><Address3>83404</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Wright State University &amp; CTRA /ID# 145512</Name><Address1>Fairborn</Address1><Address2>Ohio</Address2><Address3>45324</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Endometriosis</Disease><PatientSegments><PatientSegment><PatientSegment id="11560">Women with Moderate Endometriosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11561">Women with Severe Endometriosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11562">Subjects with Symptomatic Disease</PatientSegment><SubSegments><SubSegment id="11563">Women with dysmenorrhea</SubSegment><SubSegment id="11565">Women with pelvic pain</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11578">Women with Protocol Specified Menstrual Status</PatientSegment><SubSegments><SubSegment id="11579">Pre-menopausal subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03213457</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Endometriosis" id="22227"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Endometriosis" id="44493"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Endometriosis" id="22227"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Endometriosis" id="27243">Numerical rating scale(NRS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Endometriosis" id="22257"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Endometriosis" id="22259">Assessment of rescue medicaton use</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Endometriosis" id="22267"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Endometriosis" id="20518"><Criterion>Women with Endometriosis</Criterion><SubCriteria><SubCriterion disease="Endometriosis" id="20521">Women with moderate endometriosis</SubCriterion><SubCriterion disease="Endometriosis" id="20522">Women with severe endometriosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Endometriosis" id="20523"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Endometriosis" id="20524">Women with dysmenorrhea</SubCriterion><SubCriterion disease="Endometriosis" id="20526">Women with pelvic pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Endometriosis" id="20544"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Endometriosis" id="20545">Women with history of/scheduled for surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Endometriosis" id="20551"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Endometriosis" id="20552">Premenopausal subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Endometriosis" id="20554"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Endometriosis" id="17399"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17400"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17403"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17407"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17412"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17421"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17428"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Endometriosis" id="17429">Subjects with contraindication to drugs or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Endometriosis" id="17431"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Endometriosis" id="17432"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-01-02T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-05-01T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>21.84 Months</EnrollmentPeriod><EnrollmentRate>31.14 Patients/Month</EnrollmentRate><DateFirstReceived>2017-07-07T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-07-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="339616"><TitleDisplay>Effect of brain stimulation by electric current on eating behavior in overweight people</TitleDisplay><TitleOfficial>Effect of transcranial direct current stimulation (tDCS) on eating behavior in participants with excess of</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">RBR-8f5w2q</Identifier><Identifier type="Other">U1111-1210-8451</Identifier><Identifier type="Other">2.563.991</Identifier><Identifier type="Other">72391817.7.0000.5568</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="7586" role="Therapeutic effect marker" type="Anthropomorphic">Body fat percentage</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>transcranial direct current stimulation (tDCS)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1076120" type="Company"><TargetEntity id="5035438797" type="organizationId">Federal University of Rio Grande do Norte</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1076120">Universidade Federal do Rio Grande do Norte</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>176</PatientCountEnrollment><DateStart>2017-11-06T00:00:00Z</DateStart><DateChangeLast>2018-05-18T05:43:03Z</DateChangeLast><DateAdded>2018-05-22T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Faculdade de Ciências da Saúde do Trairi - FACISA</Affiliation><Email>figueiredoheverton@gmail.com</Email><Name>Heverton Araújo de Oliveira Figueirêdo</Name><Phone>+55-084-988945993</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age between 19 and 50 years&lt;/li&gt;&lt;li&gt;Body mass index &gt;/=  25&lt;/li&gt;&lt;li&gt;Abdominal circumference &gt; 94 cm for men and &gt; 80 cm for women&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnant and breastfeeding women&lt;/li&gt;&lt;li&gt;Women in menopause&lt;/li&gt;&lt;li&gt;User of illicit drug, use of psychotropic medication and for weight loss&lt;/li&gt;&lt;li&gt;Previous or current history of eating disorder, psychiatric&lt;/li&gt;&lt;li&gt;Suffered a stroke, head trauma, neurosurgery&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Attenuation of eating behaviors associated with obesity, after 10 sessions of tDCS, until the 8th week after the intervention, evaluated by the questionnaire scores: three-factor food intake questionnaire-R21 (TFEQ-R21); food craving desire questionnaire (FCQ-T); Brazilian inventory of craving-related foods (FCI-Br), as well as the emotional profile verified by the DASS-21 questionnaire</Description></Measure><Measure><Description>Modifications in food group intake between the beginning of the intervention and at a follow-up of eight weeks after the last session of tDCS, verified by the application of 24-h reminders</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Decreased anthropometric measures associated to obesity, after 10 sessions of tDCS, until the 8th week after the intervention, verifying weight; circumference of the waist and abdomen, as well as the percentage of body fat</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this  study is to evaluate the effect of transcranial direct current stimulation (tDCS) on eating behavior in  overweight subjects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Experimental group: 22 women aged 19 to 30 years, 22 women aged 31 to 50 years, 22 men aged 19 to 30 years, 22 men from 31 to 50 years of age who are overweight or obese will receive transcranial direct current stimulation (tDCS) of 2 mA for 20 min for 10 days.&lt;br/&gt;Control group (sham): 22 women aged 19 to 30 years, 22 women aged 31 to 50 years, 22 men aged 19 to 30 years, 22 men aged 31 to 50 years overweight or obese will receive a simulation of transcranial stimulation by (tDCS) for 20 min for 10 days. The simulation will be characterized by initiating the stimulation of the actual current of 2mA for 15 s. After this period, the current will be turned off and the participant will remain with the simulation for 20 min&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7735">Obese Class II Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7736">Morbid Obesity(Class III) Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier>U1111-1210-8451</Identifier></Identifiers></Registry><Registry><Name id="1020">Brazilian Clinical Trials Registry (ReBec)</Name><Identifiers><Identifier>RBR-8f5w2q</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20427"><Endpoint>Assessment of Dietary Intake</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20431">Assessment of eating pattern</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20623"><Endpoint>Assessment of Behavior Changes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29726">Assessment by Three-Factor Eating Questionnaire (TFEQ).</SubEndpoint><SubEndpoint disease="Obesity" id="29738">Food craving inventory</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="44823"><Endpoint>Assessment of Neuropsychological Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20427"><Endpoint>Assessment of Dietary Intake</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20402">Assessment of waist circumference</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19673">Subjects with elevated abdominal circumference</SubCriterion><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion><SubCriterion disease="Obesity" id="22430">Obese Class II Subjects</SubCriterion><SubCriterion disease="Obesity" id="22433">Morbid Obesity(Class III) Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19680">Subjects with BMI&gt;25</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15293"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15294">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15295"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15296">Subjects with eating disorders</SubCriterion><SubCriterion disease="Obesity" id="15401">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15353">Subjects on prohibited medications</SubCriterion><SubCriterion disease="Obesity" id="15411">Subjects on/treated with weight loss medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15396">Postmenopausal women</SubCriterion><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="26091"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2018-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.84 Months</EnrollmentPeriod><EnrollmentRate>17.89 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="45114"><TitleDisplay>Safety Study of Oral Vinorelbine in Subjects With Non-Hematological Malignancies</TitleDisplay><TitleOfficial>A Phase I Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematological Malignancies For Which There Are No Currently Accepted Therapies</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MT-CL002</Identifier><Identifier type="NCT">NCT00641160</Identifier></Identifiers><Indications><Indication id="651">Cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>vinorelbine</Name><Drug id="6408">vinorelbine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6408">vinorelbine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1045506">Metronome Therapeutics</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6408" type="Drug"><TargetEntity id="101739" type="siDrug">Vinorelbine</TargetEntity></SourceEntity><SourceEntity id="1045506" type="Company"><TargetEntity id="4298120959" type="organizationId">METRONOME THERAPEUTICS INC</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1045506">Metronome Therapeutics</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2008-03-31T00:00:00Z</DateStart><DateEnd type="estimated">2008-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-07-07T03:46:56Z</DateChangeLast><DateAdded>2009-02-12T09:37:50Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Metronome Therapeutics</Affiliation><Name>George Tidmarsh, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Capable of understanding study requirements and able to provide informed consent&lt;/li&gt;&lt;li&gt;Diagnosed with a non-hematological  malignancy for which there are no currently accepted
             therapies&lt;/li&gt;&lt;li&gt;Life expectancy at least 3 months&lt;/li&gt;&lt;li&gt;Agreement to use medically acceptable contraception throughout the study&lt;/li&gt;&lt;li&gt;Willing and able to comply with the protocol requirements&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Currently receiving systemic treatment for malignancy&lt;/li&gt;&lt;li&gt;Not yet recovered from the toxicity of prior therapies&lt;/li&gt;&lt;li&gt;Platelet count&amp;lt; 100,000 cells/mm(3) within 7 days prior to study entry
&lt;/li&gt;&lt;li&gt;ANC&amp;lt; 1500 cells/mm(3) within 7 days prior to study entry
&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;lt; 8.5 g/dl within 7 days prior to study entry
&lt;/li&gt;&lt;li&gt;AST and/or ALT&amp;gt; 2.5 x ULN within 7 days prior to study entry
&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;gt; 1.5 x ULN within 7 days prior to study entry
&lt;/li&gt;&lt;li&gt;Creatinine clearance&amp;lt; 60 ml/min (Cockroft-Gault formula) within 7 days prior to study
             entry&lt;/li&gt;&lt;li&gt;Receipt of any investigational therapy within 3 weeks prior to study entry&lt;/li&gt;&lt;li&gt;Known history of HIV, HBV, and/or HCV infection&lt;/li&gt;&lt;li&gt;Clinically relevant active infection or serious co-morbid medical condition at study
             entry&lt;/li&gt;&lt;li&gt;Major surgery within 4 weeks prior to study entry&lt;/li&gt;&lt;li&gt;Other malignancy within three year prior to study entry&lt;/li&gt;&lt;li&gt;Pregnant or breast-feeding&lt;/li&gt;&lt;li&gt;Presence of a concomitant disease or condition which, in the opinion of the
             Investigator, could interfere with the conduct of the study or could put the subject
             at unacceptable risk&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety as measured by adverse events, physical examinations, clinical laboratory assessments, and vital signs</Description><Timeframe>Assessed at each subject visit to the study center</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Pharmacokinetics of orally administered vinorelbine</Description><Timeframe>Samples collected on study days 1, 2, and 8</Timeframe></Measure><Measure><Description>Exploratory analysis of blood markers of biological activity</Description><Timeframe>Blood samples collected at selected subject visits to the study center</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to determine the safety of oral administration of &lt;ulink linkType="Drug" linkID="6408"&gt;vinorelbine&lt;/ulink&gt;
      once daily for at least 7 days.  The study will be conducted in subjects with a
      non-hematological  malignancy for which there are no currently accepted therapies.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Texas Oncology PA; Sammons Cancer Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75246</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7967">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00641160</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15306"><Endpoint>Assessment of Physical Examination</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15308"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15309"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15254"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13102"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13105">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13129"><Criterion>Subjects with Treatment Refractory Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10731"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10737">Patient with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="12316"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2008-11-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2008-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.03 Months</EnrollmentPeriod><EnrollmentRate>1.99 Patients/Month</EnrollmentRate><DateFirstReceived>2008-03-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-12T09:37:50Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="73293"><TitleDisplay>Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis</TitleDisplay><TitleOfficial>Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">W11-050</Identifier><Identifier type="NCT">NCT01265823</Identifier></Identifiers><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="119" role="Therapeutic effect marker" type="Biochemical">Homocysteine</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="419" role="Therapeutic effect marker" type="Anthropomorphic">Waist to Hip Ratio</BiomarkerName><BiomarkerName id="445" role="Therapeutic effect marker" type="Biochemical">Folic acid</BiomarkerName><BiomarkerName id="668" role="Therapeutic effect marker" type="Biochemical">Vitamin B12</BiomarkerName><BiomarkerName id="3726" role="Therapeutic effect marker" type="Biochemical">Vitamin B6</BiomarkerName><BiomarkerName id="7935" role="Therapeutic effect marker" type="Biochemical">Lipoproteins, VLDL</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>adalimumab</Name><Drug id="14163">adalimumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14163">adalimumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1072507">AbbVie Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="14163" type="Drug"><TargetEntity id="255014" type="siDrug">Adalimumab</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="381" type="Action"><TargetEntity id="663" type="Mechanism">TNF-alpha Antagonists</TargetEntity><TargetEntity id="1551" type="Mechanism">Anti-TNF-alpha</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>7</NumberOfSites><CompaniesSponsor><Company id="1072507">AbbVie Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="381">TNF alpha ligand inhibitor</Action><Action id="721">TNF binding agent</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2659">Cardioprotectant</Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="112">DNA technology</Technology><Technology id="168">Monoclonal antibody human</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2010-10-31T00:00:00Z</DateStart><DateEnd type="actual">2012-02-29T00:00:00Z</DateEnd><DateChangeLast>2018-06-26T05:57:04Z</DateChangeLast><DateAdded>2010-12-30T07:52:44Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>AbbVie</Affiliation><Name>Jose-Luis  Canadas, Medical Director, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able and willing to give written informed consent prior to any study related
             procedures  and to comply with the requirements of the study protocol&lt;/li&gt;&lt;li&gt;Male and female subjects between 18 and 75 years old&lt;/li&gt;&lt;li&gt;Diagnosis of moderate to severe types 1 and 2 plaque psoriasis (type 1:
             symptoms onset before 40 year old; type 2: symptoms onset after 40 year old), with at
             least 6 months of duration &lt;/li&gt;&lt;li&gt;Documented moderate to severe plaque psoriasis based on Psoriasis Area and
             Severity Index (PASI) score&amp;gt; 10
&lt;/li&gt;&lt;li&gt;Subjects naive to&lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt; therapy
&lt;/li&gt;&lt;li&gt;Subject must be evaluated for active and latent tuberculosis (TB) infection by
             using a Purified Protein Derivative (PPD) skin test, chest x-ray (posterior to
             anterior (PA) and lateral views)  and a detailed review of the subject's medical
             history. This screening must be negative&lt;/li&gt;&lt;li&gt;A negative pregnancy test (serum human chorionic gonadotrophin) for women of childbearing potential prior
             to start of study treatment  (non-childbearing potential is defined as
             postmenopausal for at least one year or surgically sterile [bilateral tubal ligation,
             bilateral oophorectomy or hysterectomy])&lt;/li&gt;&lt;li&gt;Able and willing to self-administer sc injections or have available a
             suitable person to administer sc injections&lt;/li&gt;&lt;li&gt;Subject is judged to be in generally good health as determined by the
             investigator&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Prior treatment with any investigational agent within 30 days, or five half-lives
             of the  product, which ever is longer.  Subject has been treated with any
             investigational drug of chemical or biological nature within a minimum of 30 days or
             five half lives (whichever is longer) of the drug prior to study entry (baseline
             visit)&lt;/li&gt;&lt;li&gt;Subject has other active skin diseases or skin infections (bacterial, fungal, or
             viral) that may interfere with the evaluation of psoriasis or compromise the
             subject's safety&lt;/li&gt;&lt;li&gt;Subject has a history of dysplasia, malignancy (including lymphoma and leukemia),
             or lymphoproliferative disease other than:&lt;ul&gt;&lt;li&gt;Successfully and completely treated non-metastatic squamous or basal cell
                  carcinoma of the skin with no recurrence within the last five years&lt;/li&gt;&lt;li&gt;Localized carcinoma in situ of the cervix or cervical dysplasia, with no
                  recurrence within the last five years&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Persistent or recurrent infections or severe infections requiring hospitalization
             or treatment with iv antibiotics, iv antivirals, or iv antifungals within 30 days, or
             oral antibiotics, oral antivirals or oral antifungals within 14 days prior to baseline
             visit&lt;/li&gt;&lt;li&gt;Other medical conditions: uncontrolled diabetes, unstable ischemic heart disease,
             congestive heart failure (NYHA) III to IV, recent stroke (within 3 months), chronic
             leg ulcer and any other condition (eg, indwelling urinary catheter) which, in the
             opinion of the investigator, may place the subject at risk&lt;/li&gt;&lt;li&gt;Previous diagnosis or signs highly indicative of central nervous system
             demyelinating  diseases (eg, optic neuritis, ataxia, apraxia)&lt;/li&gt;&lt;li&gt;History of listeriosis, histoplasmosis, chronic or active hepatitis B infection,
             human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic
             recurring infections or active TB&lt;/li&gt;&lt;li&gt;Female subjects who are pregnant or breast-feeding&lt;/li&gt;&lt;li&gt;History of clinically significant drug or alcohol abuse in the last year&lt;/li&gt;&lt;li&gt;Subject started receiving a new topical therapy within the last 4 weeks prior
             to the baseline visit for areas other than the palms, soles of feet, axilla and
             groin&lt;/li&gt;&lt;li&gt;Subject started being treated with ultraviolet B (UVB) phototherapy, within the last 4 weeks
             prior to the baseline visit&lt;/li&gt;&lt;li&gt;Subject was treated with psoralen  ultraviolet A (PUVA) phototherapy within the last 4
             weeks prior to the baseline visit&lt;/li&gt;&lt;li&gt;Subject has been initiated on a new systemic agent within the last 4 weeks
             prior to the baseline visit&lt;/li&gt;&lt;li&gt;Patients with history of atopy&lt;/li&gt;&lt;li&gt;Patients with any other autoimmune disease such as systemic lupus erythematosus (SLE), Sdx Sjogren, vasculitis
             etc&lt;/li&gt;&lt;li&gt;Known hypersensitivity to the excipients of&lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt; as stated in the label&lt;/li&gt;&lt;li&gt;Female subjects who are pregnant or breast-feeding or considering becoming
             pregnant during the study&lt;/li&gt;&lt;li&gt;Subject is considered by the investigator, for any reason, to be an unsuitable
             candidate for the study&lt;/li&gt;&lt;li&gt;Subject with any prior exposure to Tysabri (natalizumab), or Orencia
             (abatacept)&lt;/li&gt;&lt;li&gt;Subjects with positive immunological test for hepatitis A, B or C (positive test of
             any of the following: hepatitis A viral antibody immunoglobulin M [HAV-IgM], hepatitis B surface antigen [HBsAg] or hepatitis C virus antibody [HCV Ab])&lt;/li&gt;&lt;li&gt;Subjects with a positive Immunological test for HIV determined by enzyme-linked immunosorbent assay (ELISA) method&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percentage of participants with Psoriasis Area and Severity Index (PASI)-75 response: PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the % of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at week 4. The improvement in PASI score was used as a measure of efficacy</Description><Timeframe>Week 4</Timeframe></Measure><Measure><Description>Percentage of participants with Psoriasis Area and Severity Index (PASI)-75 response: PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the % of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at week 16. The improvement in PASI score was used as a measure of efficacy</Description><Timeframe>Week 16</Timeframe></Measure><Measure><Description>Percentage of participants with a Dermatology Life Quality Index (DLQI) score &lt; 6: dermatology life quality index (DLQI) score is a participant-reported outcome consisting of a set of ten questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt; 6 indicates that psoriasis has small or no effect at all on participant's life</Description><Timeframe>Week 4</Timeframe></Measure><Measure><Description>Percentage of participants with a Dermatology Life Quality Index score &lt; 6: dermatology life quality index (DLQI) score is a participant-reported outcome consisting of a set of ten questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt; 6 indicates that psoriasis has small or no effect at all on participant's life</Description><Timeframe>Week 16</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean score of Dermatology Life Quality Index (DLQI): dermatology life quality index (DLQI) score is a participant-reported outcome consisting of a set of ten questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt; 6 indicates that psoriasis has small or no effect at all on participant's life</Description><Timeframe>Baseline, week 4</Timeframe></Measure><Measure><Description>Mean score of Dermatology Life Quality Index (DLQI): dermatology life quality index (DLQI) score is a participant-reported outcome consisting of a set of ten questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt; 6 indicates that psoriasis has small or no effect at all on participant's life</Description><Timeframe>Baseline, week 16</Timeframe></Measure><Measure><Description>Dermatology Life Quality Index (DLQI) categories: dermatology life quality index (DLQI) score is a participant-reported outcome consisting of a set of ten questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0 to 1 no effect at all; 2 to 5 small effect; 6 to 10 moderate effect; 11 to 20 very large effect; 21 to 30 extremely large effect</Description><Timeframe>Week 4</Timeframe></Measure><Measure><Description>Dermatology Life Quality Index (DLQI) categories: dermatology life quality index (DLQI) score is a participant-reported outcome consisting of a set of ten questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The following scoring categories present the effect on participant's life: 0 to 1 no effect at all; 2 to 5 small effect; 6 to 10 moderate effect; 11 to 20 very large effect; 21 to 30 extremely large effect</Description><Timeframe>Week 16</Timeframe></Measure><Measure><Description>Percentage of participants achieving Psoriasis Area and Severity Index (PASI)- 50, 90, 100 responses: PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI - 50, 90 and 100 responses are the % of participants who achieved at least a 50, 90 or 100% reduction (improvement) from baseline in PASI score at week 4. Reduction of 100% was considered complete clearance of psoriasis</Description><Timeframe>Week 4</Timeframe></Measure><Measure><Description>Percentage of participants achieving Psoriasis Area and Severity Index (PASI)- 50, 90, 100 responses: PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI - 50, 90 and 100 responses are the % of participants who achieved at least a 50, 90 or 100% reduction (improvement) from baseline in PASI score at week 4. Reduction of 100% was considered complete clearance of psoriasis</Description><Timeframe>Week 16</Timeframe></Measure><Measure><Description>Physician's Global Assessment (PGA): the PGA is a seven-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant. Categories are as follows: severe = very marked plaque elevation, scaling, and/or erythema; moderate to severe = marked plaque elevation, scaling, and/or erythema; moderate = moderate plaque elevation, scaling, and/or erythema; mild to moderate = intermediate between moderate and mild; mild = slight plaque elevation, scaling, and/or erythema; almost clear = intermediate between mild and clear; clear = no signs of psoriasis (post-inflammatory hypopigmentation or hyperpigmentation could be present). The number of participants who achieve a PGA of 'clear' or 'almost clear' at week 16 was a secondary outcome measure in this study</Description><Timeframe>Week 16</Timeframe></Measure><Measure><Description>Mean lipid profile, triglycerides and C-reactive protein (CRP). Normal values: C-reactive protein (CRP) 0 to 0.79 mg/dl; cholesterol 30 to 199 mg/dl; high density lipoprotein (HDL) 40 to 100 mg/dl; very low density lipoprotein (VLDL) 0 to 34 mg/dl; low density lipoprotein (LDL) 20 to 99 mg/dl; triglycerides 50 to 149 mg/dl</Description><Timeframe>Baseline, week 16</Timeframe></Measure><Measure><Description>Mean homocysteine levels: normal values for homocysteine were 5 to 13.9 micromol/l</Description><Timeframe>Baseline, week 16</Timeframe></Measure><Measure><Description>Percentage of obese versus non-obese (per body mass index [BMI]) participants achieving a Psoriasis Area and Severity Index (PASI)-75 response and a Total Dermatology Life Quality Index (DLQI) score of &lt; 6. The body mass index (BMI) was used to determine the groups of participants who were overweight and who were considered obese. A BMI of 18.5 to 25 was considered normal range, 25 to 30 as overweight and 30 and above as obesity, in both men and women. Response to treatment in participants with obesity (based on body mass index) versus those without obesity was assessed via PASI-75 response and DLQI score of &lt; 6</Description><Timeframe>Week 16</Timeframe></Measure><Measure><Description>Serum levels of folic acid: normal values for folic acid were 3 to 15 ng/ml</Description><Timeframe>Baseline, week 4</Timeframe></Measure><Measure><Description>Serum levels of vitamin B6: normal values for vitamin B6 were 18 to 175 nmol/l</Description><Timeframe>Baseline, week 4</Timeframe></Measure><Measure><Description>Serum levels of vitamin B12: normal values for vitamin B12 were 200 to 1100 pg/ml</Description><Timeframe>Baseline, week 4</Timeframe></Measure><Measure><Description>Serum levels of folic acid: normal values for folic acid were 3 to 15 ng/ml:</Description><Timeframe>Baseline, week 16</Timeframe></Measure><Measure><Description>Serum levels of vitamin B6: normal values for vitamin B6 were 18 to 175 nmol/l</Description><Timeframe>Baseline, week 16</Timeframe></Measure><Measure><Description>Serum levels of vitamin B12: normal values for vitamin B12 were 200 to 1100 pg/ml</Description><Timeframe>Baseline, week 16</Timeframe></Measure><Measure><Description>Percentage of obese versus non-obese (per waist-hip ratio) participants achieving a Psoriasis Area and Severity Index (PASI)-75 response and a Total Dermatology Life Quality Index (DLQI) score of &lt; 6. The waist-hip ratio was used to determine the groups of participants who were overweight and who were considered obese. Obesity was defined as a ratio of &gt; 1 for men and &gt; 0.8 for women. Response to treatment in participants with obesity (based on waist-hip ratio) versus those without obesity was assessed via PASI-75 response and DLQI score of &lt; 6</Description><Timeframe>Week 16</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purposoe of this study was to further assess
      the safety and efficacy of &lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt; in the treatment of patients with active plaque
      psoriasis who had failed prior conventional systemic psoriasis treatment or who were
      candidates for systemic therapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Up to 150 subjects, having a diagnosis of active plaque psoriasis and fulfilling the study
      eligibility criteria, were enrolled in Mexico. &lt;ulink linkType="Drug" linkID="14163"&gt;Adalimumab&lt;/ulink&gt; would be administered  as
      follows: 80 mg at baseline, followed by 40 mg  every other week (starting at week 1 until week 15). The
      study drug would be self-administered via  sc injection. Safety and efficacy
      measures would be performed throughout the study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Mexico"><Sites><Site><Name>Site Reference ID/Investigator# 50942</Name><Address1>Circuito Comercial Satelite</Address1><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 40965</Name><Address1>Monterrey</Address1><Address3>64460</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 40662</Name><Address1>Toluca de Lerdo</Address1><Address3>50120</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 40964</Name><Address1>Iztapalapa</Address1><Address3>04230</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 50943</Name><Address1>Mexico City</Address1><Address3>06780</Address3><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 40962</Name><Address1>Monterrey</Address1><Address3>64718</Address3><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 41062</Name><Address1>Toluca de Lerdo</Address1><Address3>50120</Address3><Contacts></Contacts></Site><Site><Name>Site Reference ID/Investigator# 40963</Name><Address1>Zapopan</Address1><Address3>45190</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3434">Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3451">Subjects with Moderate Psoriasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3452">Subjects with Severe Psoriasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3456">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01265823</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6486"><Endpoint>Disease Severity Assessment by PASI Scores/Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6489">PASI-75 response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Psoriasis" id="6559"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6563">Assessment by Dermatology Life Quality Index (DLQI)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Psoriasis" id="6486"><Endpoint>Disease Severity Assessment by PASI Scores/Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6488">PASI-50 response</SubEndpoint><SubEndpoint disease="Psoriasis" id="6490">PASI-75 to 100 response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6559"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6563">Assessment by Dermatology Life Quality Index (DLQI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6577"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6578">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6621"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6638"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6639">Assessment of clinical response/outcome</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6780"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="46095"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6504">Assessment by Investigator/Physician Global Assessment (PGA) Scale</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="3285"><Criterion>Subjects with Plaque Psoriasis/Psoriasis Vulgaris</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3296"><Criterion>Subjects with Moderate Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3297"><Criterion>Subjects with Severe Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3389"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3396"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Psoriasis" id="4525"><Criterion>Subjects co-morbid with dermatological disease/disorder</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4532"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4533">Subjects with autoimmune diseases/disorders</SubCriterion><SubCriterion disease="Psoriasis" id="4543">Subjects with HIV infections/immunodeficiency syndrome</SubCriterion><SubCriterion disease="Psoriasis" id="4545">Subjects with lymphoproliferative disease</SubCriterion><SubCriterion disease="Psoriasis" id="4618">Subjects co-morbid with allergic disease/disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4534"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4538"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4539"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4555"><Criterion>Subjects with History of Tuberculosis</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4556"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4557">Subjects with history of / current bacterial infections</SubCriterion><SubCriterion disease="Psoriasis" id="4558">Subjects co-morbid with viral infection</SubCriterion><SubCriterion disease="Psoriasis" id="4559">Subjects with history of / current fungal infections</SubCriterion><SubCriterion disease="Psoriasis" id="4563">Subjects with persistent or severe infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4564"><Criterion>Subjects with History of/Scheduled for Psoriasis Treatment</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4565">Subjects with history of/scheduled for systemic therapy</SubCriterion><SubCriterion disease="Psoriasis" id="4572">Subjects with history of/scheduled for phototherapy/photochemotherapy</SubCriterion><SubCriterion disease="Psoriasis" id="4573">Subjects with history of/scheduled for topical therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4583">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4619"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4620">Subjects with contraindications to study drug and its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="25895"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4554">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="26080"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4542">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="28368"><Criterion>Subjects co-morbid with CNS disorders</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4537">Subjects co-morbid with demyelinating disorder</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>14.03 Months</EnrollmentPeriod><EnrollmentRate>10.69 Patients/Month</EnrollmentRate><DateFirstReceived>2010-12-22T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-12-30T07:52:44Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>